<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0912246375
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CARTINUM 10 MG/ML VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CARBOPLATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        45
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        242.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="INTAS PHARMACEUTICALS LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            INTAS PHARMACEUTICALS LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Accord Healthcare Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cartinum contains Carboplatin, which belongs to a group of medicines known as Platinum-coordination<br />compounds, which are used to treat cancer.<br />Cartinum is used against advanced cancer of the ovary and small cell cancer of the lung.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You should not be given Cartinum if you<br />&bull; are allergic to Carboplatin or any of the other ingredients of this medicine (listed in section 6)<br />&bull; are allergic to another drug that belongs to the group of Platinum-containing compounds<br />&bull; have severe problems with your kidneys (creatinine clearance at or below 30ml/min)<br />&bull; plan to receive a yellow fever vaccination or have just received one<br />&bull; have fewer blood cells than normal (your doctor will check this with a blood test)<br />&bull; have tumour that bleeds<br />Tell your doctor if any of the above applies to you before this medicine is used.<br />Warnings and Precautions<br />Talk to your doctor, pharmacist or nurse before using Cartinum if you<br />&bull; are pregnant or if there is a chance you may be pregnant<br />&bull; are breastfeeding<br />&bull; have mild renal disease. Your doctor will want to monitor you more regularly<br />&bull; are elderly (over 65 years old)<br />&bull; have been treated with Cisplatin or similar anticancer medicines in the past, Carboplatin may cause abnormalities<br />in your nervous system, such as pins and needles or hearing and vision problems. Your doctor may regularly<br />assess you<br />&bull; have headache, altered mental functioning, seizures and abnormal vision from blurriness to vision loss, tell your doctor<br />&bull; develop extreme tiredness and shortness of breath with decreased number of red blood cells (symptoms of<br />haemolytic anaemia), alone or combined with low platelet count, abnormal bruising (thrombocytopenia) and<br />kidney disease where you pass little or no urine (symptoms of Haemolytic-Uraemic Syndrome), tell your doctor<br />&bull; have fever (temperature greater than or equal to 38&deg;C), or chills, which could be signs of infection, tell your<br />doctor immediately. You may be at risk of getting an infection of the blood<br />Other medicines and Cartinum<br />Special care is needed if you are taking/using other medicines as some could interact with Carboplatin, for example:<br />&bull; Medicines which can reduce the number of cells in your blood, at the same time as Carboplatin, may require<br />changes to the dosage and frequency of your Carboplatin treatment<br />&bull; Some antibiotics called aminoglycosides, Vancomycin or Capreomycin, at the same time as Carboplatin, may increase<br />the risk of kidney or hearing problems<br />&bull; Some water tablets (diuretics), at the same time as Carboplatin, may increase the risk of kidney or hearing problems<br />&bull; Live or live-attenuated vaccines (for yellow fever vaccine). see Section 2 - You should not be given Cartinum if you<br />&bull; Blood thinning medicines e.g. Warfarin, at the same time as Carboplatin, may require an increase in frequency<br />of blood coagulation monitoring<br />&bull; Phenytoin and Fosphenytoin (used to treat various types of convulsions and seizures), at the same time as<br />Carboplatin, may increase the risk of a seizure<br />&bull; Other medicines which decrease the activity of the immune system (e.g. Ciclosporin, Tacrolimus, Sirolimus and<br />other anticancer medicines)<br />Tell your doctor if you are taking, have recently taken or might take any other medicines, including medicines<br />obtained without a prescription.<br />During treatment with Carboplatin, you will be given medicines which help reduce a potentially life threatening<br />complication known as Tumour Lysis Syndrome, which is caused by chemical disturbances in the blood due to the<br />breakdown of dying cancer cells that release their content to the bloodstream.</p><p>Cartinum with Food and Drink<br />There is no known interaction between Carboplatin and alcohol. However you should check with your doctor as<br />Carboplatin may affect the liver&rsquo;s ability to cope with alcohol.<br />Pregnancy, Breastfeeding and Fertility<br />If you are pregnant, think you may be pregnant or are planning to have a baby or breastfeeding, ask your doctor or<br />pharmacist for advice before taking this medicine.<br />Pregnancy<br />Due to the possible risk of birth defects, female patients of childbearing potential should take contraceptive<br />measures before and during treatment with Carboplatin.<br />Breastfeeding<br />It is not known whether Carboplatin is excreted into the breast milk. Therefore, during treatment with Cartinum you<br />should discontinue breastfeeding.<br />Fertility<br />Men treated with this medicine are advised not to father a child during, and up to 6 months after treatment. Advice<br />on conservation of sperm should be sought prior to treatment because of the possibility of irreversible infertility.<br />Treatment with Carboplatin may temporarily or permanently reduce fertility in men and women. Tell your doctor if<br />you have concerns.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine will be given by infusion (drip) into a vein over 15-60 minutes.<br />Dose<br />Your doctor will work out the correct dose of Carboplatin for you and how often it must be given.<br />The dose will depend on your medical condition, your size and how well your kidneys are working. Your doctor will<br />tell how well your kidneys are working using blood or urine samples.<br />You will have regular blood tests after your dose of Carboplatin. You may also have checks for nerve damage and<br />hearing loss.<br />This medicine will be administered by a doctor or nurse.<br />There is likely to be about 4 weeks between each dose of Carboplatin<br />If you receive more Cartinum than you should<br />This medicine will be given to you in a hospital, under the supervision of a doctor. It is unlikely that you will be<br />given too much or too little, however, tell your doctor or nurse if you have any concerns.<br />If you stop using Cartinum<br />If you have any further question on the use of this product ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Carboplatin can cause side effects, although not everybody gets them.<br />Tell your doctor immediately if you notice any of the following, these are serious side effects. You may need<br />urgent medical attention:<br />&bull; Abnormal bruising, bleeding or signs of infection such as a sore throat and high temperature<br />&bull; Severe allergic reaction (anaphylaxis/anaphylactic reactions). You may experience a sudden itchy rash (hives),<br />swelling of the hands, feet, ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or<br />breathing), and you may feel you are going to faint<br />&bull; Muscle cramping, muscle weakness, confusion, visual loss or disturbances, irregular heartbeat, kidney failure or<br />abnormal blood test results (symptoms of Tumor Lysis Syndrome which can be caused by the rapid breakdown<br />of tumour cells) (see Section 2)<br />These are serious side effects. You may need urgent medical attention.<br />Very common (may affect more than 1 in 10 people)<br />&bull; Changes in your red and white blood cells and platelets (myelosuppression)<br />&bull; Tiredness, shortness of breath and paleness caused by anaemia (a condition in which there is a decreased number<br />of red blood cells which lead to tiredness)<br />&bull; Increase in the level of urea in your blood<br />&bull; Abnormal liver enzyme levels<br />&bull; Feeling sick (nausea) or being sick (vomiting)<br />&bull; Stomach pain and cramp<br />&bull; Decrease in the level of sodium, potassium, calcium and magnesium in your blood<br />&bull; Decrease in renal creatinine clearance<br />Common (may affect up to 1 in 10 people)<br />&bull; Unusual bruising or bleeding (haemorrhagic complications)<br />&bull; Reduced function of your kidneys<br />&bull; Diarrhoea or constipation<br />&bull; Ringing in the ears or changes in your hearing<br />&bull; Pins and needles (peripheral neuropathy)<br />&bull; Hair loss, skin disorders<br />&bull; Feeling unwell<br />&bull; Decreased serum levels of calcium<br />&bull; Flu-like symptoms<br />&bull; Loss or lack of bodily strength<br />&bull; Signs of infection such as fever or sore throat<br />&bull; Symptoms of severe allergic reaction include sudden wheeziness or tightness of chest, swelling of the eyelids,<br />face or lips, facial flushing, low blood pressure, rapid heart beat, hives, shortness of breath, dizziness and<br />anaphylactic shock<br />&bull; Tingling or numbness in your hands, feet, arms or legs<br />&bull; Burning or prickling sensation<br />&bull; Decreased bone and tendon reflex<br />&bull; Taste disturbance or loss of taste<br />&bull; Visual disturbances including temporary sight loss<br />&bull; Cardiovascular disorder<br />&bull; Lung disorders, scarring and thickening in the lungs with difficulties in breathing, sometimes fatal (interstitial<br />lung disease - a group of lung disorders in which the deep lung tissues become inflamed), difficulty breathing<br />&bull; Sore lips or mouth ulcers (mucous membrane disorders)<br />&bull; Pain or discomfort in your bones, joints, muscles, or surrounding structures (musculoskeletal disorder)<br />&bull; Conditions affecting the urinary and genital tracts (urogenital disorder)<br />&bull; Extreme tiredness/weakness (asthenia)<br />&bull; Increase in the level of the creatinine, bilirubin and uric acid in your blood which may lead to gout. Your doctor<br />may want to monitor you<br />&bull; Itchy skin rash (urticaria)<br />&bull; Feeling itchy (pruritus)<br />&bull; Red rash (rash erythematous)</p><p>Rare (may affect up to 1 in 1,000 people)<br />&bull; Temporary sight loss<br />&bull; Feeling unwell with high temperature due to low levels of white blood cells (febrile neutropenia)<br />Very rare (may affect up to 1 in 10,000 people)<br />&bull; Scarring of the lungs which causes shortness of breath and/or cough (pulmonary fibrosis)<br />Not known (frequency cannot be estimated from the available data)<br />&bull; Haemolytic-Uraemic Syndrome (a disease characterized by acute renal failure/low urine output/or no urine output,<br />decreased number of red blood cells with extreme tiredness and low platelet count)<br />&bull; Abnormal bruising or bleeding and signs of infection<br />&bull; Dry mouth, tiredness, and headache due to excessive loss of body water (dehydration)<br />&bull; Sore lips or mouth ulcers (stomatitis)<br />&bull; Muscle cramping, muscle weakness, confusion, visual loss or disturbances, irregular heartbeat, kidney failure or<br />abnormal blood test results (symptoms of Tumor Lysis Syndrome which can be caused by the rapid breakdown of<br />tumour cells) (see Section 2)<br />&bull; Cancers caused by treatment with Carboplatin (secondary malignancies)<br />&bull; Loss of appetite, anorexia<br />&bull; Stroke</p><p>Severely impaired liver function, damage or death of liver cells<br />&bull; Heart failure<br />&bull; Obstruction in blood vessel (embolism)<br />&bull; Changes in blood pressure (hypertension or hypotension)<br />&bull; Skin disorders such as hives, rash, skin redness (erythema), and itching<br />&bull; Swelling or soreness where the injection was given<br />&bull; A group of symptoms such as headache, altered mental functioning, seizures and abnormal vision from blurriness to<br />vision loss (symptoms of reversible posterior leukoencephalopathy syndrome, a rare neurological disorder)<br />&bull; Lancreatitis<br />&bull; Lung infection<br />Carboplatin may lead to problems with your blood, liver and kidneys. Your doctor will take blood samples to check for<br />these problems.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in<br />this leaflet. You can also report the side effects directly to the National Pharmacovigilance Centre (NPC) (see Section 6).<br />By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of sight and reach of children.<br />Do not store above 30&deg;C. Do not refrigerate or freeze.<br />Keep vial in the outer carton in order to protect from light.<br />Do not use this medicine after the expiry date which is stated on the pack. The expiry date refers to the last day of that<br />month.<br />This product is a concentrate and must be diluted before use.<br />After first opening the product should be used immediately.<br />This product is for single-dose use only. Discard any unused portion.<br />After dilution<br />Chemical and physical in-use stability has been demonstrated for 24 hours at room temperature and 30 hours at 2˚C<br />to 8˚C.<br />From a microbiological point of view, the product should be used immediately. If not used immediately, in-use<br />storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24<br />hours at 2˚C to 8˚C, unless dilution has taken place in controlled and validated aseptic condition.<br />Do not throw any medicines via wastewater or household waste. Ask your pharmacist how to throw away<br />medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Cartinum contains<br />The active substance is Carboplatin.<br />Each ml contains 10mg Carboplatin.<br />One vial of 5ml of concentrate contains 50mg of Carboplatin<br />One vial of 15ml of concentrate contains 150mg of Carboplatin<br />One vial of 45ml of concentrate contains 450mg of Carboplatin<br />One vial of 60ml of concentrate contains 600mg of Carboplatin<br />The other ingredient is water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cartinum is a clear, colourless to slightly pale yellow solution free from particles.
Pack sizes:
1 × 5ml vial (50mg/5ml)
1 × 15ml vial (150mg/15ml)
1 × 45ml vial (450mg/45ml)
1 × 60ml vial (600mg/60ml)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder (MAH):<br />Accord Healthcare Limited<br />Sage House, 319 Pinner Road, North Harrow,<br />Middlesex HA1 4HF, United Kingdom.<br />Manufactured for Accord Healthcare Limited by:<br />Intas Pharmaceuticals Limited<br />Ahmedabad, Gujarat State, India.<br />For any information about this medicinal product, please contact the local representative of the MAH:<br />Accord Healthcare KSA Scientific Office<br />At Zimmo Trading Company Ltd.<br />Riyadh, Olaya, Al-Arfaj Street,<br />Branched from Abdulmalik Bin Marwan Street,<br />Behind Ministry of Interior, Atlas building, office No. 1<br />Tel: +966-11-217-0140<br />E-mail: mena-pv@accord-healthcare.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                07/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي كارتينوم على كاربوبلاتين، الذي ينتمي لمجموعة من الأدوية تعرف باسم مركبات البلاتين المتوافقة (متناسقة الترابط)، والتي تستخدم لعلاج مرض السرطان.<br />يستخدم كارتينوم لعلاج الحالات المتقدمة من سرطان المبيض وسرطان الخلايا الصغيرة في الرئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب عدم استخدام كارتينوم إذا<br />( &bull; كنت تُعَاني من حساسية تجاه كاربوبلاتين أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم ٦<br />&bull; كنت تُعَاني من حساسية تجاه أي دواء آخر ينتمي إلى مجموعة الأدوية التي تحتوي على مركبات البلاتين<br />&bull; كنت تُعَاني من مشاكل حادة بالكُلى (تصفية الكرياتينين تساوي أو أقل من ۳۰ ملليلتر/دقيقة)<br />&bull; كنت تخطط لتلقي تطعيم ضد الحمى الصفراء أو تلقيت التطعيم مؤخرًا<br />&bull; كان عدد خلايا الدم أقل من المعتاد (سوف يتحقق طبيبك المعالج من ذلك عن طريق إجراء فحص للدم)<br />&bull; كنت تُعاني من ورم نزيفي<br />أخبر طبيبك المعالج قبل استخدام هذا الدواء إذا انطبق عليك أيَّ مما سبق.<br />تحذيرات واحتياطات<br />أخبر طبيبك المعالج، الصيدلي أو الممرض قبل استخدام كارتينوم إذا<br />&bull; كنتِ حاملًا أو إذا كانت هناك فرصة لحدوث حمل<br />&bull; كنتِ ترضعين رضاعة طبيعية<br />&bull; كنت تعاني من مرض كلوي معتدل، فقد يرغب طبيبك المعالج في متابعة حالتك بانتظام<br />&bull; كنت من المرضى كبار السن ( ٦٥ عامًا فأكثر)<br />&bull; قد تم علاجك من قبل بدواء سيسبلاتين أو أدوية مماثلة مضادة لمرض السرطان، حيث قد يتسبب كاربوبلاتين في حدوث خلل في الجهاز العصبي، مثل إحساس بوخز الإبر<br />والمسامير أو مشاكل بالسمع والبصر. قد يقوم طبيبك المعالج بتقييم حالتك بانتظام<br />&bull; كنت تعاني من صداع، تغير في الوظائف العقلية ونوبات تشنجية، واضطراب الرؤية الذي يتراوح بين عدم وضوحها إلى فقدانها تمامًا، ينبغي عليك إخبار الطبيب المعالج<br />بذلك الأمر<br />&bull; ظهرت عليك أعراض التعب الشديد وضيق التنفس مع انخفاض عدد خلايا الدم الحمراء (أعراض فقر الدم الانحلالي)، بمفردها أو مجتمعة مع انخفاض عدد الصفائح<br />الدموية، كدمات غير طبيعية (نقص الصفيحات) وأمراض الكُلى حيث يكون معدل البول قليل أو معدوم (أعراض متلازمة انحلال الدم اليوريمية)، ينبغي عليك إخبار طبيبك<br />المعالج<br />&bull; كنت تعاني من حمى (درجة حرارة أكبر من أو تساوي ۳۸ درجة مئوية)، أو قشعريرة، والتي يمكن أن تكون إحدى علامات العدوى، فأخبر طبيبك المعالج فورًا. حيث قد<br />تكون معرضًا لخطر الإصابة بعدوى الدم<br />الأدوية الأخرى مع كارتينوم<br />يحتاج الأمر إلى توخي الحذر خاصةً إذا كنت تتناول/تستخدم أدوية أخرى حيث يمكن أن يتفاعل بعضها مع كاربوبلاتين، مثل:<br />&bull; قد يتطلب تناول الأدوية التي يمكن أن تقلل عدد الخلايا في الدم، في نفس وقت استخدام كاربوبلاتين، تغييرات في الجرعة وتكرار العلاج باستخدام كاربوبلاتين الخاص بك<br />&bull; قد تزيد نسبة خطورة حدوث مشاكل بالكُلى والسمع عند استخدام كاربوبلاتين مصحوبًا بتناول بعض المضادات الحيوية التي تُعرف باسم الجليكوزيدات الأمينية، فانكوميسين<br />أو كابريومايسين<br />&bull; قد تزيد نسبة خطورة حدوث مشاكل بالكُلى والسمع عند استخدام كاربوبلاتين مصحوبًا بتناول بعض أقراص الماء (مدرات البول)<br />&bull; يجب عدم إعطاء كارتينوم في حالة تلقّي لقاحات حية أو لقاحات حية ضعيفة (لقاح الحمى الصفراء). انظر قسم ۲ - يجب عدم استخدام كارتينوم إذا<br />&bull; قد يزيد معدل تكرار مراقبة تخثر الدم، عند استخدام كاربوبلاتين مصحوبًا باستخدام الأدوية المسيلة للدم مثل وارفارين<br />&bull; قد يزداد خطر حدوث نوبة تشنجية عند استخدام كاربوبلاتين مصحوبًا باستخدام فينيتوين وفوسفينيتوين (المستخدمان لعلاج أنواع مختلفة من التشنجات والنوبات)<br />&bull; الأدوية الأخرى التي تقلل من نشاط الجهاز المناعي (على سبيل المثال سايكلوسبورين، تاكروليموس، سيروليموس وغيرها من الأدوية المعالجة للسرطان)<br />يُرجى إبلاغ طبيبك المعالج، الصيدلي أو الممرض إذا كنت تتناول أو تناولت مؤخرًا أية أدوية أخرى، بما في ذلك الأدوية التي حصلت عليها دون وصفة طبية.<br />سوف تتلقى أثناء العلاج باستخدام كاربوبلاتين، بعض الأدوية التي تساعد على الحد من حدوث المضاعفات المحتملة التي تهدد الحياة والمعروفة باسم متلازمة تحلل الورم،<br />والتي تسببها الاضطرابات الكيميائية في الدم بسبب تفتت الخلايا السرطانية الميتة التي تطلق محتواها في مجرى الدم.</p><p>كارتينوم مع الطعام والشراب<br />لا يوجد تفاعل معروف بين كاربوبلاتين والكحول. ومع ذلك، يجب عليك مراجعة طبيبك المعالج لأن كاربوبلاتين قد يؤثر على قدرة الكبد على التعامل مع الكحول.<br />الحمل، الرَّضاعة الطبيعية والخصوبة<br />إذا كنتِ حاملًا، تعتقدين أنكِ حامل أو تخططين لإنجاب طفل أو إذا كنتِ ترضعين رضاعة الطبيعة، فاستشيري طبيبك المعالجِ أو الصيدليِ قبل استخدام هذا الدَّواء.<br />الحمل<br />يجب على المرضى من الإناث القادرات على الإنجاب استخدام وسائل منع الحمل قبل وأثناء العلاج باستخدام كاربوبلاتين وذلك بسبب الخطر المحتمل لحدوث عيوب خلقية.<br />الرضاعة الطبيعية<br />من غير المعلوم إذا كان كاربوبلاتين يُفرز في حليب الأم. لذلك، يجب التوقف عن الرضاعة الطبيعية عند العلاج باستخدام كارتينوم.<br />الخصوبة<br />يوصى المرضى من الرجال الذين يتم علاجهم بهذا الدواء بعدم الإنجاب خلال فترة العلاج وبعد العلاج لفترة تصل إلى ٦ أشهر. يجب على المرضى الذكور طلب المشورة<br />بشأن حفظ الحيوانات المنوية بالتجميد قبل العلاج نظرًا لاحتمالية حدوث عقم.<br />قد يقلل العلاج باستخدام كاربوبلاتين من معدل الخصوبة لدى الرجال والنساء للأبد. أخبر طبيبك المعالج إذا كنت تهتم لذلك.<br />القيادة واستخدام الآلات<br />قد يتسبب كاربوبلاتين في حدوث آثار جانبية مثل غثيان وقيء أو انخفاض القدرة على الإبصار أو تغيرات في الرؤية والسمع يمكن أن تؤثر على المشي والتوازن وقد يؤثر ذلك<br />على قدرتك على القيادة واستخدام الآلات. إذا حدث ذلك، فتجنب القيادة واستخدام أية آلات.<br />تحتوي سدادة العبوة الزجاجية على مطاط طبيعي جاف (مشتق من مادة اللاتكس) والتي قد تسبب حساسية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يتم إعطاء هذا الدواء عن طريق التسريب الوريدي (التنقيط) في الوريد لمدة 15 - 60 دقيقة</p><p>الجرعة<br />سوف يقوم طبيبك المعالج بتحديد جرعة كاربوبلاتين الملائمة لك وعدد مرات تكرارها.<br />تعتمد الجرعة على حالتك الطبية وحجمك وحالة الكليتين لديك. سيخبرك طبيبك المعالج بمدى كفاءة عمل كليتيك بناءً على فحص عينات الدم أو البول.<br />سوف تقوم بإجراء اختبارات الدم بانتظام بعد كل جرعة من كاربوبلاتين. قد تخضع أيضًا لفحوصات تلف الأعصاب وفقدان السمع.<br />سيتم إعطاؤك هذا الدواء من قِبَل طبيبك المعالج أو الممرض.<br />من المرجح أن تكون الفترة بين كل جرعة من كاربوبلاتين حوالي ٤ أسابيع.</p><p>إذا تم إعطاء كمية أكثر مما يجب من كارتينوم<br />سوف يتم إعطاء هذا الدواء في المستشفى تحت إشراف طبي دائمًا. من غير المُرجح أن يتم إعطاؤك كمية كبيرة جدا أو كمية قليلة جدًا من هذا الدواء، لكن أخبر طبيبك المعالج 􀌒 سوف يتم إعطاء هذا الدواء في المستشفى تحت إشراف&nbsp;أو الممرض إذا كانت تساورك أية شكوك.<br />إذا توقفت عن استخدام كارتينوم<br />إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء، فاستشر طبيبك المعالج، الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد يسبب كاربوبلاتين، مثل كافة الأدوية، آثارًا جانبية على الرغم من عدم حدوثها للجميع.<br />ا من الآثار الجانبية التالية، هذه آثار جانبية خطيرة. فقد تحتاج إلى رعاية طبية 􀌒 أخبر طبيبك المعالج فورًا إذا لاحظت أي<br />عاجلة:<br />&bull; كدمات غير طبيعية أو نزيف أو علامات عدوى مثل التهاب الحلق وارتفاع درجة الحرارة<br />&bull; تفاعلات حساسية شديدة (فرط الحساسية / تفاعلات تأقية). قد تتعرض لطفح جلدي مفاجئ مصحوب بحكة (شري)، تورُّم اليدين أو القدمين أو الكاحلين أو الوجه أو الشفتين<br />أو الفم أو الحَلْق (مما قد يُسَبب صعوبة في البلع أو التنفس) وقد تشعر بأنك على وشك التعرض للإغماء<br />&bull; تشنج عضلي أو ضعف العضلات أو ارتباك أو فقدان البصر أو اضطرابات الرؤية أو عدم انتظام ضربات القلب أو فشل كلوي أو تغيرات في نتائج اختبارات الدم (أعراض<br />( متلازمة تحلل الورم التي يمكن أن تحدث بسبب التهالك السريع للخلايا الورمية) (انظر قسم ۲<br />تعد هذه آثار جانبية خطيرة. قد تحتاج إلى رعاية طبية عاجلة.<br />دا (قد تُؤثر على أكثر من شخص واحد من بين كل ۱۰ أشخاص) 􀌒 آثار جانبية شائعة ج<br />&bull; تغيرات في خلايا الدم الحمراء والبيضاء والصفائح الدموية (كَبْتُ النخاع العظمي &quot; كَبْتُ النِّقْي&quot;)<br />&bull; إرهاق، ضيق في التنفس وشحوب ناجم عن فقر الدم (وهي الحالة التي يكون فيها عدد خلايا الدم الحمراء قليلة مما يؤدي إلى الشعور بالتعب)<br />&bull; ارتفاع مستوى اليوريا في الدم<br />&bull; نتائج غير طبيعية باختبارات مستويات انزيم الكبد<br />&bull; شعور بالإعياء (غثيان) أو حدوث إعياء (قيء)<br />&bull; ألم في المعدة ومغص حاد<br />&bull; انخفاض مستوى الصوديوم والبوتاسيوم والكالسيوم والماغنيسيوم في الدم<br />&bull; انخفاض تَصْفِيَة الكلي للكرياتينين</p><p>أثار جانبية شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ۱۰ أشخاص)<br />&bull; إصابة غير طبيعية بكدمات أو نزيف (مضاعفات نزفية)<br />&bull; انخفاض وظيفة الكُلى<br />&bull; إسهال أو إمساك<br />&bull; طنين بالأذنين أو تغيرات في السمع<br />&bull; شعور بوخز وشكشكة (اعتلال الأعصاب الطرفية)<br />&bull; تساقط الشعر، اضطرابات جلدية<br />&bull; شعور بالإعياء (توعُّك)<br />&bull; انخفاض مستويات الكالسيوم في مصل الدم<br />&bull; أعراض شبيهة بأعراض الأنفلونزا<br />&bull; فقدان أو ضعف القوة الجسدية<br />&bull; علامات حدوث عدوى مثل الحُمى أو التهاب الحلق<br />&bull; أعراض الحساسية الشديدة تتضمن أزيز مفاجئ أو ضيق بالصدر، تورم الجفون أو الوجه أو الشفتين أو احمرار الوجه، انخفاض ضغط الدم، سرعة ضربات القلب، حكة<br />(شَرَى)، ضيق تنفس، دوخة وصدمة تأقية<br />&bull; وخز أو خدر في اليدين والقدمين والذراعين أو الساقين<br />&bull; حرقة أو شعور بتنميل<br />&bull; فقدان كثافة العظام والمُنْعَكَسُ الوَتَرِيّ<br />&bull; اضطراب في حاسة التذوق أو فقدان الاحساس بالطعم<br />&bull; اضطرابات بصرية بما في ذلك فقدان مؤقت للبصر<br />&bull; اضطرابات القلب والأوعية الدَّموية<br />&bull; اضطرابات بالرئة، ندب وتضخم في الرئتين مع صعوبات في التنفس، أحيانًا تحدث إصابة خطرة (مرض الرئة الخلالي - وهو مجموعة من الاضطرابات تكون فيها<br />الأنسجة العميقة في الرئة ملتهبة)، صعوبة في التنفس<br />&bull; التهاب الشفتين أو تقرح الفم (اضطرابات الأغشية المخاطية)<br />&bull; ألم أو عدم الشعور بالراحة في العظام أو المفاصل أو العضلات أو الهياكل المحيطة (اضطراب العضلات والعظام)<br />&bull; حالات تؤثر على المسالك البولية والتناسلية (اضطراب الجهاز البولي التناسلي)<br />&bull; تعب شديد/ ضعف (وهن)<br />&bull; زيادة مستوى الكرياتينين والبيليروبين وحامض اليوريك في الدم الذي قد يؤدي إلى النقرس. قد يرغب طبيبك المعالج في مراقبتك<br />&bull; طفح جلدي مصحوب بحكة (شرى)<br />&bull; شعور بحكة (حُكَاك)<br />&bull; طفح أحمر (طفح جلدي حُمَامي)</p><p>آثار جانبية نادرة (قد تُؤثر على ما يصل إلى شخص واحد من كل ۱٫۰۰۰ شخص)<br />&bull; فقدان مؤقت للبصر<br />&bull; شعور بالتوعك مع ارتفاع درجة الحرارة بسبب انخفاض مستويات خلايا الدم البيضاء (قلة العدلات الحموية)<br />دا (قد تؤثر على ما يصل إلى شخص واحد من كل ۱۰٫۰۰۰ شخص) 􀌒 آثار جانبية نادرة ج<br />&bull; ندب في الرئتين مما يسبب ضيقًا في التنفس و/أو سعال (تليف رئوي)<br />آثار جانبية غير معروف معدل تكرارها (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)<br />&bull; متلازمة انحلال الدم اليوريمي (وهو مرض يتميز بالفشل الكلوي الحاد/انخفاض إدرار البول/أو عدم وجود إدرار للبول، وانخفاض عدد خلايا الدم الحمراء مع شعور بالتعب<br />الشديد وانخفاض عدد الصفائح الدموية)<br />&bull; كدمات غير طبيعية أو نزيف وعلامات الإصابة بالعدوى<br />&bull; جفاف الفم، تعب، صداع بسبب الفقدان المفرط للمياه بالجسم (الجفاف)<br />&bull; التهاب الشفتين أو تقرح الفم (التهاب الفم)<br />&bull; تشنج عضلي أو ضعف العضلات أو ارتباك أو فقدان البصر أو اضطرابات الرؤية أو عدم انتظام ضربات القلب أو فشل كلوي أو تغيرات في نتائج اختبارات الدم (أعراض<br />( متلازمة تحلل الورم التي يمكن أن تحدث بسبب التهالك السريع للخلايا الورمية) (انظر قسم ۲<br />&bull; سرطان ناجم عن العلاج بالكاربوبلاتين (الأورام الخبيثة الثانوية)<br />&bull; فقدان الشهية (فقدان الشهية العصبي)<br />&bull; سكتة دماغية<br />&bull; ضعف شديد في وظائف الكبد أو تلف خلايا الكبد أو موتها<br />&bull; هبوط (فشل) القلب<br />&bull; انسداد في الأوعية الدموية (انسداد دموي)<br />&bull; تغيرات في ضغط الدم (ارتفاع أو انخفاض ضغط الدم)<br />&bull; اضطرابات الجلد مثل شرى وطفح جلدي واحمرار الجلد (الحُمامى) وحكة<br />&bull; تورم أو ألم في موضع الحقن<br />&bull; مجموعة من الأعراض مثل صداع، تغير الأداء العقلي، نوبات صرع، واضطراب الرؤية الذي يتراوح بين عدم وضوحها وفقدانها (أعراض متلازمة اعتلال الدماغ<br />الأيسر الخلفي القابل للانعكاس، وتعد اضطرابات عصبية نادرة)<br />&bull; التهاب البنكرياس<br />&bull; عدوى الرئة<br />قد يؤدي الحقن باستخدام كاربوبلاتين إلى حدوث مشاكل في الدم والكبد والكليتين. سوف يأخذ طبيبك المعالج عينات دم للتحقق من وجود هذه المشاكل.<br />الإبلاغ عن التأثيرات الجانبية<br />تحدث إلى طبيبك المعالج، الصيدلي أو الممرض في حال حدوث أيًا من الآثار الجانبية. يشمل ذلك أيًا من الآثار الجانبية المحتملة التي لم يتم ذكرها في هذه النشرة. يمكنك<br />الإبلاغ عن الآثار الجانبية مباشرةً إلى المركز الوطني للتيقظ (انظر قسم ٦). يمكنك المُساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء من خلال إبلاغك عن<br />الآثار الجانبية.<br />٥. كيفية حفظ</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدًا عن مرأى ومتناول الأطفال.<br />يُحفظ في درجة حرارة بحيث لا تتعدى ۳۰ درجة مئوية. لا يُوضع في الثلاجة ولا يجمد.<br />تُحفظ الزجاجة في العبوة الخارجية لحمايتها من الضوء.<br />يجب عدم استخدام هذا الدواء بعد انتهاء تاريخ الصلاحية الموضح على العبوة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من<br />الشهر المذكور.<br />يجب استخدام الدواء بعد فتحه مباشرةً.<br />يتوفر هذا الدواء على هيئة محلول مركز ، يجب أن يتم تخفيفه قبل الاستخدام مباشرة.<br />يجب استخدام الدواء مباشرة بعد فتح الفيال و تخفيف المحلول المركز.<br />زجاجة مفردة الجرعة. يجب التخلص من كميات الدواء المتبقية الغير مستخدمة.</p><p>تم التأكد من ثبات الاستخدام الكيميائي والفيزيائي لمدة ۲٤ ساعة بعد التخفيف عند حفظه في درجة حرارة الغرفة ولمدة ۳۰ ساعة بعد التخفيف عند حفظه في درجة حرارة من<br />۲ إلى ۸ درجة مئوية.<br />من الناحية الميكروبيولوجية، يجب استخدام المحلول المحضر فورًا. إذا لم يتم استخدامه فورًا، تكون فترة وظروف التخزين قبل الاستخدام مسئولية المستخدم وفي المعتاد يجب<br />ألا تزيد عن ۲٤ ساعة عند درجة حرارة ۲ إلى ۸ درجة مئوية، إلا إذا تم الإعداد في ظروف تعقيم مُحكمة مناسبة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ماهي محتويات كارتينوم<br />المادة الفعالة هي كاربوبلاتين.<br />يحتوي كل ملليلتر من المحلول المركز على ۱۰ ملغم كاربوبلاتين.<br />زجاجة واحدة ٥ ملليلتر من المحلول المركز تحتوي على ٥۰ ملغم كاربوبلاتين<br />زجاجة واحدة ۱٥ ملليلتر من المحلول المركز تحتوي على ۱٥۰ ملغم كاربوبلاتين<br />زجاجة واحدة ٤٥ ملليلتر من المحلول المركز تحتوي على ٤٥۰ ملغم كاربوبلاتين<br />زجاجة واحدة ٦۰ ملليلتر من المحلول المركز تحتوي على ٦۰۰ ملغم كاربوبلاتين<br />المكونات الأخرى: ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ما هو شكل كارتينوم وما هي محتويات العبوة<br />كارتينوم عبارة عن محلول شفاف عديم اللون إلى لون أصفر باهت خالٍ من الجزيئات.</p><p>زجاجة واحدة ٥ ملليلتر من المحلول المركز تحتوي على ٥۰ ملغم كاربوبلاتين<br />زجاجة واحدة ۱٥ ملليلتر من المحلول المركز تحتوي على ۱٥۰ ملغم كاربوبلاتين<br />زجاجة واحدة ٤٥ ملليلتر من المحلول المركز تحتوي على ٤٥۰ ملغم كاربوبلاتين<br />زجاجة واحدة ٦۰ ملليلتر من المحلول المركز تحتوي على ٦۰۰ ملغم كاربوبلاتين</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك التصريح بالتسويق:<br />أكورد هيلثكير ليمتد<br />سيج هاوس، ۳۱۹ طريق بينر، هارو الشمالية،<br />٤ اتش اف، المملكة المتحدة. ميدلسيكس اتش ايه ۱<br />صنع لصالح أكورد هيلثكير ليمتد بواسطة:<br />إنتاس المحدودة للصناعات الدوائية، أحمد أباد، ولاية جوجارات، الهند.<br />للحصول على أيّة معلومات بشأن هذا الدواء، يُرجى الاتصال بالممثل المحلي لمالك التصريح بالتسويق:<br />المكتب العلمي لشركة أكورد هيلثكير، المملكة العربية السعودية<br />في شركة زمو التجارية المحدودة<br />الرياض، العليا، شارع العرفج، متفرع من شارع عبد الملك بن مروان،<br />خلف وزارة الداخلية، مبنى أطلس، مكتب رقم ۱<br />+۹٦٦-۱۱-۲۱۷- هاتف: ۰۱٤۰<br />mena-pv@accord-healthcare.com: البريد الإلكتروني</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            07/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CartinumTM 10mg/ml Concentrate for Solution for Infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml contains 10mg Carboplatin.
One vial of 5ml of concentrate contains 50mg of Carboplatin
One vial of 15ml of concentrate contains 150mg of Carboplatin
One vial of 45ml of concentrate contains 450mg of Carboplatin
One vial of 60ml of concentrate contains 600mg of Carboplatin
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.
A clear, colourless to slightly pale yellow solution free from particles.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carboplatin is indicated for the treatment of:<br />1. Advanced Ovarian Carcinoma of Epithelial Origin in:<br /> first-line therapy<br /> second-line therapy, after other treatments have failed<br />2. Small Cell Carcinoma of the Lung</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dosage and Administration<br />Carboplatin should be used by the intravenous route only.<br />The recommended dosage of Carboplatin in previously untreated adult patients with normal kidney<br />function, i.e. creatinine clearance &gt; 60ml/min is 400mg/m2 given as a single short-term intravenous dose<br />administered by a 15 to 60 minutes infusion. Alternatively, the Calvert Formula shown below may be used<br />to determine dosage:</p><p>Dose (mg) = Target AUC (mg/ml x min) x [GFR ml/min + 25]<br />Target AUC Planned chemotherapy Patient treatment status<br />5-7 mg/ml.min single agent Carboplatin Previously untreated<br />4-6 mg/ml.min single agent Carboplatin Previously treated<br />4-6 mg/ml.min Carboplatin plus Cyclophosphamide Previously untreated<br />Note: With the Calvert Formula, the total dose of Carboplatin is calculated in mg, not mg/m2.<br />Calvert Formula should not be used in patients who have received extensive pre-treatment**.<br />**Patients are considered heavily pre-treated if they have received any of the following:<br /> Mitomycin C<br /> Nitrosourea<br /> Combination therapy with Doxorubicin/Cyclophosphamide/Cisplatin<br /> Combination therapy with 5 or more agents<br /> Radiotherapy &ge; 4,500 rad, focused on a 20 x 20cm field or on more than one field of therapy</p><p>Therapy should not be repeated until four weeks after the previous Carboplatin course and/or until the<br />neutrophil count is at least 2,000 cells/mm3 and the platelet count is at least 100,000 cells/mm3.<br />Reduction of the initial dosage by 20-25% is recommended for those patients who present with risk factors<br />such as prior myelosuppressive treatment and low performance status (ECOG-Zubrod 2-4 or Karnofsky<br />below 80).<br />Determination of the haematological nadir by weekly blood counts during the initial courses of treatment<br />with Carboplatin is recommended for future dosage adjustment and scheduling of Carboplatin.<br />Needles or intravenous sets containing aluminium parts that may come in contact with Carboplatin should<br />not be used for preparation or administration. Aluminium reacts with Carboplatin causing precipitate<br />formation and/or loss of potency.<br />The safety measures for dangerous substances are to be complied with preparation and administration.<br />Preparation must be carried out by personnel who have been trained in the safe use while wearing<br />protective gloves, face mask and protective clothes.<br />Impaired Renal Function<br />In patients with impaired renal function, dosage of Carboplatin should be reduced (refer to Calvert<br />Formula) and haematological nadirs and renal function monitored.</p><p>Patients with creatinine clearance values of less than 60ml/min are at increased risk of severe<br />myelosuppression. The frequency of severe leukopenia, neutropenia, or thrombocytopenia has been<br />maintained at about 25% with the following dosage recommendations:<br />Baseline creatinine clearance Initial dose (Day-1)<br />41-59ml/min 250mg/m2 I.V.<br />16-40ml/min 200mg/m2 I.V.<br />Insufficient data exist on the use of Carboplatin injection in patients with creatinine clearance of 15ml/min<br />or less to permit a recommendation for treatment.<br />All of the above dosing recommendations apply to the initial course of treatment. Subsequent dosages<br />should be adjusted according to the patient&#39;s tolerance and to the acceptable level of myelosuppression.<br />Combination therapy<br />The optimal use of Carboplatin in combination with other myelosuppressive agents requires dosage<br />adjustments according to the regimen and schedule to be adopted.<br />Elderly<br />In patients of more than 65 years of age, adjustment of the Carboplatin dose to the general condition and<br />renal function is necessary during the first and the subsequent therapeutic courses.<br />Paediatric population<br />The safety and efficacy of carboplatin in children has not yet been established. No data are available.<br />Method of administration<br />Dilution and Reconstitution<br />The product must be diluted prior to infusion, see Section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Carboplatin is contraindicated in:
 hypersensitivity to the active substance or to any of the excipients listed in Section 6.1
 patients with severe myelosuppression
 patients with pre-existing severe renal impairment (with creatinine clearance of ≤ 30ml/min), unless
in the judgment of the physician and patient, the possible benefits of treatment outweigh the risks
 patients with bleeding tumors
 concomitant use with yellow fever vaccine (see Section 4.5)
 patients with a history of severe allergic reaction to Carboplatin or other platinum-containing
compounds
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carboplatin is contraindicated in:<br /> hypersensitivity to the active substance or to any of the excipients listed in Section 6.1<br /> patients with severe myelosuppression<br /> patients with pre-existing severe renal impairment (with creatinine clearance of &le; 30ml/min), unless<br />in the judgment of the physician and patient, the possible benefits of treatment outweigh the risks<br /> patients with bleeding tumors<br /> concomitant use with yellow fever vaccine (see Section 4.5)<br /> patients with a history of severe allergic reaction to Carboplatin or other platinum-containing<br />compounds<br />Dosage adjustment may allow use in the presence of mild impairment (see Section 4.2).</p><p>Precautions<br />Carboplatin should be administered by individuals under the supervision of a qualified physician who is<br />experienced in the use of anti-neoplastic therapy. Blood counts as well as renal and hepatic function tests<br />must be done regularly and the drug should be discontinued if abnormal depression of the bone marrow<br />or abnormal renal or hepatic function is seen.<br />Diagnostic and treatment facilities should be readily available for management of therapy and possible<br />complications.<br />Warnings<br />Haematological toxicity<br />Leukopenia, neutropenia, and thrombocytopenia are dose-dependent and dose-limiting. Peripheral blood<br />counts should be monitored during Carboplatin treatment. This will monitor toxicity and help determine</p><p>the nadir and recovery of haematological parameters and assist in subsequent dosage adjustments. Median<br />day of nadir is day 21 in patients receiving single agent Carboplatin and day 15 in patients receiving<br />Carboplatin in combination with other chemotherapeutic agents.<br />In general, single intermittent courses of Carboplatin should not be repeated until leukocyte, neutrophil,<br />and platelet counts have returned to normal. Lowest levels of platelets are generally seen between days 14<br />and 21 of initial therapy. A greater reduction is seen in patients who previously received extensive<br />myelosuppressive chemotherapy. Lowest levels of white cells occur generally between days 14 and 28 of<br />initial therapy. If neutrophil levels fall below 2000 cells/mm3 or platelets are less than 100,000 cells/mm3<br />then postponement of Carboplatin therapy until bone barrow recovery is evident, should be considered.<br />This recovery usually takes 5 to 6 weeks.<br />Transfusions may be necessary and dosage reductions recommended for subsequent treatment.<br />Anaemia is frequent and cumulative requiring very rarely a transfusion.<br />Severity of myelosuppression is increased in patients with prior treatment (in particular with Cisplatin)<br />and/or impaired kidney function. Initial Carboplatin injection dosages in these groups of patients should<br />be appropriately reduced (see Section 4.2) and the effects carefully monitored through frequent blood<br />counts between courses. Carboplatin injection combination therapy with other myelosuppressive forms of<br />treatment must be planned very carefully with respect to dosages and timing in order to minimize additive<br />effects.<br />Supportive transfusional therapy may be required in patients who suffer severe myelosuppression.<br />Haemolytic anaemia with the presence of serologic drug-induced antibodies has been reported in patients<br />treated with Carboplatin. This event can be fatal.<br />Acute promyelocytic leukaemia and myelodysplastic syndrome (MDS)/ acute myeloid leukemia (AML)<br />have been reported years after therapy with Carboplatin and other antineoplastic treatments.<br />Hepatic and/or renal insufficiency<br />Renal and hepatic function impairment may be encountered with Carboplatin. Very high doses of<br />Carboplatin (&ge; 5 times single agent recommended dose) have resulted in severe abnormalities in hepatic<br />and/or renal function. It is not clear whether an appropriate hydration programme might overcome effects<br />on renal function. Dose reduction or discontinuation of therapy is required in the presence of moderate to<br />severe alteration in renal or hepatic function test (see Section 4.8).<br />In patients with impaired renal function, the effect of Carboplatin on the haematopoietic system is more<br />pronounced and longer-acting than in patients with normal renal function. In this risk group, therapy with<br />Carboplatin must be performed with special caution (see Section 4.2).</p><p>Although no clinical evidence on compounding nephrotoxicity has been accumulated, it is recommended<br />not to combine Carboplatin with aminoglycosides or other nephrotoxic compounds (see Section 4.5).<br />The incidence and severity of nephrotoxicity may increase in patients who have impaired kidney function<br />before carboplatin treatment. Impairment of renal function is more likely in patients who have previously<br />experienced nephrotoxicity as a result of Cisplatin therapy.<br />Venoocclusive liver disease<br />Cases of hepatic venoocclusive disease (sinusoidal obstruction syndrome) have been reported, some of<br />which were fatal. Patients should be monitored for signs and symptoms of abnormal liver function or<br />portal hypertension which do not obviously result from liver metastases.<br />Allergic reactions<br />As with other Platinum-based drugs, allergic reactions appearing most often during perfusion may occur<br />and necessitate discontinuation of the perfusion and an appropriate symptomatic treatment. Infrequent</p><p>allergic reactions to Carboplatin have been reported, e.g. erythematous rash, fever with no apparent cause<br />or pruritus. Rarely anaphylaxis, angio-oedema and anaphylactoid reactions including bronchospasm,<br />urticaria and facial oedema have occurred.<br />Patients should be observed carefully for possible allergic reactions and managed with appropriate<br />supportive therapy, including antihistamines, adrenaline and/or glucocorticoids. The occurrence and<br />severity of toxicity is likely to be greater in patients who have received extensive prior treatment for their<br />disease, have poor performance status and are advanced in years. Renal function parameters should be<br />assessed prior to, during and after Carboplatin therapy.<br />Cross reactions, sometimes fatal, have been reported with all the Platinum compounds (see Section 4.3<br />and Section 4.8).<br />The vial stopper contains dry natural rubber (a derivative of latex), which may cause allergic reactions.<br />Neurotoxicity<br />Although peripheral neurologic toxicity is generally common and mild, limited to paresthesia and decrease<br />of osteotendinous reflexes, its frequency is increased in patients older than 65 years and/or in patients<br />previously treated with Cisplatin. Monitoring and neurological examinations should be carried out at<br />regular intervals.<br />Visual disturbances, including loss of vision, have been reported after the use of Carboplatin injection in<br />doses higher than those recommended in patients with renal impairment. Vision appears to recover totally<br />or to a significant extent within weeks of stopping these high doses.<br />Ototoxicity<br />Auditory defects have been reported during Carboplatin therapy.<br />Ototoxicity in children<br />Ototoxicity may be more pronounced in children and is more likely seen in patients previously treated<br />with Cisplatin. Cases of hearing loss with a delayed onset have been reported in paediatric patients. A<br />long-term audiometric follow-up in this population is recommended.<br />Tumour Lysis Syndrome (TLS)<br />In post-marketing experience Tumour Lysis Syndrome (TLS) has been reported in patients following the<br />use of Carboplatin alone or in combination with other chemotherapeutic agents. Patient at high risk of<br />TLS, such as patients with high proliferative rate, high tumor burden, and high sensitivity to cytotoxic<br />agents, should be monitored closely and appropriate precaution taken.<br />Geriatric Use<br />In studies involving combination therapy with Carboplatin and Cyclophosphamide, elderly patients treated<br />with Carboplatin were more likely to develop severe thrombocytopenia than younger patients. Because<br />renal function is often decreased in the elderly, renal function should be considered when determining<br />dosage (see Section 4.2).<br />Vaccinations<br />Administration of live or live-attenuated vaccines in patients immunocompromised by chemotherapeutic<br />agents including Carboplatin, may result in serious or fatal infections. Vaccination with a live vaccine<br />should be avoided in patients receiving Carboplatin. Killed or inactivated vaccines may be administered;<br />however, the response to such vaccines may be diminished.<br />Myelosuppression<br />Myelosuppression as a result of Carboplatin treatment is closely related to the renal clearance of the drug.<br />Therefore, in patients with abnormal renal function, or who are receiving concomitant therapy with<br />nephrotoxic drugs, myelosuppression, especially thrombocytopenia, may be more severe and prolonged.</p><p>The occurrence, severity and protraction of toxicity is likely to be greater in patients who have received<br />extensive prior treatment with the drug for their disease or with Cisplatin, have poor performance status<br />and are advanced in years. Renal function parameters should be assessed prior to, during and after<br />Carboplatin therapy Initial Carboplatin dosages in these groups of patients should be appropriately<br />reduced (see Section 4.2) and the effects carefully monitored through frequent blood counts between<br />courses. Myelosuppressive effects may be additive to those of concomitant chemotherapy.<br />Peripheral blood counts (including platelets, white blood cells and haemoglobin) should be followed<br />during and after therapy. Combination therapy with other myelosuppressive drugs may require<br />modification of dosage/timing of schedules in order to minimize additive effects.<br />Carboplatin courses should not, in general, be reported more frequently than every 4 weeks in order to<br />ensure that the nadir in blood counts has occurred and there has been recovery to a satisfactory level.<br />Patients with severe and persistent myelosuppression are at high risk of infectious complications including<br />fatal outcomes (see Section 4.8). If any of these events occurs, Carboplatin should be interrupted and dose<br />modification or discontinuation should be considered.<br />Reversible Posterior Leukoencephalopathy Syndrome (RPLS)<br />Cases of Reversible Posterior Leukoencephalopathy Syndrome (RPLS) have been reported in patients<br />receiving Carboplatin in combination chemotherapy. RPLS is a rare, reversible after treatment<br />discontinuation, rapidly evolving neurological condition, which can include seizure, hypertension,<br />headache, confusion, blindness, and other visual and neurological disturbances (see Section 4.8).<br />Diagnosis of RPLS is based upon confirmation by brain imaging, preferably MRI (Magnetic Resonance<br />Imaging).<br />Haemolytic-Uraemic Syndrome (HUS)<br />Haemolytic-Uraemic Syndrome (HUS) is a life threatening side effect. Carboplatin should be discontinued<br />at the first signs of any evidence of microandiopathic haemolytic anaemia, such as rapidly falling<br />haemoglobin with concomitant thrombocytopaenia, elevation of serum bilirubin, serum creatine, blood<br />urea nitrogen, or LDH. Renal failure may not be reversible with discontinuation of therapy and dialysis<br />may be required.<br />Other<br />The carcinogenic potential of Carboplatin has not been studied but compounds with similar mechanisms<br />of action and mutagenicity have been reported to be carcinogenic (see Section 5.3). Safety and<br />effectiveness of Carboplatin administration in children are not proven. Carboplatin can cause nausea and<br />vomiting. Premedication with antiemetics has been reported to be useful in reducing the incidence and<br />intensity of these effects.<br />Aluminium containing equipment should not be used during preparation and administration of Carboplatin<br />(see Section 6.2). Aluminium reacts with Carboplatin injection causing precipitate formation and/or loss<br />of potency.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When combining Carboplatin with other myelosuppressive compounds or radiation therapy, the<br />myelosuppressive effect of Carboplatin and/or the other compounds may be more pronounced. Patients<br />receiving concomitant therapy with other nephrotoxic agents are likely to experience more severe and<br />prolonged myelotoxicity due to decreased renal clearance of Carboplatin.<br />Combination therapy with other myelosuppressive agents may require dose changes or rescheduling of<br />doses in order to minimize the additive myelosuppressive effects.</p><p>Concomitant use contraindicated<br /> Yellow fever vaccine: Risk of generalized vaccinal disease mortality (see Section 4.3.)<br />Concomitant use not recommended<br /> Live attenuated vaccines (except yellow fever): Risk of systemic, possible fatal disease. This is<br />increased in subjects who are already immunosuppressed by their underlying disease. Use inactivated<br />vaccine where this exist (poliomyelitis).<br /> Phenytoin, Fosphenytoin: Risk of exacerbation of convulsions (resulting from the decrease of<br />Phenytoin digestive absorption by the cytotoxic drug), risk of toxicity enhancement or loss of efficacy<br />of the cytotoxic drug (due to increased hepatic metabolism by Phenytoin).<br />Concomitant use to be taken into consideration<br /> Chelating agents - decreasing effect of Carboplatin<br /> Ciclosporin (and by extrapolation Tacrolimus and Sirolimus): Excessive immunosuppression with<br />risk of lymphoproliferation<br /> Aminoglycosides, Vancomycin, Capreomycin: The concomitant use of Carboplatin with<br />aminoglycosides, Vancomycin, Capreomycin should be taken into account due to the cumulative<br />nephrotoxicity and ear toxicity, particularly in patients with severe renal impairment.<br /> Loop diuretics: The concomitant use of Carboplatin with loop diuretic should be approached with<br />caution due taken into account due to the cumulative nephrotoxicity and ear ototoxicity.<br /> Due to increase of thrombotic risk in cases of tumoral diseases, the use of anticoagulative treatment<br />is frequent. The high intra-individual variability of the coagulability during diseases, and the<br />eventuality of interaction between oral anticoagulants and anticancer chemotherapy, may require, if<br />it is decided to treat patients with VKA, to increase the frequency of the control of the INR<br />monitoring. if a patient is treated with oral anticoagulants. Caution and more frequent INR monitoring<br />is recommended with concomitant treatment of warfarin with Carboplatin, as increased INR has been<br />reported.<br />Carboplatin may interact with aluminium to form a black precipitate. Needles, syringes, catheters or IV<br />administration sets that contain aluminium parts which may come into contact with Carboplatin, should<br />not be used for the preparation or administration of the drug.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Carboplatin can cause foetal harm when administered to a pregnant woman. Carboplatin has been shown<br />to be embryotoxic and teratogenic in rats receiving the drug during organogenesis. No controlled studies<br />in pregnant women have been conducted.<br />Safe use of Carboplatin in pregnancy has not been established. Both men and women receiving<br />Carboplatin should be informed of the potential risk of adverse effects on reproduction (see Section 5.3).<br />Women of childbearing potential should be fully informed of the potential hazard to the foetus should they<br />become pregnant during Carboplatin therapy. Carboplatin should not be used in pregnant women or<br />women of childbearing potential who might become pregnant unless the potential benefits to the mother<br />outweigh the possible risks to the foetus.<br />Breastfeeding<br />It is not known whether Carboplatin is excreted in breast milk.<br />To avoid possible harmful effects in the infant, breastfeeding must be stopped during Carboplatin therapy.<br />Fertility<br />Gonadal suppression resulting in amenorrhoea or azospermia may occur in patients receiving<br />antineoplastic therapy. These effects appear to be related to dose and length of therapy and may be<br />irreversible. Prediction of the degree of testicular or ovarian functional impairment is complicated by the<br />common use of combinations of several antineoplastics, which makes it difficult to assess the effects of<br />individual agents.</p><p>Men of sexually mature age treated with Carboplatin are advised not to further a child during treatment<br />and up to 6 months afterwards. Male patients should seek advice about sperm preservation prior to<br />initiation of the therapy because of the possibility of irreversible infertility due to therapy with Carboplatin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies of the effects on the ability to drive and use machines have been performed. However,<br />Carboplatin may cause nausea, vomiting, vision abnormalities and ototoxicity; therefore, patients should<br />be warned of the potential effect of these events on the ability to drive or to use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The frequency of adverse reactions reported is based on a cumulative database of 1,893 patients receiving<br />single agent Carboplatin injection and post-marketing experience.<br />The list is presented by system organ class, MedDRA preferred term, and frequency using the following<br />frequency categories:<br />Very common (&ge;1/10)<br />Common (&ge;1/100 to &lt;1/10)<br />Uncommon (&ge;1/1,000 to &lt;1/100)<br />Rare (&ge;1/10,000 to &lt;1/1,000)<br />Very rare (&lt;1/10,000)<br />Not known (cannot be estimated from the available data)</p><p>Blood and lymphatic system disorders<br />Myelosuppression is the dose-limiting toxicity of Carboplatin injection. In patients with normal baseline<br />values, thrombocytopenia with platelet counts below 50,000/mm3 occurs in 25% of patients, neutropenia<br />with granulocyte counts below 1,000/mm3 in 18% of patients, and leukopenia with WBC counts below<br />2,000/mm3 in 14% of patients. The nadir usually occurs on day 21. Myelosuppression can be worsened<br />by combination of Carboplatin injection with other myelosuppressive compounds or forms of treatment.<br />Myelotoxicity is more severe in previously treated patients, in particular in patients previously treated<br />with Cisplatin and in patients with impaired kidney function. Patients with poor performance status have<br />also experienced increased leukopenia and thrombocytopenia. These effects, although usually reversible,</p><p>have resulted in infectious and hemorrhagic complications in 4% and 5% of patients given Carboplatin<br />injection, respectively. These complications have led to death in less than 1% of patients.<br />Anaemia with haemoglobin values below 8g/dl has been observed in 15% of patients with normal baseline<br />values. The incidence of anaemia is increased with increasing exposure to Carboplatin injection.<br />Myelosuppression may be more severe and prolonged in patients with impaired renal function, extensive<br />prior treatment, poor performance status and age above 65.<br />At maximum tolerated dosages of Carboplatin administered as a single agent, thrombocytopenia, with<br />nadir platelet counts of less than 50 x 109/l, occurs in about a third of the patients. The nadir usually occurs<br />between days 14 and 21, with recovery within 35 days from the start of therapy.<br />Leukopenia has also occurred in approximately 20% of patients but its recovery from the day of nadir<br />(day 14-28) may be slower and usually occurs within 42 days from the start of therapy. Neutropenia with<br />granulocyte counts below 1 x 109/l occurs in approximately one fifth of patients. Haemoglobin values<br />below 9.5 mg/100ml have been observed in 48%of patients with normal baseline values.<br />Neoplasms benign, malignant and unspecified (including cysts and polyps)<br />Secondary acute malignancies after cytostatic combination therapies containing Carboplatin have been<br />reported.<br />Respiratory, thoracic and mediastinal disorders<br />Very rare: Pulmonary fibrosis manifested by tightness of the chest and dyspnoea. This should be<br />considered if a pulmonary hypersensitivity state is excluded (see General disorders below).<br />Gastrointestinal disorders<br />Vomiting occurs in 65% of patients, in one-third of whom it is severe. Nausea occurs in an additional<br />15%. Previously treated patients (in particular patients previously treated with Cisplatin) appear to be<br />more prone to vomiting. Nausea and vomiting are generally delayed until 6 to 12 hours after administration<br />of Carboplatin, are readily controlled or prevented with antiemetics and disappear within 24hours.<br />Vomiting is more likely when Carboplatin injection is given in combination with other emetogenic<br />compounds.<br />The other gastrointestinal complaints corresponded to pain in 8% of patients, diarrhoea, and constipation<br />in 6% of patients. Cramps have also been reported.<br />Nervous system disorders<br />Peripheral neuropathy (mainly paresthesias and decrease of osteotendinous reflexes) has occurred in 4%<br />of patients administered Carboplatin injection. Patients older than 65 years and patients previously treated<br />with Cisplatin, as well as those receiving prolonged treatment with Carboplatin injection, appear to be at<br />increased risk.<br />Clinically significant-sensory disturbances (ie, visual disturbances and taste modifications) have occurred<br />in 1% of patients.<br />The overall frequency of neurologic side effects seems to be increased in patients receiving Carboplatin<br />injection in combination. This may also be related to longer cumulative exposure. Parasthesias present<br />prior to treatment, especially if caused by cisplatin, may persist or worsen during Carboplatin therapy (See<br />Section 4.4).<br />Eye disorders<br />Visual disturbances, including sight loss, are usually associated with high dose therapy in renally impaired<br />patients.<br />Ear and labyrinth disorders<br />Very common: A subclinical decrease in hearing acuity in the high frequency range (4000-8000 Hz),</p><p>10<br />have resulted in infectious and hemorrhagic complications in 4% and 5% of patients given Carboplatin<br />injection, respectively. These complications have led to death in less than 1% of patients.<br />Anaemia with haemoglobin values below 8g/dl has been observed in 15% of patients with normal baseline<br />values. The incidence of anaemia is increased with increasing exposure to Carboplatin injection.<br />Myelosuppression may be more severe and prolonged in patients with impaired renal function, extensive<br />prior treatment, poor performance status and age above 65.<br />At maximum tolerated dosages of Carboplatin administered as a single agent, thrombocytopenia, with<br />nadir platelet counts of less than 50 x 109/l, occurs in about a third of the patients. The nadir usually occurs<br />between days 14 and 21, with recovery within 35 days from the start of therapy.<br />Leukopenia has also occurred in approximately 20% of patients but its recovery from the day of nadir<br />(day 14-28) may be slower and usually occurs within 42 days from the start of therapy. Neutropenia with<br />granulocyte counts below 1 x 109/l occurs in approximately one fifth of patients. Haemoglobin values<br />below 9.5 mg/100ml have been observed in 48%of patients with normal baseline values.<br />Neoplasms benign, malignant and unspecified (including cysts and polyps)<br />Secondary acute malignancies after cytostatic combination therapies containing Carboplatin have been<br />reported.<br />Respiratory, thoracic and mediastinal disorders<br />Very rare: Pulmonary fibrosis manifested by tightness of the chest and dyspnoea. This should be<br />considered if a pulmonary hypersensitivity state is excluded (see General disorders below).<br />Gastrointestinal disorders<br />Vomiting occurs in 65% of patients, in one-third of whom it is severe. Nausea occurs in an additional<br />15%. Previously treated patients (in particular patients previously treated with Cisplatin) appear to be<br />more prone to vomiting. Nausea and vomiting are generally delayed until 6 to 12 hours after administration<br />of Carboplatin, are readily controlled or prevented with antiemetics and disappear within 24hours.<br />Vomiting is more likely when Carboplatin injection is given in combination with other emetogenic<br />compounds.<br />The other gastrointestinal complaints corresponded to pain in 8% of patients, diarrhoea, and constipation<br />in 6% of patients. Cramps have also been reported.<br />Nervous system disorders<br />Peripheral neuropathy (mainly paresthesias and decrease of osteotendinous reflexes) has occurred in 4%<br />of patients administered Carboplatin injection. Patients older than 65 years and patients previously treated<br />with Cisplatin, as well as those receiving prolonged treatment with Carboplatin injection, appear to be at<br />increased risk.<br />Clinically significant-sensory disturbances (ie, visual disturbances and taste modifications) have occurred<br />in 1% of patients.<br />The overall frequency of neurologic side effects seems to be increased in patients receiving Carboplatin<br />injection in combination. This may also be related to longer cumulative exposure. Parasthesias present<br />prior to treatment, especially if caused by cisplatin, may persist or worsen during Carboplatin therapy (See<br />Section 4.4).<br />Eye disorders<br />Visual disturbances, including sight loss, are usually associated with high dose therapy in renally impaired<br />patients.<br />Ear and labyrinth disorders<br />Very common: A subclinical decrease in hearing acuity in the high frequency range (4000-8000 Hz),<br />11<br />determined by audiogram, occurred in 15% of patients. Very rare cases of hypoacusia have been reported.<br />Common: Tinnitus was also commonly reported. Hearing loss as a result of cisplatin therapy may give<br />rise to persistent or worsening symptoms. At higher than recommended doses, in common with other<br />ototoxic agents, clinically significant hearing loss has been reported to occur in paediatric patients when<br />Carboplatin is administered.<br />Hepatobiliary disorders<br />Modification of liver function in patients with normal baseline values was observed, including elevation<br />of total bilirubin in 5%, SGOT in 15%, and alkaline phosphatase in 24% of patients. These modifications<br />were generally mild and reversible in about one-half the patients.<br />In a limited series of patients receiving very high dosages of Carboplatin injection and autologous bone<br />marrow transplantation, severe elevation of liver function tests has occurred.<br />Cases of an acute, fulminant liver cell necrosis occurred after high-dose administration of Carboplatin.<br />Renal and urinary disorders<br />When given in usual doses, development of abnormal renal function has been uncommon, despite the fact<br />that Carboplatin injection has been administered without high-volume fluid hydration and/or forced<br />diuresis. Elevation of serum creatinine occurs in 6% of patients, elevation of blood urea nitrogen in 14%,<br />and of uric acid in 5% of patients. These are usually mild and are reversible in about one-half the patients.<br />Creatinine clearance has proven to be the most sensitive renal function measure in patients receiving<br />Carboplatin injection. Twenty-seven percent (27%) of patients who have a baseline value of 60ml/min or<br />greater, experience a reduction in creatinine clearance during Carboplatin injection therapy. Impairment<br />of renal function is more likely in patients who have previously experienced nephrotoxicity as a result of<br />Cisplatin therapy.<br />Very common: Renal toxicity is usually not dose-limiting in patients receiving Carboplatin, nor does it<br />require preventive measures such as high-volume fluid hydration or forced diuresis.<br />Common: Renal function impairment, as defined by a decrease in the creatinine clearance below<br />60ml/min.<br />Immune system disorders<br />Anaphylactic-type reactions, sometimes fatal, may occur in the minutes following injection of the product:<br />facial oedema, dyspnoea, tachycardia, low blood pressure, urticaria, anaphylactic shock, bronchospasm.<br />Fever with no apparent cause has also been reported.<br />Skin and subcutaneous tissue disorders<br />Erythematous rash, fever and pruritis have been observed. These were reactions similar to those seen after<br />Cisplatin therapy but in a few cases no cross-reactivity was present.<br />Investigations<br />Decreases in serum sodium, potassium, calcium, and magnesium occur in 29%, 20%, 22%, and 29% of<br />patients, respectively. In particular, cases of early hyponatraemia have been reported. The electrolyte<br />losses are minor and mostly take a course without any clinical symptoms.<br />Cardiac disorders<br />Isolated cases of cardiovascular incidents (cardiac insufficiency, embolism) as well as isolated cases of<br />cerebrovascular accidents have been reported.<br />General disorders and administration site conditions<br />Reactions at the site of injection (burning, pain, reddening, swelling, urticaria, necrosis in connection with<br />extravasation) have been reported.</p><p>Fever, chills and mucositis have occasionally been observed.<br />Hepatobiliary disorders<br />Very common: The alkaline phosphatase level is increased more frequently than SGOT, SGPT or total<br />bilirubin. The majority of these abnormalities regress spontaneously during the course of treatment.<br />Rare: Severe hepatic dysfunction (including acute liver necrosis) has been reported after administration of<br />higher than recommended carboplatin dosages.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows<br />continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are<br />asked to report any suspected adverse reactions to The National Pharmacovigilance Centre (NPC).<br />To report any side effect(s) in Saudi Arabia, please contact:<br />p<br />The National Pharmacovigilance Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Ext: 2317-2356-2340<br />SFDA Call Centre: 19999<br />E-mail : npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa/</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no known antidote for Carboplatin overdosage. No overdosage occurred during clinical trials. If<br />necessary, however, the patient may need supportive treatment relating to myelosuppression, renal,<br />hepatic and auditory function impairment. Reports of doses up to 1600mg/m2 indicate patients feeling<br />extremely ill with diarrhoea and alopecia developing. Use of higher than recommended doses of<br />Carboplatin has been associated with loss of vision (see Section 4.4).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agent, Platinum compounds<br />ATC group: L01X A02<br />Carboplatin is an antineoplastic agent. Its activity has been demonstrated against several murine and<br />human cell lines.<br />Carboplatin exhibited comparable activity to Cisplatin against a wide range of tumours regardless of<br />implant site.<br />Alkaline elution techniques and DNA binding studies have demonstrated the qualitatively similar modes<br />of action of Carboplatin and Cisplatin. Carboplatin, like Cisplatin, induces changes in the superhelical<br />conformation of DNA, which is consistent with a &ldquo;DNA shortening effect&rdquo;.<br />Paediatric patients: safety and efficacy in children have not been established</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Distribution<br />Repeated dosing during four consecutive days did not produce an accumulation of Platinum in plasma.<br />Biotransformation<br />After a 1-hour infusion (20-520mg/m2), plasma levels of total Platinum and free (ultra-filterable) platinum<br />decay biphasically following first order kinetics. For free platinum, the initial phase (t-alpha) half-life is<br />approximately 90 minutes and the later phase (t-beta) half-life approximately 6 hours. All free Platinum<br />is in the form of Carboplatin in the first 4 hours after administration.<br />Carboplatin is excreted primarily by glomerular filtration in urine, with recovery of 65% of a dose within<br />24 hours. Most of the drug is excreted within the first 6 hours. Approximately 32% of a given dose of<br />Carboplatin is excreted unchanged.<br />Protein binding of Carboplatin reaches 85-89% within 24 hours of administration, although during the<br />first 4 hours, only up to 29% of the dose is protein bound. Patients with poor renal function may require<br />dosage adjustments due to altered pharmacokinetics of Carboplatin.<br />Elimination<br />Carboplatin clearance has been reported to vary by 3- to 4- fold in paediatric patients (see Section 4.2 and<br />4.4). As for adult patients, literature data suggest that renal function may contribute to the variation in<br />Carboplatin clearance.<br />Linearity/non-linearity<br />Following administration of Carboplatin in man, linear relationships exist between dose and plasma<br />concentrations of total and free ultra-filterable Platinum. The area under the plasma concentration versus<br />time curve for total Platinum also shows a linear relationship with the dose when creatinine clearance &ge;<br />60ml/min.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carboplatin has been shown to be embryotoxic and teratogenic in rats. It is mutagenic in vivo and in vitro<br />and although the carcinogenic potential of Carboplatin has not been studied, compounds with similar<br />mechanisms of action and mutagenicity have been reported to be carcinogenic.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Water for Injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal product except those mentioned in Section<br />6.6.<br />Carboplatin may interact with Aluminium to form a black precipitate. Needles, syringes, catheters or<br />intravenous sets containing Aluminium parts that may come into contact with Carboplatin should not be<br />used for preparation or administration of Carboplatin. Precipitation can lead to a reduction of the<br />antineoplastic activity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24months
Shelf life after dilution
In use: Chemical and physical in-use stability has been demonstrated for 24 hours at room temperature
and 30 hours at 2°C to 8°C.
From a microbiological point of view, the product should be used immediately. If not used immediately,
in-use storage times and conditions prior to use are the responsibility of the user and would normally not
be longer than 24 hours at 2°C to 8°C, unless dilution has taken place in controlled and validated aseptic
conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of sight and reach of children.<br />Do not store above 30&deg;C. Do not refrigerate or freeze.<br />Keep vial in the outer carton in order to protect from light.<br />Do not use this medicine after the expiry date which is stated on the pack. The expiry date refers to the<br />last day of that month.<br />For storage conditions of the diluted medicinal product, see Section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cartinum 10mg/ml concentrate for Solution for Infusion is filled in Type-I amber glass vial sealed with<br />rubber stopper and flip-off cap.<br />Pack sizes:<br />1 &times; 5ml vial (50mg/5ml)<br />1 &times; 15ml vial (150mg/15ml)<br />1 X 45ml vial (450mg/45ml)<br />1 &times; 60ml vial (600mg/60ml)<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This product is for single-dose use only. Discard any unused portion.<br />Contamination<br />In the event of contact of Carboplatin with eyes or skin, wash affected area with copious amounts of water<br />or normal saline. A bland cream may be used to treat transient stinging of skin. Medical advice should be<br />sought if the eyes are affected.<br />Disposal<br />Any unused product or waste material should be disposed of in accordance with local requirement.<br />Dilution<br />The product must be diluted prior to infusion, with 5% dextrose solution or 0.9% sodium chloride solution,<br />to concentrates as low as 0.5mg/ml.<br />Special precautions for administration<br />This product is a concentrate and must be diluted before use. After first opening, the product should be<br />used immediately. Discard any unused portion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Accord Healthcare Limited
Sage House, 319, Pinner Road
North Harrow
Middlesex HA1 4HF
United Kingdom
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="data:image/png; base64,iVBORw0KGgoAAAANSUhEUgAACSMAAAZ2CAIAAADVZbb1AAAKQ2lDQ1BJQ0MgUHJvZmlsZQAAeJydU3dYk/cWPt/3ZQ9WQtjwsZdsgQAiI6wIyBBZohCSAGGEEBJAxYWIClYUFRGcSFXEgtUKSJ2I4qAouGdBiohai1VcOO4f3Ke1fXrv7e371/u855zn/M55zw&#x2B;AERImkeaiagA5UoU8Otgfj09IxMm9gAIVSOAEIBDmy8JnBcUAAPADeXh&#x2B;dLA//AGvbwACAHDVLiQSx&#x2B;H/g7pQJlcAIJEA4CIS5wsBkFIAyC5UyBQAyBgAsFOzZAoAlAAAbHl8QiIAqg0A7PRJPgUA2KmT3BcA2KIcqQgAjQEAmShHJAJAuwBgVYFSLALAwgCgrEAiLgTArgGAWbYyRwKAvQUAdo5YkA9AYACAmUIszAAgOAIAQx4TzQMgTAOgMNK/4KlfcIW4SAEAwMuVzZdL0jMUuJXQGnfy8ODiIeLCbLFCYRcpEGYJ5CKcl5sjE0jnA0zODAAAGvnRwf44P5Dn5uTh5mbnbO/0xaL&#x2B;a/BvIj4h8d/&#x2B;vIwCBAAQTs/v2l/l5dYDcMcBsHW/a6lbANpWAGjf&#x2B;V0z2wmgWgrQevmLeTj8QB6eoVDIPB0cCgsL7SViob0w44s&#x2B;/zPhb&#x2B;CLfvb8QB7&#x2B;23rwAHGaQJmtwKOD/XFhbnauUo7nywRCMW735yP&#x2B;x4V//Y4p0eI0sVwsFYrxWIm4UCJNx3m5UpFEIcmV4hLpfzLxH5b9CZN3DQCshk/ATrYHtctswH7uAQKLDljSdgBAfvMtjBoLkQAQZzQyefcAAJO/&#x2B;Y9AKwEAzZek4wAAvOgYXKiUF0zGCAAARKCBKrBBBwzBFKzADpzBHbzAFwJhBkRADCTAPBBCBuSAHAqhGJZBGVTAOtgEtbADGqARmuEQtMExOA3n4BJcgetwFwZgGJ7CGLyGCQRByAgTYSE6iBFijtgizggXmY4EImFINJKApCDpiBRRIsXIcqQCqUJqkV1II/ItchQ5jVxA&#x2B;pDbyCAyivyKvEcxlIGyUQPUAnVAuagfGorGoHPRdDQPXYCWomvRGrQePYC2oqfRS&#x2B;h1dAB9io5jgNExDmaM2WFcjIdFYIlYGibHFmPlWDVWjzVjHVg3dhUbwJ5h7wgkAouAE&#x2B;wIXoQQwmyCkJBHWExYQ6gl7CO0EroIVwmDhDHCJyKTqE&#x2B;0JXoS&#x2B;cR4YjqxkFhGrCbuIR4hniVeJw4TX5NIJA7JkuROCiElkDJJC0lrSNtILaRTpD7SEGmcTCbrkG3J3uQIsoCsIJeRt5APkE&#x2B;S&#x2B;8nD5LcUOsWI4kwJoiRSpJQSSjVlP&#x2B;UEpZ8yQpmgqlHNqZ7UCKqIOp9aSW2gdlAvU4epEzR1miXNmxZDy6Qto9XQmmlnafdoL&#x2B;l0ugndgx5Fl9CX0mvoB&#x2B;nn6YP0dwwNhg2Dx0hiKBlrGXsZpxi3GS&#x2B;ZTKYF05eZyFQw1zIbmWeYD5hvVVgq9ip8FZHKEpU6lVaVfpXnqlRVc1U/1XmqC1SrVQ&#x2B;rXlZ9pkZVs1DjqQnUFqvVqR1Vu6k2rs5Sd1KPUM9RX6O&#x2B;X/2C&#x2B;mMNsoaFRqCGSKNUY7fGGY0hFsYyZfFYQtZyVgPrLGuYTWJbsvnsTHYF&#x2B;xt2L3tMU0NzqmasZpFmneZxzQEOxrHg8DnZnErOIc4NznstAy0/LbHWaq1mrX6tN9p62r7aYu1y7Rbt69rvdXCdQJ0snfU6bTr3dQm6NrpRuoW623XP6j7TY&#x2B;t56Qn1yvUO6d3RR/Vt9KP1F&#x2B;rv1u/RHzcwNAg2kBlsMThj8MyQY&#x2B;hrmGm40fCE4agRy2i6kcRoo9FJoye4Ju6HZ&#x2B;M1eBc&#x2B;ZqxvHGKsNN5l3Gs8YWJpMtukxKTF5L4pzZRrmma60bTTdMzMyCzcrNisyeyOOdWca55hvtm82/yNhaVFnMVKizaLx5balnzLBZZNlvesmFY&#x2B;VnlW9VbXrEnWXOss623WV2xQG1ebDJs6m8u2qK2brcR2m23fFOIUjynSKfVTbtox7PzsCuya7AbtOfZh9iX2bfbPHcwcEh3WO3Q7fHJ0dcx2bHC866ThNMOpxKnD6VdnG2ehc53zNRemS5DLEpd2lxdTbaeKp26fesuV5RruutK10/Wjm7ub3K3ZbdTdzD3Ffav7TS6bG8ldwz3vQfTw91jicczjnaebp8LzkOcvXnZeWV77vR5Ps5wmntYwbcjbxFvgvct7YDo&#x2B;PWX6zukDPsY&#x2B;Ap96n4e&#x2B;pr4i3z2&#x2B;I37Wfpl&#x2B;B/ye&#x2B;zv6y/2P&#x2B;L/hefIW8U4FYAHBAeUBvYEagbMDawMfBJkEpQc1BY0FuwYvDD4VQgwJDVkfcpNvwBfyG/ljM9xnLJrRFcoInRVaG/owzCZMHtYRjobPCN8Qfm&#x2B;m&#x2B;UzpzLYIiOBHbIi4H2kZmRf5fRQpKjKqLupRtFN0cXT3LNas5Fn7Z72O8Y&#x2B;pjLk722q2cnZnrGpsUmxj7Ju4gLiquIF4h/hF8ZcSdBMkCe2J5MTYxD2J43MC52yaM5zkmlSWdGOu5dyiuRfm6c7Lnnc8WTVZkHw4hZgSl7I/5YMgQlAvGE/lp25NHRPyhJuFT0W&#x2B;oo2iUbG3uEo8kuadVpX2ON07fUP6aIZPRnXGMwlPUit5kRmSuSPzTVZE1t6sz9lx2S05lJyUnKNSDWmWtCvXMLcot09mKyuTDeR55m3KG5OHyvfkI/lz89sVbIVM0aO0Uq5QDhZML6greFsYW3i4SL1IWtQz32b&#x2B;6vkjC4IWfL2QsFC4sLPYuHhZ8eAiv0W7FiOLUxd3LjFdUrpkeGnw0n3LaMuylv1Q4lhSVfJqedzyjlKD0qWlQyuCVzSVqZTJy26u9Fq5YxVhlWRV72qX1VtWfyoXlV&#x2B;scKyorviwRrjm4ldOX9V89Xlt2treSrfK7etI66Trbqz3Wb&#x2B;vSr1qQdXQhvANrRvxjeUbX21K3nShemr1js20zcrNAzVhNe1bzLas2/KhNqP2ep1/XctW/a2rt77ZJtrWv913e/MOgx0VO97vlOy8tSt4V2u9RX31btLugt2PGmIbur/mft24R3dPxZ6Pe6V7B/ZF7&#x2B;tqdG9s3K&#x2B;/v7IJbVI2jR5IOnDlm4Bv2pvtmne1cFoqDsJB5cEn36Z8e&#x2B;NQ6KHOw9zDzd&#x2B;Zf7f1COtIeSvSOr91rC2jbaA9ob3v6IyjnR1eHUe&#x2B;t/9&#x2B;7zHjY3XHNY9XnqCdKD3x&#x2B;eSCk&#x2B;OnZKeenU4/PdSZ3Hn3TPyZa11RXb1nQ8&#x2B;ePxd07ky3X/fJ897nj13wvHD0Ivdi2yW3S609rj1HfnD94UivW2/rZffL7Vc8rnT0Tes70e/Tf/pqwNVz1/jXLl2feb3vxuwbt24m3Ry4Jbr1&#x2B;Hb27Rd3Cu5M3F16j3iv/L7a/eoH&#x2B;g/qf7T&#x2B;sWXAbeD4YMBgz8NZD&#x2B;8OCYee/pT/04fh0kfMR9UjRiONj50fHxsNGr3yZM6T4aeypxPPyn5W/3nrc6vn3/3i&#x2B;0vPWPzY8Av5i8&#x2B;/rnmp83Lvq6mvOscjxx&#x2B;8znk98ab8rc7bfe&#x2B;477rfx70fmSj8QP5Q89H6Y8en0E/3Pud8/vwv94Tz&#x2B;5fBhlYAAAAJcEhZcwAAHsMAAB7DAbyXl9oAACAASURBVHic7N09ru3IeS5gdrezqxk4sQFDiaDU6MCBcYegSSgzBNjDsAHBWU/CQ7hw3A4bSgQBUuIBGOgb9u0bLImi&#x2B;Fv8qkhWFZ8HJzi9z1ok11q79/4&#x2B;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&#x2B;AACgJV988dXnLz/&#x2B;&#x2B;MOzVwIAAAAAj/vixx9/fPoaAIAajaHaKRI4AAAAAN5D0gYAb7efqP3w/a9SDvLVT369/wAJHAAAAAD9kbQBwIsUCdVSfPm//i3ljOI3AAAAAJomaQOAPt0fqp0igQMAgNukrwyvFAeAsyRtANC8ykO1dIf9v7YfAAD27RTVO&#x2B;W0kXAAECZpA4CWdBOqnSKBAwCApVioVuT4Bc8CAK2TtAFApd4Zqp1i4C0AAC9xdah2ijocAKYkbQDwvJ1OtWCiNrQcqp2i8wcAoF1VhWrpTIAD4LUkbQBwn9umqQ2vCdXS6fwBAKhNo6HaKYbBAdA9SRsAXEKo1gqdPwAAN3hDqHaKOhyAbkjaACCXUK1LOn8AAGKEamGKcABaJGkDgBOEamj&#x2B;AQAYCdXuoQgHoGaSNgBYJ1QjnU3gAAC6J1SrjSIcgEpI2gBgr0Mrm6gNQrWXMfYWAKBFQrWmKcIBuJmkDYB3EapRA80/AEAlhGrvoQgH4CKSNgD6dOfaj4NQjUI0/wAA1xGqsaQCByCfpA2A5gnV6JvmHwDgLKEamRThAKSTtAHQEqEajDT/AACDUI0bqcABWCVpA6BSQjWI0f8DAL0SqlEnFTjAy0naAHjeTltSPFEbhGq8lTtTAEBDlC50wLcxwEtI2gC4lVANqmL4LQDwOGkEr6ICB&#x2B;iPpA2AqwjVoF36fwDgCkI12KICB2iXpA2AAoRq8BL6fwAgkVAN8im/AZogaQPghP0qX6gGr&#x2B;VWGgC8mUoAbiaBA6iKpA2AdUI1IJP&#x2B;HwD6I1SDmvk/FOARkjYA7l77cRCqwbtJ4ACgCW7ZQx&#x2B;U3wBXk7QBvItQDaiW23kA8BS/heGF/I8PUIqkDaBbQjWgD24BAEBBfrECO0yAAwiQtAH0QKgGvI1bAABwSKgGlOLnCcAOSRtAY4RqADvcAgDgnfwGpLj/82//OQzD//7nf3z4OqibHz4Ag6QNoFr3J2qDUA3ol1sAAHTDLzWu8MnVEonf2OfHFPA2kjaA5wnVAJ7iLgAANfN7iiucCtXSid845Gca0CtJG8CthGoA9bMJHAD3cwOai1yUqyUSv3FI7Q10QNIGcBWhGtzs3//xm/0H/NN//vKeK6FX7oECUIRfKFzk2VAtnfiNFH5UAg2RtAEUIFSD2xzGafuEbVzBXQAAtvgdwXVaydUSid9I5OcqUCFJG8A5tYVqf/c3fzv7yu/&#x2B;8PuLLgOelZOxCdh4hLsAAK/ixz6X6ixXSyR&#x2B;I5GfwMCzJG0Am7YKtesSteFkqLZD3kbfxtTtE6FNQ7hYqJYS44nrKMJdAIAO&#x2B;GHOpd4ZqqUTv5HOj2vgHpI2gGGoL1Qb/pSrfQKzxIztd3/4vSlucGgnVBuztP3gTeTGFdwFAKiTn89cTa5WhPiNdH6wA8VJ2oB3eWTtxyFhptqYh52auLYkV4Md9nijRW4EANzGj1yuJlS7mfiNU/wWAMIkbUC3KgzVhmH4u7/522kYlpOrCdVg3ydXm8VjiWFbIFQzDY6buREAkMNPUW4gV6uT&#x2B;I2ztn5l&#x2B;H0BjCRtQA9qDtUy56itkrFBwBi8rUZiZ5Mw0&#x2B;OokxvHAEt&#x2B;NnIDoVrrxG&#x2B;c5ZcLMCVpAxpTbai286/peZsIDQ7NIq5HIquzMZtcjce5EQC8hB93PELM1gdhG0X4TQTvJGkD6rVVnVyaqA1HodqQsOTjJzBbPmzr69N/BUaxeWNFYq3MKWvhy9g6r6yOi7gRALTLTzBqJntrhXSNe/idBd2TtAFVaDdU27eM1sRpsCWcqxWc5XZ4DVunW90TLv90&#x2B;1cSfi4cshcFUBU3KOmA7K0GcjVq4xccdEPSBtytzlDt7PyzRHI12PfU1LFE4&#x2B;WNZ7ku1ds6xfIs//6P34jZeMT0N7jOH7iIe4484qn6Svx2Kbka7TLuDZojaQOu8tSGasPJUC19E7UdEjVINI2RdrKlqfy7Hikz1TJPcXjq5WS4dHI1nrL8Vf75Df7VT36tyQfyCdV4XEp5dnMlJnsLk6vRvcT7bIerNwFXkLQBBTQRqhVJ1AahGiRYTgXbesD&#x2B;w3JOHVb2ZsrsrUgM3kRrPGUrWpuRtAFnCdV4XNNjnsRvS3I1Hpd&#x2B;i6nUfaT/93//efXrX/3k16tfHyt52RvcQNIGnFNtqDYlUYPbrO5PFriRkXkLI7zHW85J8x1GknC1xGhtRtIG7BCq8bimQ7VEb8ve5Go8azaMe/nFma3tSM7eaNqK1lJsxW/DMPzw/a9kb1CcpA3Y9NSGasO9oZpEDcLO3sWYLRd59l7G7FmPpGvXzcaDe8SitRlJG/AhVONxj4Rq1Q6W6iZ&#x2B;k6tRg8Dtpv21lFLuPuVEa4lmCZzf11CKpA0YhupDtSJz1JZkbJAuZauzm7dbS5lIFz5pOESE2hSJ1mYkbfBCQjUe92yodtHxr9ZE9iZXoyqn1oTcf3Al0drHcorbD9//SlUPBUna4HVqDtUuStQGoRqcsbyhEFgcslTEtXqcwysMy9nmreabLLzK6i/6sr/l9eTQN6Eaj8sJ1XImnCWOG2t9t91n4ze5GpV4akj3s9Ha8jF&#x2B;s0MpkjboWc2h2qrVQudwlNDswYHzwkVWm9iGesvEexyxGwqBCWrL88ZWoUw8fsoF5B8E8t0Qrc3oyaEbQjWetTV86oZFwqeniJ20p1Lwuuytod6Htzm79dqq&#x2B;metHT7Fr3soRdIGnag8VJsVK8u9YWfVyWFxI1GjQuEGtf7&#x2B;M38vitVI7M7bGaeGHi/vvHy&#x2B;2NP9FJp2f7Q2oyeHFgnVeNZqqBYeenX1gpClzrVz9voLy0B3U39fwzul5GerYdvhzatVNUdryyOoAaAUSRs0ZqdDrjNUS7EsaARpVO6GFVd6alMDo5LvvHsyPel161JCjsejtRk9OVROqEY9nlpIIL/&#x2B;zIzETl1AQwXntA/qqWGhG/lrQgbuRzUUrS0PqDCAUiRtUK8Hp6kNR6HaFetZj2OFxGzUppKNxJtoZQNjhFM2Zit4xv2LKXUoyFRbtDajJ4d6CNWoSmZhVrAYS6wwMwvR1YNs2Z&#x2B;xpxCFgOL3phLvR7UbrS2Pr1qAUiRtUIWaQ7WP9OUcT83KhwpVkqulqDx7S9xr7epTXHRqKKvyaG1GTw6PEKrRikv3&#x2B;j08y6WB1uFL21&#x2B;WvMg1wGtl5mq/&#x2B;8PvV4/Q2YKQZ0&#x2B;nhIBSJG1wt8pDtf3CZaxLlmtVLx85O6B0jTo1lKulqDB7K7UXhVCNzrQVrc3oyeFqWy2D//VoS5EFGFfX9040PW9gz93DjeL2L0wJCjmemq/20Wu0tjy70gJKkbTB3ZZt80W/RFNmqs1s7fKakqjtPB3q0VmulqLC7C1FkfspUJWmo7UZPTkUJFSjEtPqq4aC6qlqMHbeGt4x6MnWbaiteWlbD04/40uitRlVPRQkaYO7ffHFV9NfokV&#x2B;xQZCtS2nBg2J06jcC3O1FLVlbyar0aueorUZPTnECNWoR8pkrHFK2VBulYLAxRwKXNL0pR1ez87x948DJCo7fe1te63lUNVDQZI2uNssaZs5/AVcMFSDzsjVcjwYvxk4TDeeXSD6TnpyOCRUoyr5UdalSdsosAta8bPMFpwse2pgeGhZyNtytY/Zzb1q2wFVPRQkaYO77SdtM8vgza9AGIRqt3gke0vc2R4q8Z5obUZPDlNCNSq3rK9mlVXZPGn1aPcEdcsLyKH&#x2B;hCIyc7XV5SLrj9aGRjoCVT0UJGmDu51K2qaWv7YHDTzvIFerRG3LTsL9XhutzejJebnljwL/R1CD/RFLKflTTraUnm&#x2B;VnSG3XL/Rdr/woGkqdmpPtS3pu5aI1gJU9VCQpA3uFk7aZgRv9Equ1hDZG90Tra3Sk/Nyqz8Z/E9BVS5ahnH1sNPkLFGpTEuoBs&#x2B;aBWmfVCx/ElviI0Vr&#x2B;VT1UJCkDe5WKmmbEbzRKLlaZ2RvtE60lkJPzsst63lLvtOrcIR2/w5n6buvAUWkJGrp09osCPkIVT0UJGmDu12UtM0I3qiWaO1VBG/UT7QWoCfn5Q7recEbLSqyvZlAC/qTvwLkUuLENdHa1VT1UJCkDe52T9I2I3ijNvK2NxCzUSfRWj49OS93tp4XvNGKU3utDWt7pF16oti5gLPC0do0P1tdWPKQaO1mqnooSNIGd3skaZsRvFEbwVsH5GpUS7RWnJ6cl8us5wVvtGKWh&#x2B;WnXGcDtuUTJW1QViBUO9yMLX2jtUG09jRVPRQkaYO71ZC0zQjeqJDsrX6iNaq1Fa0Nr&#x2B;&#x2B;lS9GT83Jl63nBG50psgrlIFSDa3wSsjEMK7IypGitXap6KEjSBnerMGmbEbxRIcHb4&#x2B;Rq1Ey0djM9OS93aT0veKNRhwHbmJxNH2lxSLhTfq52KlT7EK3VTFUPBUna4G71J20zgjfqJHu7lFyNyonWnqUn5&#x2B;XurOcFb7Tl1IS2WK62GsuFd4yDN1sGb7/7w&#x2B;/zl4UUrTVEVQ8FSdrgbs0lbTOrwdug56cCsrccojUqJ1qrip6cl3uwnhe80ZzM&#x2B;Wqx6E7wBqdspWuite6p6qEgSRvcrfWkbWordRv0/FRA8LZDrkb9RGs105PzcvXU84I3OlNkj7d/&#x2B;s9fStrgUqK1bqjqoSBJG9ytns68OMEblXtt9iZXowmitYboyXm5aut5wRtNi8Vs4jS4gWitV6p6KEjSBnertjMvTvBG/XrN3kRrNEG01i49OS/XSj0veKMDq/GbdA0udXOuNojWnqOqh4IkbXC3Vjrz4gRv1K/R4E2uRitEa93Qk/NyjdbzgjcAVonWXktVDwX91dMXALzFrGya1lWze69&#x2B;zfOUZWRVYfYmV6MhO9HaoJ0GuNeyGleEA7yTaA2gOEkb8AzBG02oIXsTrdEQ0RpAKw6Dt0EdDtAL0RrA1SRtQBUEb7RilnsVD97karRFtAbQh&#x2B;VPbJPeANp1f7Q2LNI1vQDwKpI2oEaCN1qRP&#x2B;lNtEZbRGsAL2G1SYCG1BCtDdoB4MUkbUADBG80ZD97k6vRHNEaAIPgDaAyojWAqkjagPYI3miLdI22iNYAOCR4A7iZaA2gZpI2oHmCN4AcojUAMgneAIoTrQE0RNIG9GZaBc5qRA0/wCBaA&#x2B;BigjeAANEaQLskbUDPdqa7DYI34DVEawA8SPAGsEq0BtANSRvwIoI34CX2o7VBOw3AcwRvwGuJ1gB6JWkD3kvwBnRDtAZAowRvQMdEawAvIWkD&#x2B;CPBG9AQ0RoAXRK8Ae16JFcbRGsAFZC0AawTvAFVEa0B8EKCN6BmojUAPiRtAEkEb8DNRGtk&#x2B;upf/vvzlx/&#x2B;9a&#x2B;fvRKAUgRvwLNEawCskrQBRAjegOJEa&#x2B;Qb07XlF&#x2B;VtQH8Eb8DVRGsApJC0ARQgeAMCRGvkW43Wdh4pbwM6JngD8onWAAiQtAGUdyp4G/T88BqiNYpIT9dWnytsA15C8AakEK0BkE/SBnC5abm8LKYHk96gX4fR2qCjJk1OugbAIHgD/kS0BkBxkjaAW&#x2B;1Pd/vQ80O7RGuUcl20ZlobwCB4gzcRrdG6aWugkoc6SdoAniR4g9aJ1ijo66&#x2B;/H4bhv/7hf56&#x2B;EIDXEbxBT56K1oZFU68RIGZn1J3dl6FOkjaAigjeoH6iNQr6RGv3M60NYJ/gDdpST7Q26AWIOrWmhXoeaiNpA6iX4A1qIFqjrKfSNQDCBG9QG9EaHchcLl7YBlWRtEGTfvqz//j85be/&#x2B;cWzV8KdBG9wD9EaxVWYrunMAcIEb3A/0Rp9KLsZs5Ie6iFpg7b99Gf/IWx7LcEblCJao7gKozUALiJ4gyuI1uhG2XQNqJOkDbpirtubCd4gnWiNK0jXABgEbxAlWqMbY1/wX//wP1efy7Q2qISkDaBPgjeYEq1xBdEaAIcEb7DqwVxtEK1xAa0BvJykDeAVBG&#x2B;8TUq0NuioOa&#x2B;nFtoAWID7Cd54LdEanamnL1DVQw0kbQBvNG0qVlO3QfBGa0RrXKeeLhqAzgje6Jhojf7oC4Atkjbgj7u7/fY3vxj/8vQVcauU6W6D4I36iNa4jhYagEcI3miaaI0uaQ2AFJI26McnJytyHGHbmwneqJZojUtpoYHbjHW7qpt9gjcqJ1qjS/oCIEDSBs0TjHEpwRsPEq1xKS00UA9rS5BC8MbjRGv0qvXWwFZt8DhJG3RuOtEtv3U3/BbBG5cSrXG11ltooG&#x2B;G0HGK4I0biNbolb4AKEvSBj0rtZ4kbBG8kUm0xg100UDlFO0UIXijCNEaHdMXANeRtMGLTAfJrvbzhtCSSfDGIdEaN9BCA41SjVOQ4I1EojU6pi8AbiNpg27tjI3d&#x2B;ifr1VCW4I0hOVobNNXk0UUDjTKhjXsI3hiJ1uibvgB4hKQNOrHTon/Cs88DDrO0/c3YM3M4Sd7LCd5eQrTGPbTQQGfUydzpMHgb1OEdEa3RPa0B8DhJG/TgopGw08OW6vyFbYwEb90QrXEbLTTQGRPaqMSySDPprWnPRmvDornTBVCcvgCojaQNuvLb3/xiq10f/2l8wHSu29Ls65&#x2B;EbPZcKCgWvA16/ieI1riTLhp4g1l1rermcVabbEtt0dqgEeAC&#x2B;oJ9X/3Lf//wr3/99FXAe0naoH83zHgb3AWgtGljtpW6fej5byBa405aaODlpmW2BSGohOCtNqI13kBfADRE0gZt25nElnOE2bqRs8lwq9wF4DqJ090&#x2B;9PxFiNa4mS4aeLP0KtpcNyoheLvZ47naIFrjLvoCoFGSNmDPqR5&#x2B;Gra5C8B1BG9XEK1xMy00wGi1il7&#x2B;q7luVEvwVpxojVfRGgAdkLRB56YdeHj229mZc7O7AIO8jSsJ3mJEa9xPCw2QblaBJ26urOqmBoK3ANEar6IvAPojaYN&#x2B;rPbV0&#x2B;Guy8GwZw&#x2B;&#x2B;&#x2B;tzEuwBwD8HbFtEaj9BFA4TtD3dbndZWaq6b0XIUJHhbJVrjbfQFQN8kbfAiV2Rgn/b7cNLbfs9v9Ruu8&#x2B;bgLT1aGzTVlNNcC/3td98Mw/D3P//l0xcCvNF0R&#x2B;RpPTyrjVc3Ud6itKZyrw3eRGu8TXN9AUAOSRt0a9a33z/V7NQUuivWvTEUl6W&#x2B;gzfRGk9ptIv&#x2B;ZGwAFdoqoRNHue0fUHlMVToO3kRrvFCjfQFAPkkbNGk24vWw0z41DDZTkeNPN353L4DrtB68idZ4ihYaoDY7Rfjs69NKeygXvAnzKKLp4E20xjtpDQAGSRv0IdbKXjfX7WwQuE/Tzm3qD95EazxICw1wha0FJFctM7PVQx3a2uNtyOgsAs&#x2B;CQ5UHb6I13klfALAkaYPe7KdcO1s&#x2B;7MtZoCZmZ4932Rv3qCF4E63xLF00wCNOLcM&#x2B;JJfEiVGc2IxqPR68idZ4LX0BwD5JG3RubKdPzTObPeC2mC3lnsLW6jdwtWkHu5&#x2B;6DRnBm2iNZ7XbQn/73Td///NfPn0VAGV8StxplXuqwF6tkAN7vMUq7ZSn2FCZIm4I3kRrvFZzfcG4B7OmAHiEpA36l9PBBrrrZzeBG/&#x2B;14IYTbgGwdGq627AbvInWeFxzXfTH2EsDtG66gOTsn7YWqHhw2tl&#x2B;va1y5kFFgjfRGm/W1hKkJAAAIABJREFUaF8AUANJG7xU&#x2B;gjZnDb&#x2B;7Lo347OWT/l8cfVQs03dxy&#x2B;evty1I&#x2B;cfhDfIDN7SjwxFtN5Cy9gA8iO3nSfuDG6b1dtyNWp2Knh7NmATrfGg1lsDgEpI2oA/N&#x2B;rTpnp1j7dTnfzZxvvw8bPLG87vM&#x2B;deAPc4G7ztPx2KaLeFtg4M8Cqr89umX4wNZQtfzP4DlpsoF4zfFPCUlRK83Za3idZ4ULt9AUDNJG3AXyjeyt62mOTZvSvGI5S/LPhLh8GbvpqL6KJnhHZAJVY3Ucspm&#x2B;&#x2B;ZXma9B3pyGLyVLdG1ADxLXwBwNUkbsKmeFCplOO3swWdvBMjeuM0P3/9q2mnrsSmovxY6c6HIb7/7ZgzVrDkJVG4M23aWUh825rotH3zllf5FvX1YdS8L9UHJTX2WwdssGwsU7flHgLB2&#x2B;4JP0W5gHNAcSRtwwqmW&#x2B;LpBr5dOvLPhBNCWdrvosmbd&#x2B;JirrQZs0wQOoB7LRd0rKb/3Je7rNvzl6pc5JbeFJblaLHgzcY1ntdsXGBIHdEDSBgRdEXcVPGb6CjzLh802nCi&#x2B;28TgvgCQod0WurhlWqZLB7pxdoXJ&#x2B;2O2rbl3iU83vo2GHAZvW4&#x2B;EqzXXGiyXc1fAA32QtAFlLEfg9sSNAOBZzbXQRei6AWZic90&#x2B;ShW0mQdZXkZOXAePmMZpX/3k19I17tR0X6C8BzomaQPKm4ZtgeAtJ6jLactn89gOH198gpoZb8BU0100ABc5LBT3H7Cs0m8YUnZ2H2Wj3ACm9AVLy7lxAM&#x2B;StAGXmPbGOQs5bj3sot47PSOcbe02iMeAbFros0412J/HGEgLdClxrttTK098qvfV6vrwkqYPUG8DL/GeviC9OJ9W/tNn2YAZqISkDbjDpyu&#x2B;oTcOh3A7z4ptRO9GAJDiPV30WVtd9&#x2B;rXVxvsWRMO0Lf9avZUoHWFMWzbekDiRXa5Uj3A8IK&#x2B;ILEyn1b1W5V/sWsCKEfSBlTqqaQq3L1vhXxmvAFT3bfQAFRoVuKOw&#x2B;DGBSTTDxUe2Xb4xLN1&#x2B;EVltpFzwG20BlOzkXMSNaAtXz59AQB/NFtwcv8xs5sCZdvg/fG2sUem3DXQzEOvvv76&#x2B;/HP09dSkW&#x2B;/&#x2B;&#x2B;bzp9TRpv9pDRmAmU/hml6&#x2B;DiUmus3OtXXA69IygKpM&#x2B;wKtAUBPzGkDKhJbp/FxgWlwWxmhsA26oXPeYnQqQD1yFmMsuw7Ejs/jz&#x2B;6mbGEJoBL6giGhBTg7Ts5C8UBtJG1A1Za98VZrPV395rb9G8KL56weodTtALcV4BFa6BSJ/bC2GejbrFJ9tmyb1aL7jwysNjnLycKXl/JPy7OMxbYKGbiNviBgWv&#x2B;fTd1W92wGuJmkDZqkUZxK6bHHr1&#x2B;xNM2pRXi2jrD1n4GjhZ8LnKWL3lJqLcf9waqGsgJ9yKntCxa3s7Xci1SV40u7bSRcyvV8aKaAgvQFBS2Ts89/jpW/XA2okKQNGlaqURwb4FYCvJ1d3FIa&#x2B;MPHnH0fYu/b4dVeN9j5isQRXkILHVNwnOmYrn0OKGwDulFbhbZ6McsKNv2a7wzbpufaemNre8OB5mgNABhJ2qAfW1t/BY7Tcc95ON0tsf9f3ik49b59Hjlb8XL/KUU&#x2B;lxqGEkNztNA7VgeWZkZfxXdxAOBZj/QXp4I9RTKQQl&#x2B;wZX/tRwPjgDeQtEEnps1hc1HZRYvezOb8Fe&#x2B;fLx2Wu3rk5aZu04u56ErgnXTRO1Zb5cNZa6sP2H/K7F&#x2B;nU9kA&#x2B;pC5h9kjYmXnPa/xU5&#x2B;fWpqikmUtgWrpC3ZcF6EJ54DmSNqgbadWIHxbGHP29QZ67Ho6c7cJIJMWOtFh05veFadkZnps4A1OrXNQp8xCtOALP9xtLifdbPcDAtLpC1ZdvUeaNeGB1n359AUAF1oub/jUldRg7Ipn7XHKso3Lr3z&#x2B;DNuz6Er5bCB/eElLL/&#x2B;4IcXXX38//nn6Wnqw7I0Dffj0IFvN9rfffaMPB6jNatV6KpcqUr6OhfpYrqdLudrwwVNcd2Rgn75gX0qJnvLcfdauAJpmThs0bxyqORuemT7XbXqo8GUsY6cKbYVtO4/82B&#x2B;&#x2B;Wnwy2XLLvZSRznpyONRH5zxrVkt1pOPqjmXHqxYfnTo7msgN6EPHixPMXtpy0NtY5eafK/8ggQ/izYuIQNP6aA1usKy3d9aN3&#x2B;kgVvsC6RrQDUkbNCzcyG11j69dDmUaUqa8A/Ws8HNq9ZumN/ODsM5a6CuCpfGYZQ9&#x2B;ddt8uDNcIu09UKcmxrElauJVFNl/To0NNeusLyhu2guMFbJhbQCJJG3Qp&#x2B;XIysRkqKeW/qwi3XXZ8cj7h1pdnyf97NNvhjd/7nSpgy56deLaaqObGTjlNM87V5V/8BTh43&#x2B;uXMYGVGu2TEV/Rdrhbmqljn/pTMHDg5vuBo/roC&#x2B;4zg3D7PY7BdU40BNJG7BJZ1jnfumr&#x2B;7pvbfZ&#x2B;6mi93srhDfpooS/NpVbHqF6q&#x2B;MvZD/YSX5R&#x2B;HqjfReFQnZXe7KqKvPYbYraddHDsAkx3g0f00Rc87jAGC&#x2B;RkpscBfZO0Qf/G9nW2BcJ&#x2B;jKQzHK2&#x2B;8JRw687NNk4ternvzZ81bWm6i74h95put7bc2&#x2B;zqk5aSuc2bXA3ow7I8m1X4h8Vbl5vAXZQdHtbMnzNOH5Y4Pm/2OS73ZgZi9AUpp8g/ePENmIfSW0QDPEjSBm9RqrteLpZY5LAt2t/dfV9impUzqe6pI8N1mm6h8yW2tZ8Ubfrgi1Z3HJvhsi33YY99uJW6Lh1o2qy83K/WpotMNl2Wr15/zqbUj7wb08/r1MKSF12wFUroWx&#x2B;twUXj4UoV5&#x2B;kpYOyyd67zilQP4FKSNni71QZ&#x2B;tTNc7QBb7&#x2B;ozpU93W7X1sP0M76J4bHZr4M0fK1Vpq4UuNVz00GwdxVm6FmtKDzddC7sz&#x2B;hKzAa2bTVOL7WFW50KR&#x2B;w7rz7PD2rKvKFXKZS/XC5k9rPh0NyPq6E9bfcGqWbNwUZKUs5Nx4nC9K&#x2B;SfTiMAPEvSBp3L3GB81hlq2BKlvO0pg0ynLfel6VfOrRwortEuOr05rGF45g07kM9uIhQ83TQU1FEDfCy3B8vJ2x7J6tLjpUuXZzh72OVlJ26rnHjwthJTKKvRvmDqbOWfXqWvFsOZjcbOTLIaWphV2gGgEpI26NzW6MhM6fOfWhxRW8QVb7sYjF4110LP&#x2B;syLursWm8b95rzsK2rx/QEI2yq5ZxHO1tIUF15ZnpyRXqsLToaPlp9pBVZrTFlwUtjGqzTXF&#x2B;y4LpqazTwrMknu/tI6f0UN7QBQFUkbvMinSQs0n6vPOnWol2/3Pb7qrXdy57nL1npnwc/Y2zt9lmlt3KatLvqwAyzeSBfvG/db2ZxN1/ajNevAAFxtv35brltYW0Ges/nx/tHqqWxX09Aiq0rsdwFn38yXd208pa2&#x2B;YNVY8aYXrqeK5P390m5YrCLfqVxt6&#x2B;XU/zKBN5O0wVt8uqaCI0bDl3HPcojVmq0qk/IOpI9vreRWAqxqtIUuHqGlHLBID3n1LuIpLX21i8wA9GGnkgyMinuwMi976vAwslgtvXWKzMr81HL0j3&#x2B;CcFajrcFFVuv2zFUcr&#x2B;4FEhuWnL5Grga0RdIGTUpposbebJbHPD60cxa2ff7ywrbwcO/01Y9p9VlXjNt9Zw5KcVrop&#x2B;hLAdpStj6fTZZKnPTWa1ozvhs7D8hPxca/Zw5wnB7w1GzFIWMJk0Rv7t3I11xfkD5NrdqxZcXDtitajOVFamSARknaoAeHrc6pDi18qBzLLdz1b6fGsUI9muuiA26YLjY913UnynTqTaj5hQA85f5aLmVFhMT9mJt23QC1WVOTeDHjoVJOcerahmsaq15zWcpqqy&#x2B;YRmvVhmc7ru4glss/ljqLNgHog6QNerO/M8FsuGV44f7YhR0eYbaBQcHOrdFWcGvXiscnJsJUWy10pvv7wJv3Xcjfkzzl3oR2GuBQwWL4VN24ta9bo&#x2B;X0jiuW/djZkrls9T7rEWYTE&#x2B;EpzfUFtyVqO9Vvegk9e1aLcSBAxyRt0KH0BvjqTQtGy8Gzy4vcWv9k9oCe2vvRzibw4debfnem49HKXKe5Ljps7Ip3Wtn0LrfIQa5wdZ43HlzGBrBjf4XDq8/75hUmh7UVIM96JOVarjOZmBruNCD5rFPyKs31BWWr7tv2YF49bHNhm14A6JikDTq32tscdl8pDxhubCavm&#x2B;vWrv0Jix8575U3mZnmWuie3DytLd&#x2B;07W/rygHuEchCLrW/r/POkobjg4uUjvXEeInXMN0Ye/XrS/d8ptMt&#x2B;lIuQ4fFWe22Bs1FUx/LlRvvZzc1gH2SNmDP6q7aZduw5YIqh7cetIIfsRj1Y&#x2B;s9tOAMU&#x2B;220ARktu6zZlvvDbBvf/raU7OjVsv&#x2B;/ZUnxqhJfb4jZfflzDcw/dtma3O&#x2B;1Vl9yy3oeCd9wVnT0rr4ELQrKu3P2L7lNmyNZpMA95O0wUulr45yuKhjEbNebjo&#x2B;dCsQWu388y&#x2B;sg70odtrsrV0c3BxhpIu&#x2B;TmdtqolrAD1JKX1TxsPNHl/k2uqxfEVn35PVp6xOjKuENuHN3tAXpCwUv&#x2B;Pss8aVKs5uyXbusqI661YAbiZpA4JTo&#x2B;5vBZfR2lYKuLxTkL5j2eoBYxecrvgpzq54M9Ta23OPN3TRbWllAKmADeAis1L8unJ0uVDkcn/l6TU8Nd&#x2B;uZrM90tKfeFGjkX7YxB0BlmMcZW&#x2B;9eklT8Gyl3dyy8KvswQywJGkD/ix9EOt1DXbBI8&#x2B;Wo9QQwsxLeukK7e9erl8FYMgLM/b3XbvIU0PWahCY6/ZRQ2wpPX25t3UEKu2zlp2L9xBglaQN2BTuGC&#x2B;y06vvX9h0Icp214QsZfbaV9&#x2B;6N78/7/G2pjrdp5Ms3kAeDpt9pGXdz/wAaFpi3X44re3w4MsJT&#x2B;lrY3RcdlaeYB0OshzOBIEv&#x2B;Uy7oRHYd3V5fEP5vdx07axpbyJaA0jx5dMXADQm1jiVajI/nf/nz&#x2B;ySZruyHx5n/FPkwpq2zN6euhJuo7te9e1334ztaKAvLd6Cph8w59Sz51beSH8&#x2B;I&#x2B;kgwKwenn7985fEKvdTD28dLefyti5jdYuyXo2dy2r/snzwjZc2P3XBS&#x2B;r7M23U119/P/3z9OV0oraKdFbGl4rZAEhkThtw2rTjKt5HpYyBPdvyHc54q63Xvd&#x2B;rXiz1d9cXzSrbOtHH8nQXbaKQfqL99rhgbz89e223DKZqvjaAZ6XXclev6Bg4&#x2B;OySOt4MbGdJz4Iv9v69305t793fx1qt&#x2B;mv&#x2B;92hrGQkxG0CMpA3IcqqrT3zWstOOrWmTfnnThSWnJ015LrSl8pb7nqVUhrV299JTTw&#x2B;ekp/pb5cauj0B8KzVCCdl5FlstcNZzZxeSF8xwK4tZV9dKzPJuv9YH1d5td&#x2B;llD2Y6w/bNCAAmSRtQBmZ/dJqpz1tw1LCtrOr5aTs7jaI3OjIaxvvcdJYzuKQicI96qlLKrUazP6svj6Mr7HXFwiw9Piif4eHSsn/to7ZcXGevjva&#x2B;NZVFVyd2t3NXLfiXlvqX2Q/G8vcg7n&#x2B;4A2AsyRtQF3GXnFsHcd/KrupeGxlm/Bz4XF19t6XTuHKb19TFpBsYrfw8cJ2rrCzbr&#x2B;zlwOQL3GQ2alnFb&#x2B;MmVlrMPtiWfVEVmcv49nZbLEWaX&#x2B;QJQF1lvqPa2hUWZHaVYAH8CBJG3CHaUed00Fd1&#x2B;rPFpBcmrX3g7wNspXtA4tMXUrvTi/t1VevYevadq4k860I/2txDd0lAajZ6poQ6QXwzjZjmZex/Ndl7T27sFL9xQ0ZXo6d6ynYGZXtbvIvbLmDQG2fS1VkbKPZGL57Mqf8zZ7Lbg49bRkqD95U&#x2B;EBnJG3ATWI7uq0e5&#x2B;phmynt/ZTgjfpV2IFfFLPl2&#x2B;lIn&#x2B;oA0897wxXW1gbPPqzaLg&#x2B;gfqv7um1JXBZy/8GnVkc8JT&#x2B;YqTBsO&#x2B;VUz7W6x951Dpf6n11S5SFoJSos8qfujFIOV4kvGGjlrCp5gybq4RreKICyJG3AY2bN0mo7PVtJMrbozUV2WkF9IFWpvAM/pWC7Ptu57fCA17Wsp4K0nWCp7GDYUoeaKr5YqBYdoIjE2vVssb162JyK/VRrMBQK3mZnr8psgGCFV7jv1DbbwjaWaigFD1O3lNK31AtpZZZYDR8cQHFfPn0BAH922Dut9mB3Bmy//c0vUhq8ZzdLgPrtTBob/ywfP3tWox3a8tWdffrq3/OPVvCwl/r2u29Wvx/Gf739igA6NFsoMv2JYxn805/9x&#x2B;dP4Ss7fyVDwuy61fFzs2dVW&#x2B;F/OpTwLtTtBnVUOJxurNMuPf5t9V5O3R6&#x2B;yFNnXG2dVq&#x2B;h8go/0fgNoOYHKmROG1AXDR6UVWEHfsrhOjBNSOls07dhK9snT&#x2B;f23b/53KVPHPVxZwF4oWcnVO3sylbkYpYLtq9a5kCHU9lWH3A4IyplvcrpQZqY7rb1T1tp4lN23vwb9g5oVOtFfsAN7cAVReNn1cpSoVf6cxvqng5fVEOvBXgzSRvQgPSVYa6&#x2B;jNn17HTsljehA9PNtG8&#x2B;Y&#x2B;JJy&#x2B;4f/rj9xSGvPvWlxy/eHqcfsKfvEIAHHVa20wp56zEXTZ8qVXhvNR3Lry//U&#x2B;UfsNzuevZOLneS8z5/1BmzFaz3CuZSiVd1/4Cz9GubPqXQFV11wCLXcMMQQIArWD0SuFZsJZPV4yz/c/XID3ZfpV4sPG62Isc968Bcd/yGjC1l5iKTbcn8BlhdaxSgZuOyirHhYs&#x2B;uyjhKqXvvrI23QrKdzcBSqvfYSxgXz6zhk1pavqjwJ5X/ER&#x2B;&#x2B;SzqsJjy4esGWwz2YLyq2Cy4UX&#x2B;oiL92DOceyjO9jRRPgnSRtQDPGHQjq7LXqvCpeLjbcdaurye92drbXYvTajK1g2AbQhJywrRKrg&#x2B;HSH3/1a0&#x2B;sz1cfNru2rRF&#x2B;Kc&#x2B;tM2&#x2B;bNlZFGpnir1F7taXCCW2HVdz&#x2B;RmJFdt7aKqFvrhLP7rIWfm43dnqBnW&#x2B;Jd75XQOWsHgm0bbrBw9nd2jVvsHRdDFYkZgusslKttvrDggt1jodabacPzzJ7bltvI8CWnU2/2ipZx4UW9y87PZXZX0a&#x2B;7CZeKYc6bCIqDNX27WzIB5m2FgYcuqjqp68uvLB58Q2Yb1uLvsjH1/r3AMCUpA2aFAiW&#x2B;hZ&#x2B;K1Y7SSEcfQgMdz1sdc7GLWV7p8&#x2B;pO2jLh9byoWff8D4&#x2B;cYAdq5t&#x2B;tRt4ZBbSmaX4bNOv4U&#x2B;Tt67Y9fnUpbbSYuRc5Nlv3Z2FPdlS4YS2Q6vbbjVd3aVU8qsV7A0twD1dRs7Ht/rcnVVVzPwDWiFpg4a10q3dL/Ft2Rk7DJxl5&#x2B;pelVo1NP3BvosAppZj7JouXFeTmGVfk/KYRGdTnLPrZGz9Zx8xUuJufONrjL3Ypr&#x2B;lW3HbVKfxdIHBUuE6sM7qcfYO1HmRAJQiaYO2CdsSFRkX7N2mb7FAZfYsMcnLpQ/dLT4SFqBF04XQ9/U0RCxzhtnWohS5l3XG4UvY2r/t8LNL2R/uKZdejFVbUhTcg/nSol2pNnphZ5S/xrsFLYBGffn0BQAlfXbbbnrU5HV22rblP3kPYdjeV3x0aumPnBNRrenHHW6JffrAO81its8ih5&#x2B;/H0ZNrRernxc7fckp7nnVxc&#x2B;SuR5jnZ/17LMrlZDV&#x2B;WKbtlOeZYYZ3373zfgn5zh0Y/bNkP6NYeYf0AdJG/BSsfYeWpG/hcPY5GztqSBW4fM9kHmHZdx&#x2B;r9hlAXRhrFFTZkFVm8ekGAvyZWU&#x2B;fn38yqmXmV7wB5qCncsurokPN/1NWCbKTbzALgVKuLLRWjcV4GfgYCsvp&#x2B;CHuH&#x2B;ow7NsvWmtvJMAU1aPBPizrXVgxq9rAulV&#x2B;s4NKW3P1nI0WqY&#x2B;nN3GfPaV/G8DS8oAXRpXzztVcE4f3Mf6e4HEazovMOewgZr/tne7iXXsA1dY82qZtQkMpCteL&#x2B;UPuZsah1up6&#x2B;500R7M6Yf1iQO9krQB/IVTW5drBXmVaUASWyKy6OUc0L8V93lLA5/jfjtd/JMS6AJNO9z9Kz0ESsmf9p9eT627fOEp1zZ9CXfGkMuzfK7/7KyvPgb5rb7qIrtoc5H0EXi8gaUdARJZPRLopIUrbrbUTD03GuBqyw7qcC2UXpuuXl9XovSFZWZv1J3v27iC5W1nBHhW4lKKy7lup1TYIOTsCrb1cu5ceDPQTczWpazwQylLw1VWqZUh7cHck1Of5v2b8B1&#x2B;2/i&#x2B;AmpmThs0bxwdmdN6VTVktVqzoZeJ75j3lu7VtvBL/mW8toUrMmQ1cX3R2MFvOBpAiw5nCC1bhhYL1PzFCVvU6/SvnG/Ipr&#x2B;NnzJWaLPCaWvVd15o/N7Y6uy2vluWTcR0oVHfYMBLSNoATgivvRN&#x2B;LgQEdnF4uTe3f&#x2B;OakAXzqpxDvfmzAF4uPHvp88RpHpPy9J5Gg62uLdllOtWfbr4Jr1awvN8JUbaesh&#x2B;W1DPejpjMj6/gN4BYDmiapA06Z7jfzBXvg06eF5q1QO121y/v5Xa2tT&#x2B;7buTWQOlTB8n38g8U6EPBDGx/6Yvl19ttGVKuvOlX9/mwespHd7zhNV4tca&#x2B;1zMLp/gXDKajIW3o4xS3Gxw20yD5t0LPM7RlIpxukaZmdTEON0GfTiBduHfHZZSFzr4WU9y2wr9s0ogvvDLf6gBd&#x2B;0ECLZmXkGKgUP1FKrnbd2e832&#x2B;RstVwfv7h84cp7ujctk54dKUVt9r8f9j/6hnpDgLLMaYMXmW3PoHu8iDeW96inj9pZtMRdgPBuHLNdFrYesHWiU2L3dxLHawM0ofh0pcOjHSZqHXQN6Re/FbMFPpcbZp4tV8u89HSP6/4FXmpZIKWMWBpqKvVtwxwzK/tjb&#x2B;PN3wz1fNcBnCVpg24lds45B5&#x2B;umqj52eKdoVc1d0Hv7KXTbYVtObss5Dwx/Hn5oIHOlJ1MtnO02aqSh2uhdzzZK3Ed&#x2B;Mq7npesKjl61Yu9X231lZgt5vO&#x2B;je9eo29Co5cNvJOkDTqR2EgX6cH6WE8GeNAs0fn8vaGNIiq0Nbsr/d7Eg29gzaktwBVmBfky7Lk/SJjuBDb7p9lXug91thbVzFRwguDq9Vz0uXQwr7EDX3/9/f0nbbQ80xFkHqHgvmvpn0XOaD&#x2B;AekjaoAervVbi8MytQ&#x2B;mmgB3LXuiRBqn&#x2B;XrpIiJh4lnrsfzPsT2KL/RNA62Kl&#x2B;0c4YvmcdPnc8WJmU9&#x2B;uUMNsua3z5nwoMw8OVcyJyoywfI&#x2B;CS4LfT4kYNival&#x2B;/ksxv4zQ7lgwYqJ2mDW33xxVeXHn/WDQZ2FNj6iuAN3my/Adv64nXq77KWW6MNl132agP8SbPCcVfONaQc9mzTXv8nDpCveL2dkpOFA5h3dgeHr3o6NfCGtyg9Cn180iStkLE14WztverwiaX2YE65wv3O5bUfNNAWSRu07dSeCsvnbj1m2bNt9Yo3DHQFqrJMaG7ofNpqrq64Q1Fqcch67p6sttNtfdAAj5v2Aqtj5n77m1/sZyrpZfxh2d9lllNwWtt1bo73qN/92&#x2B;4WtywUVYmj5ZC&#x2B;xIFup9YgKfXNYD9m4D0kbdCzU23h4YM/ndvWSpXnrgxo1lbPc1Fn3lOLdXYaWT03O866ei8HgJcYa&#x2B;yc0XXD9vqBsblQiS3GmPq0Hv&#x2B;EL376DhS9oj/KeVenH0qXESkBtVWe01Fi76wSV1/7zmoWN13WkfA3Uj0vASBG0gbdCnd0sUVItGTQrnr2oO6gv7rnnVxtpyv5HFevwQw2gEz5xfaliVd6ELizTkYf9ica1mZrKuQjF8ODytaQBeOxd5aL048j/GbmLGixnFBYQ5cBUDlJG7xCzrIn0&#x2B;AtNloWaMssxTlsq8ITmMYnVt5Cp19nynu1My41/33YaYOrao8r/8QBKjett1fr/LPLCaaMtEvsJmY5k9ZgajaN7OY35&#x2B;wEu/pjQsJSwptT4Up&#x2B;ElN/cXjbapb7Gy1fdNId&#x2B;690/F46dW31f9wAAZI26MdWq3aqhUvf5XtL/kS38Qg6c&#x2B;ibFmu5y8Jw5m3ZSuku7fxXD57SXfu4AYqbBTarVfphXlK85E4c5JeyJ3Sjat7dLeXalh9HZx8QH1uDye6v2eqvEpeFbv6CjemLQ66ebr/8LvuWWhASIMWXT18AUJetvqv7ZV6AqbGbqmoi1G2&#x2B;/e6b8U/Ocf7&#x2B;57/caS/PHjyxU31kgO3OZWiwAa6WuI/yVuleMBPK3Dls&#x2B;qfUJT3lt7/5xWzqYeabk389&#x2B;4fNvEKqUnP19SmP94vk2hRfMWLaZeR0HJW/h5VfHkBx5rRBk&#x2B;7sgnL6utWttrVw0ISt3bZOHaSz/mp/7OrWkjJnV1PZ2oMt/QgprjjgbGR0Z58&#x2B;QHOms5fyK/BT87S21rRMP10fk6jCL2FrecmL3pOtUZUdRJ4c2irYCo63a7omLPU&#x2B;lB2/eOdbmnjls5an6Q8dIEbSBs07tZxjznFyLmm2OMz4sOVzO15GBmpWcJtrbdWO8c2pcJeF&#x2B;o8PwJZT61KkPz12tMTnnt0crqe&#x2B;ILDA5uq/Xrfy5&#x2B;zgPb35pMivVI27CliO25t&#x2B;ZXUFy&#x2B;nf73m3d07k4wZeTtIGPSg7CDGzZ9OGQa9mO4Hdtit4i26YlHbKasLnIwOozdk6PFDwz&#x2B;KTlF3cVofQla35V1O35X/21Gj09Fqo3CwaOUzRYjFbK4XlqWI45b3af28T35bVbdhm/7mfut1suZoFAJI26M0VAxuH82tITnvye1YdGXvvzppwqNZ7eqr8CX/779Xh8fPf6rKjXN/z0QPcZlo531nK7odtNa828cKl6d/zSrnO4wnNgz71cE5hv//c1X/KLMIvrbovbXAAXkjSBj2bJU85iVeRvi7/MrbcMNIWurffOjbUSl06vrJIZLU63LXOTSAGQ1YBrpdZpWcusTh9yuGV3DCEbrnN8/Tsy4bi/7N3Lzm35MahtpfKp&#x2B;eagTsSIFSnoK7gcWgSBQhqGPA0LOBvGAZqEjWODXWF6hQESIOQm7L/Rp5DUbxEBu9B8n2wUdj17bXywlxfLkYGGbRk3Bk4AAAgAElEQVSWAmyUO/3kZETWUYNSrn9Y17XbrkNY1z1OFvDo1Wnv2PkfgfolAFCBTBtwPheVvdaHkWO2mekr1t8GlsiFfBtFVtvlhNxx&#x2B;o3fJZ8nF5kp2v4ujQkAd&#x2B;rYP5cDB00ertfBBFPWlCuWnTTRrTFpCoxwWJ&#x2B;wrsudHIVWkTbrmLRr30hus9OWfwOAA5BpA&#x2B;7yRF&#x2B;aGCyIrtvzXpqEnzBw9cNMNWAKF1N9joulb2A5XAcA5NgcZOaOquLwup/Oa2n6IMl3UsotyeZnBnaUZnGYwyRLtkavNdgqtjzt6vAxAAC9r1YfAADrzIZwZg8MOMCzhsHqo0CBXvVnuO4AsNBPP/7GVGbIHU9wVAsPMiiV&#x2B;Xok33z7w6lRg52Lgk0J6R86hDI7sdIf/vj980f5euGwjZwRAOyLOW0A0kX/fWaj02fsqtnDA3CM13HB/r&#x2B;uClP1y7/5JSuHHxYAQMEvfmgzZSIf1biVwzpusHFBO4POOAsMUrEG8yU9w&#x2B;5rpCWnA7bswp8GJ2yn/SwuueIAMAeZNgAhocxjEMtZS3FZOx4AxllIjyUpD6buMYGpMwUAoJEfsyQLSOb&#x2B;lzSVnx&#x2B;lNY7EGsya7Se3XJ3E6nucQbTSZVHnja4&#x2B;AOyF6pEAJMF0t5ZN6dNg&#x2B;sXkhnpKzZC9A07iB6tB/KwPp19f2XeQbB1/1hq1gAAAE8S999H9eWVffXlYsYVgSiKNdoy470dvsJTNFiuNOGyeBQCchDltAF4kY&#x2B;YR&#x2B;afcIufVQyzPqw8DoJo/AvQzPdTUTJ4bmp8jtAYATJCbXtZrm0l&#x2B;EOF2Kk9oi19/MP05MsTwVPQDj8fqawBgAXPaANQwFZT65S7XHgmAteJparkVwvU/NO7mNTYA4DBn5Dl&#x2B;&#x2B;vE3z58R26zYcvD67se2o45lSwAMkotiNIgFAGAJMm0AKulj3WBs6dCHCLnj8XfqykKe8TgDwKsJKbTqgPY5tpYjDIpDEloDwI4O7pfWJbfit3TsvZNekpNtycYffkxADy0Jqnbj&#x2B;uHPll/H2BELAMBCVI8E0KooUp0cpMXVZvSlKQcVyQQwgakIc8K6bqbOFwBQan6fc6PluILuerI&#x2B;fK7Db//sjBhR9hOYb225&#x2B;CVuOEcA2AWZNmBvpiKiLscQbKTluYPyeFz0/uzriTOfn1hoVQA5LpaujjCfN1orGvl6OkTUAHCJQasOB8UetujxykFB9VJku5z&#x2B;BMl2YOgh1pJ76cFCyEVd&#x2B;tLXJ3cd98n/8MfvWzrqmqMiEAAAs8i0ARglqEmiXMk896/VMbC/a02g6Je4JPAGSrVnvzQbty8XZrvCL3XnQmgNANAQurJxf3httkmz6yDjmDwF4V/RgiaFNU83O16eecmRfKb0zwkBAGALrNMGYLhnTQVTWSvlchFuNYiW8NLP8xGm4mx&#x2B;iNt9jYTtSiw&#x2B;LVB62MFBstYCAFxLLoE&#x2B;Ye/zO65BF12o8f78pddEN8jqVtoDOnKFKIpWOF44Sq9613HPn1gAAHZBpg3Y2F5pmyfZZipOU0bp7jXuj34XwpBb4DBDQ9kRaba1Uevreua51wAAzuN6yEFJ86Ky6qXdTn/7QT1JOwPFXgMH/whfZ1&#x2B;ZikQAGFG6prK&#x2B;puWjtEv/jLRzf4reCwBYiOqRwCGsTRoTHJBqMrU8HjBNsBZC7p&#x2B;Cn&#x2B;vjw2Aj2wWWrzUh5TPa7nwBAH21LJR1QAc7p66/naucSbINMK5lqbPG1dfq9hj/cKOK9wCAjsi0AZhHSAc&#x2B;DxGUFR1HrxbgjyZWYl03oJEQkdqvD1PHYGpt6DJ7AAC93Mpkyg6zZnZX8pXJdxkc0qdcBFo4bIMnBdysV0&#x2B;&#x2B;V7JtTtKOLjcAnIRMG4DhgqcDwsuE974&#x2B;AviUPHp4fU3uLXJZHvJtOMCcXItm&#x2B;lrLgNZVhJjc/rlsl6oEgEvoh3/FneH4J8qeasXIs8n8ECN3Uo3ZOOByQwtOdCkOP6376gKT5B6LQgD7QQEAoA6ZNmB7oyd4ncd/4hC3nhxsa1rbbb9oy4Bx7XPOhFfqt&#x2B;BCU&#x2B;Eto8PXiu3fEFELxUUBAHqa2VpdprW5rRUcnDH63rU/ek&#x2B;TogMQd7ZNDYObn8FqzOrZaToAwCBfrT4AAJVeI3D3Z9ohCeIgtigwdn9eXzzzfPWnYOdCALJetVaSW75kytRtA1efK1u0UDwAQFaxllhdxui1gyrUdbBJ03S7nAswx9Beem7jpvqKLcvCyRs5OwoAAASY0wacz8giBF2OofsEvtKtydUv5SU0GDyLG8TxZOPoV1NxuNI9QfWOVwcAdlGX5dL3/EuLum/EP379xL7dzxooVVGyoqhj7zby/KW0h7y8n1landJ//T3hAADAIdMGnCNXtDB4zfOXfSNJeTm3VYfx/O&#x2B;SSp48GsAIQXA4J9AVFj/wX7DE8lB/LSpDAsBaRaumVQyzO7gnWV00HjjJhMKPQZKpS&#x2B;V5y&#x2B;xPYiPtBwCTUT0S2FvRkFU/tqRqSoVkowk1auSr41f4bL8cXFCMc0YwDKVf/&#x2B;o7Oc/K5wEAZvK78UUF1UtnwlUfYfvbp3GtV1GfE9jUnBLu/i5KK0a&#x2B;5oEWJoouz1HdU/8fALog0wbsTa768prpady1qaBas5xbUISn&#x2B;vgrhgmzYgTs6xhHaQLmywNXg5IXpXppDcJyADCuV6qpsV89Hzk24FMy50xYgzm5Xm&#x2B;RZ&#x2B;OW44LkGsyWD7gL/7LSqwcAJapHAlvSz05zZVI0JSU/p0SeyqG&#x2B;RdtUNmDL1oL6n&#x2B;3XgsKSaDctsmqMV&#x2B;&#x2B;MALsXdWwpMvNaKQgAYM3rMsOXuPbEcbz2jln3NZiNKF2AbdyR2CEnXy9pBABowZw24DpBJBmkfLqUMbQ2ptWfUpZb5q1oa/7/tp9sbu99y0sCKJUcr2onyOye04o3SNoMAJYrqhX/Ka&#x2B;LSJIJuNDCPh7dSwDAqZjTBhwlORY1XkFdnuj2bOTgBcPjs3s1LtEV5&#x2B;1OampsqiiZVBEtVyerNKMpu2TC7KTTcloeUmgqAgGvfvazf/rf//3b6qMArhB3DoO6BXFPVehPdq95UNG1BjDZkv7ea8EDeqFLEAsAwCDMaQP2pl8XXbMp4V&#x2B;PXNTt0zzsN8hfVqzfltxskqkGxHn2Gl7a/Wif6Ws3xJnVE9eCxiFEB4Dl4soHqwZs9YpHAHSU6&#x2B;PNHCeHhZIBDkUsAGAcMm3AxioCWj&#x2B;1E9dUfE22NVYytJYrKq3G076pCnMeW1CjEq8ODrBfT233&#x2B;LNuPfN4EbiDPwMAsJdeq/mO4CpnUAUdMGhQtzbO6OyyBrOp/u0f/vi9&#x2B;9Nxm3VvNNUyALAFqkcC&#x2B;0kGq33Ltrxu6siAuXRi2YQcGKODYcTCQOvXv/rOjw8bw87GExnXDs951W0/967dE4QAAIGFYu9x2fNcjKApkE4RdQA3W7gGs6ZEPwDgFXPagPMJI0n1s7UujHs1jwOMHAkw1AFxl&#x2B;VTaBy1&#x2B;loQpvGfAABmVZdDf8jLNivf3teRg/mA4w3tafdag9l4ofj23njf/jwFLQCgApk24DQjAtRr1zl/XQYvWIi&#x2B;pZWMp9Oo/HOtreMr&#x2B;0F1R6UZO79ZLmkiADhS9TrBn2GZLbdZvyOt3JcyyRe8jG4qICjq6c0cgDV6Xzd0cf1qk3I4wNA6ABiNTBuwH&#x2B;Wo1eoBql32fhiXchPOvbFt2y&#x2B;NZiUMVssADlM3JY40GwAgsN2qw8FAt1zsQ78Xd3rtH5rqAXafjyUPtrOfc1JeneSJaM7unsGIADAT67QBu6pOtr3&#x2B;E2R1xXlmpic1xUKfv1&#x2B;YNMUc3aNlZcTYcadztlyhY9sqz8vU6W&#x2B;K1S8AmCKs8eb&#x2B;6em&#x2B;yiGDvifZsc8ZH5KfbKNzC2jY6Zb06tn2Xe14sqARNDnCXkU17ScdAWAjzGkDDjQhwlyy4rrN7GDQFLmWGTTFUG/5AeBUr2HeiAg23qaROHmExoXchG0qt0wE3ogGBGCQX7BB031Vdv6DlxV1NZN1JuMtxEnBV3GpSfrAwCp9O&#x2B;0Ga8Xr&#x2B;9hJ&#x2B;ql4I3YBAGjBnDbgHK/Lic1cS8xfnkH416JtmpU7xwNODTDi2oDQhdDPX0a0A9Otekm2JGk2ANvpu0JzbvKcZte5w8hthL438Gr3Xt/ux6/Xd/oaAGACMm3AmfzUmpyB8&#x2B;vDjDiS10C9Ytf&#x2B;eRmsglh0MJrKPEX7fd2U8mVyrhTAIEsSM8pkm39sxPwapNkAbCronZrtDbrjfD3COOJgVBywnRv6n3W9x6dlhJF5dEoBYAIybcDJ4sKGcn5lRFZMs5eDA91cWsu/Fn3L1/gtKWxZTrJqRhPjJDYzKO5I4sMjVnTmXC/mvb16PpN&#x2B;Q/EpBbA15ZrQE/rw8l5ODSIAUyb3aobublyhiFXcuZx0UgCwIzJtwF38BM8Tl/oZl&#x2B;TLJtti/GwpZfbrM&#x2B;yUmaCGadoDYzlEXJW9MJKMbDn9xjXPS99LqA8ANwjSYH6fU1hiTd6Icr&#x2B;fqI8dbyQY3EZPGHjV2GPssouh3UhrfdT21qbO5GTnJWsB9EKmDbjOnAgzuaR5/Jp4ffLgf8&#x2B;LhytWcZ&#x2B;sYm358y4TJmsJVCYEOaYmJ7XM6uv16ERo84NjzqKJfUZSswAwgeuxFy3JlttIsIWKfukrs51wYAtdOjZ&#x2B;p/SqkhVDu4ilGaBL2rwvGg2A4KvVBwBgvYo0iT46/enH3&#x2B;QGun4UCbmzw2C/cYKGmrP36tfIKVJsrW/wIEd6v/7Vd8&#x2B;fjnvsrkuD/OGP3z9/St/YvXH0ba7ftfEr2FHdRQSA433z7Q/tY7CCjSjf8vqa3MEIB1lxJABKbREI9JKMBQb1KpObvaSdO0p2&#x2B;wkEAMjItAH4fLw0Ty7fo5mj1v1gks6Le&#x2B;fn2JSCbKjzutrfedcIsqLIrW&#x2B;YZzxorE6w&#x2B;fqeY3t5Gf&#x2B;Nlzwf0VzEG9oBAHxDu69Pf7JX4i0IZITN&#x2B;jsdMZ0OwMfrId&#x2B;QtzB4mtaOZxe0G4BXVI8E8HfKgLlLPPm6kde6LgeHtTYTb7LcKh2fPU/nNoPWYwhSMi3b2W5s5ugijRXcIemrIE5YqMOOXL2doAUqLkpR2UkA2MjCMoylux56qEdWvAcec/q08zucZgt9z6mleU8PvxdaDIAGmTYAaS0rJbTstG4X5HVkg65dck2OWFAyFEeKUzLd564N3b7&#x2B;MObvdBBluBivonE2smIAUKRL707ZpZS3cPAgPGBrcs8q7pFeuAZz9wWYSzu0rwX/y45sf/IVubBBACiRaQNgy2u4rpnrdl5GZ/4Z&#x2B;Xv02zxOm7l/fW35Iy8NnNEpmSUhjTzcdcmjgVea0LoobWnhpEbr/sAlePZBAg8AXuWqI3TcflFFSnqtQOyATqOpNFujCRPgtrimFXLVLF6d2iAAuiDTBqCAy6m0jxtNjl1NbjOXnmkf/XohvzGnNR2jjO9xVeCRjGnlhMrM9mkJua&#x2B;6jnpCs5BIA4C&#x2B;9P3Vvp3Mp9dKjg2AoKXy5Ija7O4YqufGJf9&#x2B;g1wf/qoS&#x2B;gA6ItMGoIw/k6nu7clKj4MyMcFmjwybB&#x2B;WxNBPUPoc2KZBUPfJxvqLI0J3RFqc232uknfvXYJQx2TgAKLWkt0nnFtCskTyoV2O2s9RxvbpeWRyhmkhd9shs49fJ9b0bG58uPQABmTZgV8fkkHqF0P4UtydLFOefTh2jWnRSucapI2znyKYGccWjNEKz0G7J6NrCgVkgP3rwc2a5FhPybQyJBYBSgwbh&#x2B;fU55F3TjwXG0WTyBjmmMxxXKdd0OI0sfT3Bc5pkxQBMRqYNOMR2OaTggJOJw6ElB&#x2B;P1xs6WXGtt5t4n7xEj3Bao1CVI4ojOTrsF0bWdA2vXfl65dfhaWokcGwBUiMvLz&#x2B;9JbhdbAX2NTsmMXuBZeQzxD4u6lHb60vo&#x2B;p51jniMIzbp8qkngAcgh0wZsqWg9s8n0xyAvwDZop27Xwd8tNF13mpPSvIZV1mDN2vBm6/TJYWHh/E/C6x63/ngAgEHJzmo8Zk7TXy3q0xqJrT6WjgRXGd3FMtgpDXpxphIqcYqIPmcLO1cWwEm&#x2B;Wn0AAK4jTGUbt0c/CJd32nJIrxtfqyUfmdya37DYnTDWz5Q//PF7U4f361999/xZfSBZxg&#x2B;vzvMx6P5JMPXRAoBrBctCxx3sZB/1tV9a0UvPvWVOn//Zi6uNP3p3wOWS/UALncOWqvVHBgJFKk5fU9rUwgcDgEHMaQP2NqHKYhev&#x2B;Zh45bBeJ6VMBfljRQ8uLOl/YHJnF1yL1wtxXivhBucVUTy4MuQjF9D2HW5csTXGFANAd/6CakKqqaiWRrBlAM55/UYNv064tTWYg&#x2B;5lXXHIOy/rR2wu/3IL3X4h2Ua3H4CAOW3ACYqqplggF42cNjNsxNDXLejnosUtkPywGZ/Mh611DGbcLKi4Mozm7fbHhLoJdsaPs8ig6Wsf9fxIwmkAV7HTqQtmtvUiTxE7uKo8EDuv3yjr1akz0mLxYRg5sF6qQ4DXT7X7V/r5APpiThuANeZHsLl8pGZkq/&#x2B;CuiM3Pk8uOKq60b6sIYHuegU/1WNC4xefPW9sUxWfE/cWN5r1dSPVc9f4nABAo2QZj3HdzqdPqwkQ6PoCB5A7eKZWawuYPbB27WFg3DgVl1IfKQDAh0wbAFPmlHNpXK6MoNqhKYCFDg6tZUvCXc3uji/gCeAeNvt4fknJ9k3JL&#x2B;gYklQ35nO&#x2B;Bi8EtuB3SyznitxB2jlCCoMv4X8SOo62zE1fE&#x2B;rSv/4EAHLItAFb8lcseKKvY5Yc0J9Ir8gzt7vnSJL/ekPQG6zoFszqc/97xqcOD2sBeWlUE79&#x2B;&#x2B;SmMc/CpybqceG7pBX3InfvXa68LAMxR3QPv23UvClgad9TydsC4vlXin780dsaetxtMtp3ayRzXzsktvwa5Bi89gI2QaQO25yfb/B&#x2B;6v28XoeVOJFYdu76&#x2B;MZm/PCadqTdohQzg1etC1vrXH&#x2B;DU0Fpj/gy2sz9LACC7sLvrG3T6Ll6rqyfP6nE4yYjxfEGheOX2jVcF9FM&#x2B;h8UCZtscABqRaQNOEERfJ1U77L4EenX83HgkyeUl9pVsxn0/Zhiqb4hYlGbLRdrG4&#x2B;p7jJ4N9mxfueW6zwOfIgCnGhFBbJEx6lijMuB3nrcO0IDlBq2sZi2hZe142k2YwRY0mhAPthzMeZcGQBdfrT4AAJXi2EzI4sS5tyHHNNJPP/6mLhwN6hz2KuEyLV2Xq2C5XHAu8qk9Z2HzROAbOsK01wafP303a8evf/Wd&#x2B;7P6WMZSLpbQvv3clv1lGw7&#x2B;RAFAqZkZIJv9w&#x2B;q4o4jBEwdGW9vjst&#x2B;7tn&#x2B;ENo34XOXyczeEaQCqMacN2Njr9Kz4BX7aqS7r8zEwELUx3dV9OxpGmq6vw04HD4ORgzwzadCYVg238S7RncGWH6du4YQJxyCLB8nm/gkADtOxK3vVdC4/HEuGZvc0BebbfQ3mzzV9rYNP7VUcTA1Kx7pfB/323VtuvkAAipBpA/YWBGx&#x2B;tBavNJbLuu0b4CmPPJlIKz3rLtk4V75y3zZ/dfnyHtjIoPWuSyOxGyK3&#x2B;YtMxBPmWnbtv9fCgyoAGEHooMZdu75jyM7uG/tK68nTqcYl4s5V3Es/rw922OnoDYrCBNW7u/YaAahDpg3Ykh/cxgFbY5XFuhSUwfBYTvmsDemDA9MfidnW9hk/PNjXGAvJb2&#x2B;Ml4LIkKqDAmH9vMlHUk25LiBBOIAzJLvH8ai&#x2B;xiIZLW80oiIBFgyI1LQhaTZYVpr3Snb/SntQwk7nJ29aXNt1nHniFZPYSl8MAAEybcCNhKqSn81D39cjl899FWWbWzjUOkx0g6y6MkwuaCdGWqio8dtXI&#x2B;9&#x2B;rf187XmjpwFA5gZ1KXtuQnJu34DCF59g6YA515gHFBTBdrr3lEb0seMCfaV7sd9bs3&#x2B;E7YKrNm79b6Gce/y/ADATmTZgY8LQSOFdcVVJectbC05TjpPl7RS9vk7yUM&#x2B;4EJ&#x2B;DTgRmWYhg42OwcFSjGVnAoH22ovu7EKLHT6yWnzgAdBdkhl5frOzmxQFIy2CsaQFLafYx&#x2B;XbhJ/JUQj9R57&#x2B;MvB30zPZVcgv3zj&#x2B;SccdgtvH7Gl3tM6gpMqhVLXz2AGyNTBuAtJOSbfFPSuPkpzWSwW0vLJAOO7pUd9FsfNPIUzM6eNNTK9UYjvZqpbq18ZQDY5Nvn7/yHACMUDf5rMsQtJbKk&#x2B;0badzvo&#x2B;OuS2tIHlOPBBMY7Ku0DNKKsyx90zldhs0ZbPPu/Iu4Y4JKXhrwhisIYISvVh8AgCZd8j3&#x2B;iMib4zT9uN1eAa2mwZ/dte8LUDK4ttavf/XdFtHOFge5UC4Ury4W9LxxSbM/n0muOIBqTwfPVB&#x2B;vLt/2KCoUkRwGV7TrmXLddeUxz7nELfMC&#x2B;x4JkLRRJuYPf/zeyEgym572UTZRY4n4EVsO&#x2B;vDuXDb6iAKwjDltwJbiZbSFUZalEdQNS2pVl5H03zL5oUD7RaHIDF4RYyhRQvCj/rQMahlhs5oD46MOADFN&#x2B;BBUO2&#x2B;f2dby9mnkivTKLbi/a856Tu36D1PiMExdAYBcB3tcz40FnjXWNlH73uWrzAcAQC9k2oATBPVDFh7JpoTHBLmlEeYfiY&#x2B;QGCPYiTG2iHgvTK1VWFUfUn67sjhMy04pLwmglKkRUcKyYbkfxr3T1/5qXdjiesuTRwdqClEErxTiC/kFr6&#x2B;M83At0UGXyKKuEilO1aUnb6ETZeEYlpOvZpwcHRTH5bYs7DFZItL/YfK9XHQA1ci0AbvKxZaN64orX3ZeEOXOSGjAQcG8/7zgU57bM/VcBmfLrT5NUXuYFS/JNjmJO27NdgCYSRNiuL7r64sbk2R&#x2B;v716I&#x2B;PoV3QrPf4gOihtxnHJsKDaivxKm1fteEOLMVwywOjss3s0Xsq&#x2B;TVS6lHLdG4Po4IarDGAcMm3AxuLgKihLMm6kp5DdaaysYkFw2HJxzmmSh8Fy6OilLv0Qv&#x2B;vUvMJ5J9V4pTQfmLWB62tWOPeauuP0l4X/bDIvE4Adq4pSFHUdNfUMZ55Iad5odFd5zhy7INSK1xQYfQDtdjnOYyQ7JB177HUdHlNda2GyVPLvp7LQd63O8ClzhB07/wAQ&#x2B;2r1AQBo8sRX7k/wr69lXtoFW5P/F73knnTQ4OjIXyw6KReMLQ/SOh5AsGg2igQXYuEHY&#x2B;gV9JeFX/7hB7A7&#x2B;xkIIfSwzFWMGLqXZLN0aajkRr759ofG4Kt6Ye/cdmR&#x2B;UrBld9CzuTbVFl3rLQ5yle4h0riYi845gJnItAEHqg7n4sUVehzO/93U1gFVkNEcseZEL3G8vXvjY4kdY8vXsahwnraqjjxtPrWRxZ&#x2B;ELp&#x2B;N5LTO158AgG/TftozM6k65bYqUTdhXKAroWkzHzmuHv5nh1QxlrDfIXeZHobZCUYk2F5fo&#x2B;lIK4ttqI5J3Au9egAyMm3AmZLz2/xBi8IC3a/5pNzPNSulvx75GVx&#x2B;a84p5y7WnY2Pdu0xz6oghPin1FXN1V4C6KrmAjDfdlkKv55895Rb3450UGN/9B5HXEplC1dPa2u33Qf4eK/9Fpv9eSwxuVpJdcYufmP1&#x2B;m1F&#x2B;HUAoME6bcCx9MVA4kUFXpc9kDeuX8Xhhnhs0FIEwlJ5wQuAFk/V&#x2B;1PHdZ56Xo61BepfY9TRx1m9/dwaJ/K&#x2B;iMkBvNq0wyYM2pNf8LqF4F9zHem&#x2B;tTfita7lvS/UUu9x6Epyr7HJ6ANAL37vJViGFlj4kdAk2JJFLOiQA5iGOW3A&#x2B;fxBpt3LHmqycZij10ILQCCOWOyEKxVLXt&#x2B;p4yUr2tSdl8DOLwiAjZzUc3aFJYUXNG6/5e1FWzDbr25ZMK/7SS2cSIecut5IxdCivZxaH3JOYQ9/ZeKNPhWll/s5u9w5bnTiAOYj0wZc5KmI8hrYzA&#x2B;9JtdaHGfJegyv7UYoi1KlsdMu8eoWB3mSp7Vf23xQvDo5DJZPk5gcgCxeLNl49/i15KNw2I0rpVU3iL5LHJzC6xmt4lq7IgbxT6dvsKBpKL9tcwsQGGzwrWm662a7K/6B0Zkfweyld4LrnvwYjFiD2X7LADCFTBtwozgSWzgdasKy5PPNT7kF4WhQv4VkGyrIo/mcCeFu3ajJYFEuwvKklma5Z0Lh8qKXAI63Ywc47utaOAt9hqbiaC2cYCzImRUlFOcntJIL5gkr5804Jnw&#x2B;H5Nrtj07JdWhN3mq2dp9aXJv7Xvpu30AxyPTBlzHfsQSZIwqIkA7Q4CVdTsB4yyEuLljGDekcXfVsaLwRk3OaXlec87eLfxSADhS3INt7xsf47Vxci97CIPhjhz8p2TtZFuOx9q5GBGMP3N/sd9hrutu2T&#x2B;vanuVbRytpRaoZkSpe2XV0QG4EZk24EbJaiG5WW7TxHtMRs6v6t41wfzCksHeV&#x2B;0aZ7AcY/jx1RZPDSpUxNXJpyqaHX1mXe6hDwuS6wtW7M7yJx/A2Xr1jafJhRUjdhGrSJXdVoDd2mcm18LVLW&#x2B;2zqc1&#x2B;/aWXwsq7HtqRfp2oS/s6zae8oUtBkCJTBtwkWSxjuAFS1Ya8w/A/V0esqpnMNbq28hrLxmuMigHk9xgRZB8Q2hdkWwrahb99pN5rLo3av5pFQJpAKPJXbjX3vvH2IpWmnIOfsSR68TKby/6uVKQJvS3ZrabXV05o3pFt&#x2B;5yp0BRkL5e&#x2B;zPBCxZ2qkv3a7D3ON&#x2B;0deyWfDCm7ZHlAAG0I9MG4Ci5JbWVP9za8kQptrYknKD&#x2B;SYWFLaZcITwoxmItatU3IB9OADMFXVPNEmi9Kq4XvWUaTa4u&#x2B;XP3v8Kpyem9jfrSmkqYyR8qo4YJH49BqVMElAsw&#x2B;yx023zxGszWjnC0EV3TfT8PAGAQmTbgLstLRAqeQC4O&#x2B;fyf6IM9OXS0VlqkIj2WbBPLj0tg3xbh021x9ehkj799ZSJN/tfqA&#x2B;5&#x2B;TS3kye75oALoTsicyZ3GC7uCQUMpk21JpoKjFkGb5NrnQ3mMK8n5tgm9l&#x2B;UHcIC6KvF1Ozos&#x2B;LITrQA4D5k2YEstIXTLzCf5XRX5sE9bMIH4o/EAACAASURBVHyq1wskNxTNiGpm44fDAjyf8KyhPVfkj1&#x2B;en3nK7XRJERgLiTcASCrqk2uq6p3RFaybn1c0LK/XrpWmXRc/KGsZh&#x2B;fGQcY/D7bcPVHH8MEJLHeNgr7ikYHAtM65cke9WnhmNYtBDXjehw3ANGTagF0ZDz&#x2B;qQ69c5RzlRjST9uRVLqw1rGaViHiKHuNSUc2NW1weY9g5kiW6pNm6b7NFbuxt90vc/TTv/AQCmE/TBQ1eo&#x2B;y1Vvdvp3WMg064cqearn5Fxq7o9XY27htXkjFu3udP3TjOZPBV&#x2B;jH4mA&#x2B;NzRrUM1RuVn7Z5YFAUkVrJMu5x/&#x2B;a/KeKj8fMWKNuX1TLBDAUmTYArSoWDNcvRFGR&#x2B;qqbDdYYkw&#x2B;Ve4igmQ5o6kSwnaJwzvLAWPv0lRsHRX3tl69iBfuZT0&#x2B;qd9RyhPxSAKgm92ZzVSUrqpEbGZ4VTMOKf96ioj88rgu9MNk29FqXhmxxfcsuLWPnI72ctT48eYukisZP9p83nT3WrujAzJ4FgGP8n9UHAKCbceU7Xr3u8acffyOngoQX&#x2B;C8r1ZI/C1JZRjyHJJ&#x2B;IwcPGSX79q&#x2B;9eoxQh2IvfTuD9&#x2B;MMfv3&#x2B;aYtrzjpnR5qBl2Co2G7&#x2B;lelMAMI7fEe2em1kYNQhew4Hcu56/tMxdy3X7n0OyGRRojCjq2HeDmj1qzmLTC3Seur7l5X0wFwKM2HL7iy2saiZvalwDAkAp5rQB6Eyu3ygMVzwgFJzGjdbUNFpcWxJIqi4SUvrGaSt42xevZJBrSU1DvV6I5EbqrntuOpr&#x2B;h9XcAb9uNne&#x2B;yh1RsAjANEK6KLdWVm4Lue0k32KtqqSmDrzwXv18JjrGMwVJTeUr0c54N&#x2B;bU4pCakozV6auOazBr3h6veRwHLxOu4Ko1pwGgFHPaAPRXnTNzQ1n9kbZdZrMVHcPHy04l1wAPXrxWMMvNX9muYpED3CkIoibES&#x2B;cF1YNUVP7RXMGho1P9lOGSC12006J2A4BVgp5edfdYU2J9bf&#x2B;2fe/yLLe4iP3rT3qxEDhUkD82yg9krt6p5r3xazZtySVc38ZCluKejlayV9kynE7eQstRlW4h&#x2B;fNpNUuMzP8DgBwybQAmkaNWIYRrr5wTD4/NVZUsDduMPJKwcAA4Vd1spxFHcoNeMWouCm2MIYuO5&#x2B;aPwc3nDkBJTl0IQ77it3dJC8WzjjbtW/qd86JW2rdE5ASucXIBXcsHsiJ5zMWqYCrldqH5zd5lj/pq83N6v12KZ0wuoQ/gKlSPBDCPHBElq9AEE8gaY6pxS2TbnDRGCIpG7UGIKwtzT&#x2B;6hqLyJvKBd0U4btxC8Zf4l61sTJrk1/eDiLruTdw0AgWS3LR7U5VcsmFz44TzJKvfj2mf09odyR/4aT&#x2B;kDENcgFW0ij&#x2B;As3dpV4j5JrpfSpTd7WxfIL5YQ/9AZ1yy9Orev127ale2bFbvtAwlgMjJtwGx/&#x2B;&#x2B;u/rT6EldwKCn6Rw&#x2B;TL4h8WhWGNQ30rclT6FQhmktsZSHpdP6BXfugk1tYPqDgYt9ZC6dw1a49R/Gccdq4IALwqWoj3oSwV3tizTW5wr76lH4MoV3Tr25&#x2B;3Ex3oJavoL0kWVvxG4FG3BnP8xt07hwt1HNelf&#x2B;XoDvCINZjrIpfcBkvfMm5AHoCrkGkDsIxyOGSwcluv7beTl3CzE&#x2B;b5T222eyyCVV7nSHWp3XGAcQm23DYHRX11167liifbbaPc2IWfdgBr&#x2B;X3jcQuJ7d5RrDh&#x2B;zdp1fdkJE151&#x2B;Tzos5uffOPEb2dam8DvoFYn2/T8IhZ0kHwts9mmDeOTL5x&#x2B;EuQgpR&#x2B;q6o89ALRjnTZgb1uvo&#x2B;AE1fnlDFbpljXvrV75vGVResCOumr1T8zzvPHOoHp0CFe66HfLdVyl&#x2B;8LmRQN&#x2B;O&#x2B;7XufN3AUB3yu59Yye2epsVMYhbW2v0IlvVyTa69EnC56Elr6lvbf8DU/2BByyo6yXKveXqDq3&#x2B;YCx0bpXHQIINwFpk2oATyMubfTZJxZXG6sm3CD8f1wiEfLiBfpzjkVzYZvl8i2JLOycSPD6QD2x&#x2B;BR7LuwBwm/Y&#x2B;Z8eUib/B0kqMo5NtdSqSQJdIfvDa1892f1dmdj//b2abXzTV4AfJuC6jsux0IzcSNJo8Qi74p8m1LrroPpxumtyRW25tAEaQaQOusGkQEgd1yrOoPl9/sG3RG92hbtrUAATTwqo45O4So/qbnRnxDp3v6G&#x2B;2dEcd14rXrGKy6VMGADb53WOhmF51T7juqITSFDtqnHd1ntGDOPUNnhxg6h8PIyCTXH9SWL9KubTVVb0av02UJ&#x2B;5asntDVdSuqD6GXgevCWQ0QUrFhVDuve8eAYBMG3CX7apNziky4&#x2B;sSm23UwsBDH2DfZnQ9Rn3YnHul/PbnYA6&#x2B;iO70B5XWkR3csADMGtHP7JWcOCzhdNK5JCmvV5C&#x2B;GneVmVbYS3LwVvJlwluuZbMdJqTZGru1g1KM&#x2B;mGINi8cgKuQaQP2Jk/AytXW2G7Y6YTjZPwjkAywSSQo9WqoeMTxhNUXhnodT9rxOCsykQBwiWl93cOSbY5wUguDiJZhlJYLclTXlhx4TBcIYgEjPcmZOnYa4w7wzGqKy6&#x2B;dciRcr31NPt/lzQvALDJtwAmEfJscVLcXmbEmqOK4Ku7dbu4g8CBs0Bv6JKJxWLGF69h9QTXlegmlTWehrQCgr9cu6OQ&#x2B;KqPZPupMZ110NiFb5g/ZnPz5aaktiVJX9YvmZ2iUe9x6mN2q5dkoXwHAAjJtwJkqqtXbHM/YojRSLc3MJacJ5o7hsLYFLjEiZnutrLJvjm3owmxFx6BUWuez4jCezB9ROoAJqnubcX&#x2B;1ImOh6UgfnAgR1swLXrP72m8LD4nakn3d3DkxVfAg7ijuOG5sbZN22TsFVAG0I9MG4B&#x2B;cN8utSFGhkuRrco1Gyg04WBCVvWbRlNOzinZtIcZ&#x2B;KBNLcYWiuAXGhbulzVXXvO5dJNsAxE7qHD6ncGcx9qLM2dAjuUdpyHYnOW1wc7dkZjYluWDea&#x2B;Nr1mCeb9qIumC82ujd&#x2B;fw93vw7AqAamTbgTK8hh2ZMpc1xlK/qgvxp9R43bVVgL10SG9Wh3YVplQlhcK/Bqu0beeU/iZi5TAWATS3vHAad5&#x2B;6pi2Tn/ODhfTNzP0/bHtaARZjoJsglKuiQJA1qq3gNZmF3yq0tVDeirmj7yb&#x2B;3b1kpd3Zk4ABokGkD8HfJGNjFxtZCOOF4/Dxiywrhg7h42GbDArt7AqG1iY1Be98otGsPgxsHYi8flEpqDYBgSVbgtc85OmeTG&#x2B;p3QK6o1ym8rrEd72VcsLNXqELKLcmleeiTFGlprmQf2P9hRQ/Z1OUr&#x2B;jjFr0yOSJPf/pp&#x2B;819voZo9gGuRaQMOpJzQFv9kRFgyqDCOct210s02Bskdl8cAoJcLqKw9VqgO/IS3jB7XqUlWycUzg/&#x2B;deVFMXX0AyGns/vWt2bg8S3Fer7gozprc/kIjL/8k1NkrOzgNPSKne7dZ2b3X71dflH4Cfb9dGZLkij28ziTTG7cM84NMHgABmTbgZNUj&#x2B;4SA8Lzot1pRCwRN6qf0gnI9NCxggYUFsbcL4V5j7L6tmtvaqhlsq3YNYGu9JkI1vnHJEmvxTrfuFecO&#x2B;Pm5Ji5TzjOb/JmJ92jw0pBgQ3ddSiM0dn0tdCxLu7hbNJeFhgVwpK9WHwCA9YKYJA6lgr8E/7rjgEd5/Oa4M9KEf732vuN1ASr4QyMtpMfa/fpX3z1/it414ty7DCOtW5eieu2K5SN/g5&#x2B;44yGkB&#x2B;DY7KQtyVLIO7XZUAH/FJ44ws&#x2B;rJV9flOVSpt&#x2B;CP8rtV3g2bvPSyHErttalo1s3saxl5ea6N35s9GnrxrQF76poydITrwudijwz8Py9nBF1AuiOTBuwpaJIeEKkoS/0H/xkYaIuiHKTTbp8XGRjwLy2hYF7tAR4fpy2PKjOkY/K/9eKsDMOyOsyfKua7pgUL4AlTPXTnu7xnPWulN1sU&#x2B;2jVNf9FgqHyF16uQxJtSCDOGIXgNLyjlbuALocWLIHu/aU11aw1CfkZvb/l38IAWyBTBuwK2E4ZK/weGieKa4Vc3O0phnc2tJEpNywr6Koples9brTID3WZUc2c2xK7WM8G4f9Vr8XAJZznTQ7XbUg5TaHn2paPtytiHy0FeeinOpH9z5nr88PYslhTKaST766jujkRJGvelhbclM9jkjahf&#x2B;v/p&#x2B;O&#x2B;5X5BVSm7bTa3/7jX1YfAnA1Mm3A4bpEX6&#x2B;xyhnBjB/VL4nwc3U7k1pmuVW8EVjiiWdKo5oJoVeXMK9XtDbofNsPT39gx6TZTB2MBtE4sERuNa&#x2B;PpWTbw2zSq6Lww/IS8UXbeU22vZ6L8mRnfuQmtL/ZTyy6aOkxGkmTLEywfcZUYsgtaBf8ryZ12j2dCQCTkWkDzjF58Km1BwG9WAjPlCulV9eWPPXa4WDVq3ZVbG30PLMnxDUS7ff1elL&#x2B;vDdNCywZuFok&#x2B;XDB7NEC2AXVCD5vyyoL/7tK91r0RVGJJhLMfa5yDZgsIKnMBcb7lffVzkIQhy72mkKkpO/QzulGCnuxVtl&#x2B;yTHk4rWTPpMARiDTBpzppDDDSPC8kLK2pPD2otcDeykNvermyflvHxFiLQ9i65S2xrjVLCwwe2AALEsuypX8&#x2B;z2qh5GZylD2Svy4FJq8waJz1&#x2B;e9OgaVE5JtOM&#x2B;0xEa8Mll1vy7OVO3VRRw00PB1j8lLYK3prB0PAGvItAHH0oRkpVYNIL0wHmsZNxpbstgGUGH0ZK9x9VKWGxf4tW&#x2B;5YhqfwdA6yT9I/VxJANCry0&#x2B;MzjlN6FjmTtz/X8ud20GNv7C&#x2B;/YURGUawuQZzcqcVe7e8BrO&#x2B;Efwsl/Au5QZ7rQk3RxyzJD8P1i4uACPItAFXKAqGx403FLa8UR5o&#x2B;aG2XJddGhmX65WTqMh8BOGxHFsG/1p92AZDtb7lOks3UrSd5RmsXZKCAIxT1jCom&#x2B;&#x2B;1dcpN2PXrayZPcZvTFHVD6JLtoNxI3/MiHrnZ8m6brKhTd0NpwbozaiyVv0W/&#x2B;rxrDaCL/7P6AABMZTaw&#x2B;ebbHyqOre5dXcxfDy&#x2B;3x59&#x2B;/E3dE4SFrQcE5sQqpXtRDuH8wx&#x2B;/jwNCfYjYGEw&#x2B;R7I2Io1bYK&#x2B;xqx3lPgw2o/G//ce/rD4EAFlPJy3XxzPbi5P7pSOSXm6P8san5dsar0vRlU2uo2aQu0Y2P7SYr7r7Wtdd1Ayka&#x2B;mI2uzmCSpq7wdVHJ7/DRrz7CrxAKBBpg3A3ykj1SCE7hUybZdsm6x0JTbhxZZDcSDJeNClDCzj2N74eZUanWALXrw8g&#x2B;U/J9ruIQuAjSS7u2aLKLYfzNByhfZTPnXRzZwaj69DAHMsNzjse60z4V4264jetRzMwi5uctCY5l2al2lG5tUdwAi5w1gegAgYRQcsR6YNuFrRkMnGooV1C5uXFr0kigMO8BpfWZjIVafvMbswb3lQWhpwThvFbIHZaBzAMeyPPKsLJYaelLVUpd9ELRdUWQbDz5lpLk2vsXr2P6voq6KP6jIZmjc29rJsZulGOHix6hGO/zwEfvazf/rf//3b6qMATsA6bQD&#x2B;QRz5zI&#x2B;F/AUVNp191XHJCmJRHE&#x2B;I05RBzoQ43N/X6xIOt8VmeprW24J&#x2B;BXizjyEY9ApY5rp/yZ559&#x2B;lEcxYzez2M5Ly9Xgcm791gxDHtkGaeu8F2xgTV3aEunaigdKT8yuBQ5QMQtrZpX/c5X02zV4yxe20TI43mDtVyNx6AWWTaAIT8QJQ0T6PqlFtwFXLbqVgKPhniPq&#x2B;ZvGg8EOuVhlkYqhmJEjUalyv/FC5H94xQPiZkFQqBHnOOAOxT9jONdOmFPq0v6I727Z0&#x2B;BxBv08I4v6BlunfOjXwMcI/R86jk/02&#x2B;Pfea1/detQZzUl2V&#x2B;Fxwt2NvecdjBjAZ1SMBJIwLw15jRU0wuV2hSAvz2&#x2B;KGzS3n0FjUZburg30py9E0ZpJyb0/&#x2B;U5eoeE4pyDmxYjL/1PcEB7WVf5DBIw&#x2B;56bYIwpnQBhin7Iz5rxHeYrBvVpRsW1JgY&#x2B;HeYx0rLrYUgWSxZ&#x2B;gZ6Q7Nn0vXJc22vCy84&#x2B;KdojZpWYYZ1ejeAxaQaQNQQyj033EXH3FM66aRXmkT&#x2B;aH1iAcluSlujXthDQbouQIdwV98cdojKX5vXahcVLVyxMhTOwF2nS5XoWJHM9U9egAABIJCDpN7&#x2B;H7Ekey&#x2B;Tu7TJiOgjoKorW5HdQ3S66QMZo5RYeuOriMEL43GxQLKzdbNYBv04mlyzS4MvgQAH9UjgS0tKfSXrPfSfbHuq6wNU4v2SGFJjNar&#x2B;F5jRcSK8pV9Fx7zJ35pdp3bSNG8q&#x2B;ql8uIKiqOXYdAvnlGxQf0/VezdzgMFRrwCNystGH52D9BsPNIl4IqvXa7EhXL7LZ&#x2B;EXsMlD/40nkSo&#x2B;lDdd9XspVpj39VOH6&#x2B;Rsn5D/K57lmE&#x2B;qRI&#x2B;gBGY0wZgkvYxqkdGVsqF1horvXyi1ov3G7zMDeCNA2OzTyVwAGV6iQgnMKFIo/4AzrZvgg3AFnJ1I7pI5l2s9ev8/mdulWJhCppGUasmdzGinodmvxWSJ/u0ob4lG0vNHxnEQamuIzStt&#x2B;&#x2B;nAIWK8ROOpItcpY0RjXlSRKZZ4W/OkVRjIB1gBHPagHNMHnOqWc&#x2B;8y15G78KUoH6O&#x2B;3v7lc1tWXhZDtEy7CiaweZGXNYNvbQ8WjM3E649LKye8pXU2IZdqjXGs&#x2B;LiDSZ3UTqI1eYHhjgcMKJoobIL6QONxglSz59cSu91j5Yv04jPWGNoJry99GAstzyq6assTMt89FqDuX0j&#x2B;r2M3l3QxbWfhWrBJDYARZjTBhzCn4r0mZ6g6r6mgnz8mnUFrK1krve6WMWI09E8Sgh&#x2B;3uUwJowIhmVbrEZm/widXH5o9LOJ&#x2B;U1UPW9vQmGijT4wANaylmzbsfMcH3Ndo&#x2B;XelVy2Lf5J9dS60e2cq2xR/dGqeKMmMVkxtW6Xj&#x2B;id3GynEZ2ilhLx8hbiSVobpdkmmJBdGzdPLvhAvkYQe101BtIBdpBpA04QRB3C2MxLNFY4MaVjFlNZIkZI7yWPpEvQu/U1QovXOMePuNpD6zsNWqdd/&#x2B;LnIm50FSri/C3OjjgcsClelOu16Hf77raeEqTsHi9Z2/j5i6k06mtBzr0ccAo3CLIyyXqG&#x2B;lXBpoUA47pzpanH0iMZlxma3MVd3qPeK8cGwBoybQA6KI0VNcFn7jXu57kYe&#x2B;sHB0l24sm4zV8XWgd6uWR2kTwK2DVCRfjdcZTotGsxaEB037TfLh8z0mzA5Yo6aY2LBE8QHF7QW1YeuXCOr91v/71xcxlMayXLZky4yn1HDXbZDmZylbpbuoL3SHbX/Z8M7XZO21Gwx2dfXbr9FZ&#x2B;03WNMeviAKWTagO0ZL6NhJEp3qTvjzTWNZg5ZrtGmXVCDDynQUTKqYQabkgsjg4Dcj1TjtzTuMd7dZ/zg3yQhaziuWlFwAEO33xcROLAdv7s1qCNU1KOzWXug&#x2B;pCSzVu3aFlQwH8j/uBF/Ytb9iU0kZGAEasE/Tp9lzWYFbdX90wpXoNZc5qNo8qKKitaa3bh3P2hhxXDEK2dKQCDyLQB6OCJjqpnoY07qo&#x2B;4NoDNpwZKdUdedwnmtNLWlwMtciVlSrdzfPDz2iauBUYvcjDBayK2i1OrRDrk2IB9LekU3VNYMvnG7i9mqJ/Pb4qibn/8YkbjmdVeNqCup1e00436csrW6NI9Xhh8tXxsWtZsrsjpWkNXH7CGTBuwt2TYtjAy7/UyQd98DNkdDc0DiwMezWAtZrAFGmPO19d0yVpNaPwlc&#x2B;amHcM4BN7AeUYPWYu7xJvONJIPOxiEF/Rg2&#x2B;OC1y7xjk06gjIKq8jMYa2WzEeRHbtnXSxf/HjckL464xrE&#x2B;GeM3j5gEJk24BB&#x2B;7LF1KOJi417rQyQ3kvzhbaNN/c&#x2B;J8JnRPClYNW0RW2ssFGk88lmiNHVUOv53fq2Y7rvwK8asOoahCLmBs63qoG7XMW6pCdllR8ou8alzs4TzSpbcVKbc4plt5zXdDSo6Y8Hbex/RJEVrMMvZI/9fu09o07Rw43BAodx9xdZy/1tt388YgOXItAFn2iLw0KwT1rL9uFZksHchpVfXgFtEy6XLcgw9mHh3xlsPy1kbRGnHhGaZHHb23V1R&#x2B;&#x2B;SeelhGjg24SkV/6c7hUKPDDf2OLqTv2OeuwoWf2K1pSn8zg01PbqsuaapeGS/9Hj/ll1I/ZU2IE19DyL0&#x2B;YHT7AbPItAEn2yLx8/AP0siDAL&#x2B;ezBZtGKg&#x2B;Zn94qYULAXxSwc&#x2B;qlc&#x2B;XF2xxhg4EDmYczj/l1z0mA&#x2B;Zkm5ydmiXSBkCHTclvKGuNFo8IXHUkW9so&#x2B;D1brzWYP7vlP5KEHE9R7qelQxt37FumFdaJ96UfQDk6GNnrY0bnH7CMTBtwvpaiiKaSTB0LS5ae18Fhm7JVg/Kkkw7uAn/767&#x2B;tPoSVSkcXLs9yLczZNO56rwDSVz36tXGPxhFjA/CVdmuP7NNqyGP7GptFv7Dx64tbrpH969u&#x2B;urO8EID9FrgHM9j0XstFzjmMQS0vl4t4PXHlUZ1aHP5B5x/YApk24C4VgceSWMWFT7ncz2tslgzhgoUBcosHuDcmX1ORdeu4ynpfwQlaSKERG19FqO&#x2B;hecvkGGlmiMsyA4/cvLqOOVdhvLDN1iPMBs6wfBSXhV7fcsEst7qN6IcAxrvQ5JyKPiobXda&#x2B;a&#x2B;ltdOKXuHYGW7u6paxLmy4Zbqxq/2DZOf1h6Cfn2e/hC&#x2B;j8Axsh0wbsLZiQVPRes&#x2B;mfhzuquulrT4PIIZxfHzLYqXL7pUdlRHDkFlZuG1rDZ&#x2B;uLdRU57Fk706h9jlTu7EaUweyytbOXxHPrUvhjbC2fLzE2cKRxvXF5g6QlnLqWnzBYLbeLLfq0RQcpvDgIEHKNwOfZiJau1HbJj3ZFyaERJi/S9hlwlSsOfqNPGp1/YEdk2oArxOMlg78bj9kas27CFjTnPi4JtHw4syCOYJPjcCdHthWlUIMjtNzmt9loaGGXEHRC6ctx219St7MueH59l5zyNIgwG7jB0P7Ja60IVIvbs2WqVvcpbvb5MwKLhjwm/94yCBXz&#x2B;dOYVi3APJOmOz0/dTSnzfvupbSVzHbyc&#x2B;j8A/si0wZsr0vMvFHMVnG&#x2B;wfhHYQvyMunj8m3LW14zt2/ao5lcg8Q5s9d243HSkYYGhPEqAo2xWcc6kBXFNjeiTOZVD5cuXVV&#x2B;easSYwMXclmHQVPc2pc6voF&#x2B;LFffy9Q&#x2B;snA7Livm/rd0YF9yRB0Wahnz9FkxtGv5ItC&#x2B;oi6uncNuUdSxb4&#x2B;qjDcanX/gAF&#x2B;tPgAA3ShDi2&#x2B;&#x2B;/eH1lZrXLPSUhfSLQwb/&#x2B;vwlCN4&#x2B;3nm91ntRrgPXwmALx606c02IiiY12IZQsjmhzT&#x2B;qXNH/lrXK4xe0DOD99a&#x2B;&#x2B;e/5UvFe/i&#x2B;Aven5hxo5KH988/ysff/yvCz&#x2B;TX758/eXL10TawPFy/djH6JLa8t4hmLnCMR3dB5/VjQj9tGTHNegunroGc191/f9gweOuR1TgueIVk9Kqj9n&#x2B;Vf7bf/zL82f1gQDogDltwNWSJUr8cYULjqmQfhWKoJxI0XDRe8aWxnLnPnkqnjANsXqxPexl8jJayQhWU/JlXBw7fzWFT/Mjj7hBkht0ec1k0ku51Ln/lnjL/s/trADv&#x2B;/Ll69WHAGC2m3uYJ4mv44jL6vd44374wR&#x2B;koJN/8JkeqWWM2lB7rcE8YoPzzbniRnKKGmTXgPOQaQPwD/YNXYKZWNXLuWneOD/DtDZ75DeLnHjr9fmR03jKMjKk3MzadLF0C/Gt8XBRo7RKz9BTtnBNSbAB&#x2B;Og6LX0HOSWHo0HjtSM6ogtatE0L4YNGsIJgcsE25Up4fIYtsFmyImmXNZg/5lvSgmAsnf16&#x2B;yTYgINRPRI4QcvK23cSGqq9ok5F7U37Fy7XLH1L6Gia3S2297pf&#x2B;616pyD4sRPzjMvolJ6j5kjstBuqPYUiVx8FgJ106dske6qaKhHGy8vP5Jey13dNl3iumqlD8vmr07kfJj9vyTAkdwmwF02t72px4cGhazAn/7Wu2GP3KvEzJ3tVFNWv4JpoUNX67qgSCRyPOW3AveRlt1&#x2B;roBgPZnJLuCVrY&#x2B;ZaQL/lmDyzSr&#x2B;onuZlkxkZVFs0dnWXsb1H2iLs&#x2B;fxjdcq6ZclyP&#x2B;nVAru0ZM7a4/ev6eRKpAEj2TXuigByuDN0NK3curwowMwjKZUsTDK0PAlGKJ3QNmfsnd8b71KGXfl2zekku6OWx9JV1KVoP51erbS2YcmuAfdgThuABGUFmwlHMlkQjubKJFZvc84bJxv0adnl9NHCWjApDx1Vhtb6RcWSr/F/6D8d2DfNZrP8Y/dhwq&#x2B;eGWym0mwAbiMXJ1C&#x2B;BTl22iq3IvUWN//ccEn92xvLk2AOI1GAfBijJ2YF3dE5tShbZssJIwvrtlZUycOfwaZ8S/J/pzHV&#x2B;QcwB3PagC0l4&#x2B;TSAYCvAxtzM8Di7SQPyaY47NTMOZsfl24RCTsdC&#x2B;bIY1GVH7NgsYeYXIsGfeXmDxkJsGNysq1ilK7Sa&#x2B;LNMdt01fSTzEqfR6ydvvawFmDv9f0CXGvQurMVk37oKem1dInnzDkzO7PNF8zPs3/AqOtrLe/QKnv17ccptM/ybmqLooNvOdP4EgjXZWgxUiVrnX8A05BpA1DMz&#x2B;rFS8TZj4X8Rwzx0fZabEy5nfOKnBSd/rgD0H8Ot3jisDsL2Q6951BLw7OWc9yocZKSsW7cIKVNFLy&#x2B;Zfpa3RsbGYmxg9Ewh33jADdwHZVe3ZXq7dBfKmKqRsiOEQeft11stAZzUceyYv5W32SSKXEdTuW7KkIqzWHkfkiCDcBaVI8EzjFzDQDBFlFcXFdEOK&#x2B;60iuauiXd1063s&#x2B;b5oE9j9anJl8NCix3Pr1Uyv3BfteQIymm7TraStabTV8usYO1klXYpFMNDTGAvdFf2tbaeYbDrXHl8PmBQ8ov&#x2B;7TJcbGaXvigRNegYZlp&#x2B;Fn55yVXHsEvnH8Bo7rZbTgAAIABJREFUZNqAo0wrTC/vwuV79orZXteuqGjY5OXYqE3a1TXaiCORXXVRoOGCRn1e8DUxpg//chGjtcyTPrSuW2pueehexP5iDBTOBXZHd&#x2B;VI/rTj7tGT27hyjt12ERxWSXbtTPVUX/vwc4of5t64Vy/XuFXjOO13/gFMRvVI4EyuyEwyTArKPxJKOXFhyeVVEBsPYHlVT7OfruXXF3vxKxnmCqHkHjcIqwholmEz9cyiiDvB9mI7lhvBcnSdu8WRZgPsEzoqZM0PoAnB1l5c6qvjDMGgt46rKQsvdjsN3pjbjuWObi9C4&#x2B;tXVnMboUokAJvItAGH61vsUZ6elXsisFecJh9qco26&#x2B;YeRRNKoAplmKFWE5XUR4EaRdm6lhC7L8m0xztd&#x2B;mJ28xW30jQzgIXQ79&#x2B;pmwxfUsTfYI3WfrmDJT&#x2B;V7S9&#x2B;CXTydVeMT2nxCbkazkNjxVRk0Gpdbzr2m7kgq3tWL/c4/gLWoHglcRLks2Yjd7auo4kqppzbLGQ0ly51jrtjp6Da5oc3RxVMYpzRari44afYJRZHS5vJfX9fgk&#x2B;1eKMbgw1wAevwKn6q9av2gI3EoLAlf0N3dtxM7bZ6ZUOWi744a5Xrj8XGWHvm&#x2B;H5jdO/8ApiHTBtxFuYpbLoK6M7Lqu/Rdcs5f7p9aNqt5y5wL&#x2B;tp6mub1V7DocEyAwpzFG57nFKtWF9iCnZY5JsbmRgocgK7RedyS24PSbEVdbgEfOTgbdWLXVh3MFUi01nS91mA2PmxOb4vOP/dkwA6qRwI3ctU85K/kli9seaG4rU0rIDnZoNMZNBew&#x2B;zYBp6L4of96awFzX67GjjvlltGsn6jpbIbl9gPsCod9hQHw&#x2B;V19ftNRQRPvBB1yPmnYRa76pf69Le&#x2B;yHCko26S6u26zn5&#x2B;0UeefZyOAKcxpA&#x2B;71BE7BqEmGx2oMHW1aodfFMlUTxlQLA/jkF2bT1Hv0V4Z3Lx5Rl6avLcaxAriKvhq8y5QMPyaM1LFLPPTDwCcNe6noYb6&#x2B;xXIWrV1jnmyLNNt2VSK58QLWMKcNgOrrOTc77chZa3NYTmq6Q1qe69KsFb/8IHEbYVYWArknDkKOzcJDio0C7CLP3dIvWcz9E9iXGzP32pPkl/02/hUvuvqaku9CBvfZl8HQBvCtms22o7q2CtZgjqtWGGyWLTr/wf2cmy1gEJk24EZyPRA5QCKCEtS1TGN7zhmdauQBDZ89LKSJCQ3GjUtsmozcIsbWyz1d5UYKHMMl2/Svd38vfZeRriCUF2LcfT4YtKE5DD48MKJuDeai7v2&#x2B;sUCv7nq8HcuBwEad/&#x2B;CuW/eFDmA0qkcCt8tNEhLidp7QCTRlfOKXdZnfdkkHy/9kUmESI8SDLoOV3l39Q03VxGMol5EP2kpp&#x2B;VMJO4Vi&#x2B;n7D5rZmeVI1YN/PfvZPqw/h7&#x2B;TfYuGXnV//ewy91kFvnM8VznBJDz95mnHsI2tcs3kVO53/RjwPAUwh0wZcKjmVLfkyP6sx/LCw2i65q9LjJOxHBTnI1Kwxhk&#x2B;moYysDL/dYgxJuRJewuu5JQJbC7pArzl1gak1etFXkADTXOXST0IyThQGa1Z/3viIogVddEE8xLBoKKFcx8Jgy5/R&#x2B;Xe2eHQDXIXqkQDq8b2uNK5Ul766Y90iDRuFta&#x2B;NzCIl0LhkBGs7FzmXtpiR9dgsB9gVN6v4Lclb4ka3dOAeFb/vn5K&#x2B;pfBK/&#x2B;d0k86g&#x2B;WBMuNDxYcT/W1f1FJjg5nBAc&#x2B;5&#x2B;FCC8/nnZ89&#x2B;6UpwdWe75V&#x2B;CuCJhFpg24V0WU5dflJxovYiF3VbHomnI0dOlmBylddBCoEy/r/VmdN1qlKGy20ETWwuwJ36fPbZA7IXCYEQsnk2w7QzC9bMT9X79N4RPF5w0WaOqizzmS&#x2B;fzK8LmEmR/1BLX0i/a1toLFql33lRtFx40UMIVMG4BifJe3GNR6jAwF2vlBoxwQHhx16ylj7GRicjKbMba7FS8Zv8JXOWBWl/lq8ruevwjP7OyMo0Kj4EMy7oIqZ08GP0&#x2B;u8canDn29jpD7wx&#x2B;/r67WcLw46ima97aKzc4/gOORaQPQimlDXbhmrB6XxFVICh4YATnE1XqMYx1Bf/NXZuZy3848wQTsm/B7GmQ1gkqSyb9jU6VrGw/Nxrm9xPsN/s63FbpL9kifbm2yc7s8XTRNy8C4eFYcJeLHiW/RTGsDTCHTBqCDvg8H0c5IU9sZmrr8AGCQpmQKArs8hjAeYxcts5SLnyviau6EwHaEytjkwDCIZqW37pVL644EeEUnf47l4YDxzn9fwU2YZBtgB5k2YFdf/fPvg5/8z3//&#x2B;5IjCTDFrVrdynn6&#x2B;kLPX&#x2B;TXH99LO/vsUGGX1JFZ1trKfpgt3ITlMf7VO&#x2B;K&#x2B;B5xhaB9bs/G6u8rxfcuzDbp2RZ839798kDBCbtSdtS5uX/6Iw0fF6EMLTWS/5z8IlXsAm75afQAAuvnqn3///Fl9IDzUm&#x2B;qnH3/z/On1&#x2B;m&#x2B;&#x2B;/eH50&#x2B;kAARzLQoD9&#x2B;PLl6&#x2B;fP6gN5Edxai2aEJ7fAvRq4ynPTmNPTfu1eKmfl9jsimFN6feMQo2gLfJxQqnoNZjtd3Jn2mv&#x2B;3Rc&#x2B;/C&#x2B;HhjHI4NYBpmNMGbElOpz3/ameK2&#x2B;pD2FvRrLVBhVzOvohnnx0EuQUJ7gyt6/gLyC&#x2B;xV4Atr5pWcQMnqAau5Xp98tip0Z2c6nLlzE/aQunkxfZXMksDC90cAgQxUVFWcrKNOv9zvumoKQWYQqYNOJbLxhlJuaFaXVXJEUcCHMbaCt47WpVs2yjMjhXNQq4Lngm5geNVTIqt20tpBkV/YPRXDZp/UeKxff6njofIqLbXDK0lnm78Lg21V&#x2B;e/ugOfuwknN8jtEbCGTBtwPjtT3AinIageFg00Irum4VqpaNBrd3vF2AH5cWHLw8TcnZM7KnC5ac/ggiK33Hzu8VzuCZ80PlR4JWSM6O3n2F&#x2B;gbuvOf5EuM4MBrEWmDbgFU9ygsbzSN09nACSdEWb7dbG63OuSGyH8Buw7u0b3tOwL5og/pf711V9ofXHII38vAPvspNn26vl37NvHz0OC71O&#x2B;WwHLyLQB17EzxQ2WEd8CkM0JxfcKswVFwwiEh9RBri7eLOE3gJicKRmNcVTwLR/Yh9vYyR5BY9/O/6oiPXzDAnaQaQMuxRQ3zFf6nIV6ksC1do&#x2B;xP6l7l3wPDB44FhWQST4x5&#x2B;YJXG7aemn&#x2B;/cfdjuSbGDeoA2i&#x2B;euRPl36KG6ARL8D8Ic2WkVuebdUCzJ&#x2B;dO/&#x2B;B0tF1n9rvRL5JAYPItAG3I&#x2B;V2EvudLX2/k6gbsGl0&#x2B;H1MmF1HM8tEU7DL/tcBgEfQNVpSVbJXp4s7z77q5jgGqbJcQWM//8qENoxGak0pl2ybb9/Of&#x2B;4&#x2B;lhwGFyfVghe83ofdC/i2Bcwi0wZs75c//4X/v3/6y5/rtkNVScwRdyiDvwC40L4xdpJ7&#x2B;KgcsF&#x2B;RMwui8WCPAA7Q/TdaXvqlO2H7PCs0qPpyVLwxOQ8SwGTJWYDTHNb5b6H/uud7EzDuq9UHAKBJkGZ7fhL/UO&#x2B;rf/7986ftuGDFTz/&#x2B;5vmz&#x2B;kCyCK2By3358vVJkXbyfhs/3fb/Vxh/kCxB6b8yeI3luz2ACgu7SdW7Tq4J13w42Ezuon/z7Q&#x2B;aj5byZQAazS&#x2B;2&#x2B;fT8d&#x2B;/8&#x2B;/covzfesnwyNz3gAMxpA870y5//onpy24MpbphsSbkkAKvsHmALgrIwcrYsnpf28SaoBT/nPgmcbf5TtuTsWF/dIVWsy1vxRhjnf7pyE9fkb0wmagPTzMmxjd7FQi05Nvn1ZOCAjZBpAyBhFTcMIheKoTcJnOrsGNuXvI8lF2x4CA8TuSUCcDR1F4uSE8kpaG5VrfIDLBPfFcmsnISrCRg3oYDk2Z1/4Tt09I4AGESmDTiEm8HmSkf609r&#x2B;87/&#x2B;3nP63W9rBisxxe08&#x2B;r7a6GVCeKoC3ODsMLtC9TQObpgAgO3EC5cm51CybBsw36AJbcd3/ks78JqbW&#x2B;PcOABrkWkD9vanv/w5WJUt/omfZnv&#x2B;ty7Z9mGK28VGLFyv7Gu27JpKa8Byx8fYOfpJIR3npgDYUcuQo0FdnWQnbehcN3/j3PcOllvN1H2oqCYK7O6Gzr9f2r3LtLbk7Y40G7AdMm3A9uT12II0m/thdbLtQcrtPNNC2cYdjcj5ARjhhjDbKbo19X0ZgGsFiz4OqkCgGS6QLI3b93gYPnU5UrCAcVf1/B&#x2B;5ASJCuXifm&#x2B;nrvkaDpSuDVwKw76vVBwCgyS9//gv/z8erHilLZuAqfPXPv3dZN9xJ/yCmYpu&#x2B;b779wR/uyggvwKYvX75&#x2B;/qw&#x2B;EIt&#x2B;&#x2B;vE3hMoAnJYbQtwRGtQ1mnbjUi5XSQ/wSJrPGJcesOnUnn/ymUPpgwj5xXFOzv1xPyR2ADbCnDbgKHLdyN/99rs4wRa/pmK/THHDOPJjF/qdgBFHBthFhNsRdyoAr7pkEYJlrrrffOSKWC2LbD3vVZbPogd4JH8hN64vYN/Znf/qL2XGBAA3Y04bsDHl9LXHk0LzE2n/&#x2B;V/fvybeSjHF7Uj6WHdct5IOK2DWqeNYe3meOzMTF4BGRYJBHpPU/c7z5MNyO21ZmYabJD5M/gZ2cGHnv0uRZLnI5Mf7hn1eyf0Q2A6ZNuAKfoLN/T03fa29sOSTbyPldqfkeuZ9CQ9leJwNTEOVSId7DoC15Cdxg3pHwdPALtuUD5K03J140AwYcVXnv&#x2B;4bx59T7raQHKESzD6PX8CtD9gRmTbgBH/6y5/9P8p3CRk1VnGD77VnGfcaxxUWFx7oBGt48AgGGOSeGLvFhGEHAOBYW&#x2B;ZK/4xSM8Y/9&#x2B;IYg66OJM&#x2B;kBDDUVQk2X/K2o1xSNNhC8MXElxRwKtZpA07wy5//Qp9g&#x2B;/y/2Wx&#x2B;Oi3&#x2B;iRO/rBSruJ3BWnDrFgJpWRQEgN6FAXa15B3J2l0UgB0duzH&#x2B;GmbzU2ulK6i5AlxF2Th5a&#x2B;7v3HUBoAWdf0GynuRDn43jewo4DHPaAGTrScYLuSWXdtNjitvB6CMCp7p2HGs10mwAZqpOp42Y/lV9r9O/0cL6wQBwMDr/guQ3i5xm48sIuAdz2oCN/ekvf/7lz3/x/N1Na3M/qfO73373mkv7z//6vm5y2&#x2B;NJtjG/bSPKJxpuLHPFe/WCgua5I6E7C7QjwC6SS7BxOwIgqL5L&#x2B;G985m/JXaPPiod9RWcnvLglmxicO&#x2B;MeACCHzr&#x2B;gdE0N/&#x2B;d8BwGXINMGnKMxxzbZV//8e5JtR5rWd8z1dN1CbjzdBuoQY/cirCsJALGW24WmWOKS25FyAbmilW9eXxb0A&#x2B;O/c2cGAIfOvy/&#x2B;ShKeLRQNSgZwPKpHAltyOSp5eTY386yo5OPvfvtdPLMtLiz5/OWXP/9FUYav9PUAgGkoFNMRETWA0YL7zNZjjDoePLdfANCgSmQLeSo5gDuRaQO2JyTbeuW0njSbUDGydEfP61mzDRVGLOMBXI4wu1E87pX7D4A5dr/b&#x2B;MevKcylv8G6l8lr6nRfqQ4A7KPnn9P3mwjAbageCezqf/77312myl&#x2B;hLbdam7&#x2B;4WukUN//v7r3Bam3&#x2B;HuWZdrhWr/6osNYIXV5AjwC7I24&#x2B;AAbxy1i9rgepqSFpQcVBdjmvXAUwVtABcAM6/y1Y9RPAK&#x2B;a0ARsL1jn701/&#x2B;HKe4/GTYkyQrSrPFhJltwExuNBl9XKAU41gBYK32Dow/GWvrvlA8LTj5Mj&#x2B;bqN&#x2B;yvzXlinHKjQPARuj8t&#x2B;CrAYASc9qAvfkz23zCzLb4xcHstF6Y5YZXjY88WNMeKEKADQAG5SZauZ9rZqoVvTiwvEM1c9evDbXLvEAAeEXnv8LrgA/hNQAux5w2YHv/89///vyJ/&#x2B;nJby2ZhRYk&#x2B;X75818k13JjqTY4pSOakz9huBmQxDhWALDsdYrbhOXE7Hei5q&#x2B;p9uyRtdwA7IU1mDvi/g9Aj0wbcI5cvu2TSbbFhSXd3&#x2B;UKk7n13p7ylX/6y5&#x2B;TSbVPao4d4BMeM/k/dyORJx0WsC3CbADYTlFhyb7dIZudqwlTB5JtHrSGzcYBAB89/3byQF5WrwAgoHokcBqXbAumi/3ut9/5ibE499a4fhv1IdFdrpjSh4cdgIgAGwDOkOwLCcOSOnaQSheBW16CMlZaB7JvAwLANHT&#x2B;&#x2B;0p&#x2B;8/IFAeAVmTbgWE/Kzc&#x2B;3xdm1IP2W/KfGVdxyK8YBGsE69rlVTCYeEWAaYTYAHOb16Z7LJ1U/BIzfHvy9qK81IuUWbE1e1u71ldWSTU1HFMBCdP6n4W4P4BXVI4HDCau4PSqyaPLsNz&#x2B;p5ia6MeMNXWh6t&#x2B;7ZB4POcA&#x2B;qRALAwZ5aVe6P&#x2B;6F7QceFxJLbqdj4wm5Yl137U/pel9Cr2CwAtKDzPw3lIgHokWkDblG6ipuvsbDkg2Qbugi6uaOfNwHGEWMDAPrqW4JyRJdMk/3qu994weBgd5qN0DsF0IgE22Tk2AAUIdMG3CWXbwuSbc//&#x2B;j90yTZ5sTcfqTUMEg/rBm5DmA0ASHaEOvaO/L7WFlmiCT3D10qejPcCMAI9/zmSk8gBQIl12oAbuWSbvIpboH1m25/&#x2B;8mcWbMM4LFOM4xFgAwB8HTs/FZvySyx2OYYR3HmVLjin33K88S1aBoB9dP4BYCNk2oCrPSk3P98W&#x2B;N1vv&#x2B;tSOhKYg2QbTkWYDQBIGp3LyXWu/B/6f1&#x2B;bW/KPNj6Sll5iML3v&#x2B;d/Xnmf39B6AS9D5B4DtkGkDkJ7i5uSSbbk5cG7i2i9//gsKSGI&#x2B;eSENYC/E2ACAVTbtR8WZrWQ&#x2B;rC4BVtEmT7Jt08YEMBmdfwDYF5k2AH&#x2B;Xm&#x2B;IWJ9teS00CFjCIGPsizAaAG5xXZvC8M0pyM9tKs2j&#x2B;lDgAcOj8A8DuyLQBWxoaodWt4gYAaEeMDQDopSgJVDfp6olHWiZszck8BU3Ra3e5E39tloqzphAlcCQ6/wBwDDJtwMZGh1uvq7i9ooAkAGgQYwPAhSZUFGwJFjrWPLQwkato7/G5VzSFZhU35bFRfBI4DJ1/ADjPV6sPAECTCUHX//z3vz9/kv&#x2B;aTKT5P3zWbIv/DgD4fD5fvnxNpA0A8H3z7Q/uz7TdJf/pqY74ugVlEuvmdJHcRDe3DHAbOv8AcCrmtAHQyk1xe5219sxsI80GAA4BNgDAoNw0rL7T0SxMcXtoJpMlX&#x2B;N&#x2B;WJokEwpLjqhvCcAIOv8AcDwybcBRJqxAnlzFLRak1kizAcCDMBsAoDcuKSUk1eKfj6hav8tELvk4By35xqpswDHo/APAJageCaCSUFISABB4CsUQaQMAkpaknYLikEFq5zmkaRUsJ&#x2B;zlld8g&#x2B;qlsLQcvpNPcZo00DoAidP4B4DbMaQPQJFdS8hNNawOACxFdAwCSXtMnQpnBvjTJngmKZnHZqT/p8pHVByPXk/Q3y0Q3wD46/wBwLea0Aejgmd8WT3H701/&#x2B;/Pxx/zv90ABgDQaxAgA0kjPJ1lqbzvnm2x&#x2B;ePwuP4RG0w5wrFUw0DFhoFgBJdP4B4HLMaQPQU26KWy7HRv1JAIchwAYAdLF2AlOwWtugI4nXhAuqMi6fwhUfgH/M3fNeRedrZ2IfcDM6/wCAB5k2YHsuBLUzwtHlz/QpNwDYHWE2AKCUnCZZ273XpHB6JcNy4Uzp9vdNPsXz51xr2M9HAnei8w8A8JFpAzCQsIobAJyBGBsA0FGcVvmYz6bYGfA3R3yN5lyd3F6MfzyAw9D5BwAkkWkDMFxuihulIwHsixgbANDOz5EE&#x2B;ZJcys3965wjzHGHNyLNJp&#x2B;7Bd3bX392yVeSbANGo/MPAJCRaQNONmFxhSKk1gAcgDAbANAoqP6Xe1mQcKqoGWgnM6f3HKqfyUsm3vDJpCQB9EXnHwCg8dXqAwAwCTEYALT48uXr58/qAwEAXKc9ofLNtz90Dwc2yt7NUZT77LU7f05kry0D&#x2B;ND5BwAUYk4bcAhNfRWKigBABQJsAIBB/mSvZCd/QuplRJrHn4cXb9b4LK72ZFv3JrVW5gSwj84/AKACmTbgBKVhmBCQAwAexNgAgKHqcio2128bsV93UsvPrpoyL1h3gpphlMHeCQMBAZ1/AEALqkcC5/NDqWB1hxFlZABgaxSKuQFffwBM0Wc&#x2B;goKB3bff7qcffxPvzs8ptt9&#x2B;Neml0h2Ni4zc0QqHXX2B6o65&#x2B;jSJH3EkOv8AgC7ItAFH8YO03N9jyoGW/p&#x2B;WgwQAm4ixAQATCH3p1262vh8evHLyNKaW3XU81JlZKA39FLQ5AReRHS5H5x8A0BHVI4G9yQVJ9GHq6zIPAHAqAux7sF4pgAMENSqUb0lONRutNBgJ3tglCWTtzv9aMnRQ6ktoUhZyw23o/AMARiDTBpxsaJwGALsjzL6KcqYI33EANqUpYrHwFqdcsezj5cbq1rF73fgnaocl87rar4WmSZ/X&#x2B;BUs5bdYS0wCfdH5BwCMQ6YNOJYm7pJfRqAF4EjE2PiIi5jy3QdgqORNRp&#x2B;I0u9FmMC05EYnZ870P9Tv63m7u7EHtRmT68mtqqao2XX8DaVJRpZea74HcR46/wCACci0AbeTg7o4CiXuArApYmw4I&#x2B;ZJAMAEvcoqvubbhibkguBiTh1F5dasTftT5r3GpdPcIREGYjt0/gEAM5FpA86RC37aA3LiKwBbI8xGYHkVNQDI0XTaS7v3wvw2U3dCd5zB0ZZONdPnkBZOYkvKzbdW/jB54i2fqIpFAQEL6PwDAOb7avUBAKjxLGk&#x2B;Ynij7JtvfyDEArCLL1&#x2B;&#x2B;fv6sPhAMp/96El5p6nEzgAu9zjCL/9LlxvXcGBd28pVxTd2WlT98mAp2cs1SNC27JUNppykAJTr/AICFyLQB29Msfg4AVyHGRinSbAAs0A&#x2B;ne/QqI9lray2es06uneb&#x2B;3n6EwV7sx0q5ZnmYSg0CC9H5BwAsR6YNOMG4caBu&#x2B;8FP3NBXQjsAdjCOFTl8WwHYi5Bw6nVDEyoNWki5xX9/dA9Acu1gLdhpXDm7KIkbV&#x2B;8s3R0wB51/AIAdrNMGnK9jfJis4K9Z4IEVcQCMQ3SNmP9VFXz7WFuVBwAEyVuWvy5Xyw3t9e2rFnJLJhq73LpdVCJssCLYmUM&#x2B;DOFf24&#x2B;fr06YQucfAGAQc9qA07ixijMDQuIuAEswiBVJwrdS6Zo9ALDchO69P9spzjMN2uk4r8ecm6w2ulJIR6OP08/mDt0RUITOPwDALOa0AQgph20m57d9iMoAjEeADUHu4emOD4sBIDDobmZn2pZgzp08uQvXPsKE6fmK1vNjWhu2RucfAGAfc9qAk/nl&#x2B;AeFgsFm7aypDuBIjGMFAFzO9fD7du/9ZMzyHFJO6Yk3ltaUd7RXsGNhBT6gAp1/AMAumNMGXKFvtFw6fJKIDkAjAmwoBfOq3YPFiu9BVhgFcAO/rx7fLZP3QAvzujSrRAvlgvXhiWufLab9yQjKsBE6/wCA7ZBpAy4yNDg8IPgEYA0xNnKOTIMdeVIAkjr&#x2B;vo&#x2B;b2ZZ7QdHrF9Ks2dmefAq2YK01GPWIvdD5BwDsi0wbcKPGCDAXreVmEuReAAA5hNkQCNMvHqVTFgDgZl2SMZZTbj7/OEccs8F2INmGLdD5BwDsjnXaAPydH3YOjccI9gAkPSsxEGkj6fluiqdT5F485aA62OhQAZzKTw4pb0rxtLDREYRGcnE1oQZm9QE/O1p&#x2B;vkoVa/tZyxfiVHT&#x2B;AQDHINMG4H257&#x2B;rNBn8BgBxi7NsMeiDb8dHnoC/HgHCoLrNo8Enu3/76b6sPAUAf7iZTdMcTXmzhxuUfXnyo7cdWVGDTmtKvNuOng33R&#x2B;QcAHIbqkQAqVSxvkCznRUlJoLsvX77&#x2B;13/96&#x2B;qjUCHARo7/ZZGcoHDAbLaA8MVqsBwZAPtGlEYMti8PF1h445K/OIq&#x2B;KTQDOF6rFptaidPIYeBOdP4BAKdiThuAf9A37iqdELDv41EARSgUA5lcIvL5Znn9fqn4Rpszj03A9yCAQTTTsKpvgGffu0qHFXbZ1BxFJSWtHTz2QucfAHA85rQBWxo6D6xislpHTHEDzkaAjaFev0Tmf7XpZ3XwEBPAUNNqHsaTwORpyrmD6R4OxAc2KOLQ3PntT1Z2zcXXE1rQ&#x2B;QcAXIJMG4Cs12h86DLgpcGn/WAVuBkxNvRmPtEb/cWhPJfcy4Z&#x2B;zwJYbskIs2Bf3e8z/vaT8YK1qpLxCyoapK4NDcYv1o4Hj40qwzt0/gEAt6F6JACVZNA15/Gffk11HkcCjp3glkIxkD03&#x2B;eSt3i9pVbqmzutbLDxM1ByhheMEMBqdWIO4KB&#x2B;&#x2B;g1CFzj8A4E7MaQOOMnSpbbfZ3EjPXKGYluMJ1i0n2AN2QYANDeE55rgbPl8lAOAL&#x2B;vDBpLSPIgp43WYgmOu2/LacO9ppybY5NS3rMLsaSnT&#x2B;AQCXI9MGHGh5HZJeBxAHdctPDYCMGBsy&#x2B;Wldr2d5ueEgXTbeIvcsWzMJD8CR/KWwglvBwpKSHQWnIye0KlJ6vQT35OQ0a/m9HQ/YWsizdhlvGEfnHwCAB9UjAdR4Knr5db1i1ZHY65ZL5eqSAWebHPdSKOZCpbfW&#x2B;fdhUwUYTa1UBMAm/0axtu86ukhGUm44gnFu5t9Gx1yne5iGrdH5BwDAR6YNQKsJS7jFRWw&#x2B;4tI&#x2B;OSTbgO6eGNtymE2ifQS/VZUtnHtN9TM7fQWzio13x4cQQOx1NIDZW0fFgZWOzFieaIxnHuvfWPTVk5zFGORclzcIlrPT2bbf&#x2B;QcAYAmqRwJHWVVGf2ilF/cMQl7soeKfgON9&#x2B;fL1v/7rX8dtfNCWYZzl&#x2B;6or4WUkwRZr&#x2B;aJkyVIAM&#x2B;nnnylpZuyZuoFXHEnjjTq37rX7u53GwYXo/AMAIGBOG3Ca5QU9gr3nxmY2svycFzjbFuNYuUWMo5y&#x2B;Jkw7Tn5PlQ7/l9cxMvsg0lQ1SwBm&#x2B;ffJ5LrF04/o70bcdV8r0pv9Ws9dpqIDFqKnmNmmwMG26PwDALAcc9qAoxgZ7a6pgaMfkumvfNASW66a8Aes1Wta25HRtZF75r78&#x2B;6q7q7c8XlTuq3FT4yhXGOLLCEBpejzdAAAgAElEQVRSUUV0Czc9QfcbnTzAYpqh9/b4sia3af/qY5ChxSqSu5u2LwAADsCcNuBARVH6Ls/7codaFGcSlOJOjXHydoNY9ZOu9K/HI84kld5X&#x2B;96H/drFHTdbIf6SEgqjTTkiABvTDwRZWzc&#x2B;&#x2B;b/dV&#x2B;UMWLuL9p3k5w8xDDa4/JsO99iu8w8AgAXMaQOOZWquhj8Xwf29PU5&#x2B;XcLNWigOrFIxBvaYAHtQDdvL5b5cglRc0ciPop&#x2B;P1v07tGLCX24jAG5Qev&#x2B;cfH/QVzgMvguEm6H&#x2B;W&#x2B;PsSV3C2VGiA6zBDACAWWTagMMZKbTScgC9QsqzY3LglT4yJ8xGhaJlZjSEO//om/nrl45QJXLQ4A&#x2B;&#x2B;v4Aj3dk7ras2nNuU&#x2B;/trXUd/p90nWDfGXMF3x&#x2B;sH485PDsYx3vm380wDAAAB1SOBW2ieG04bI1lRbYxeNdBOLgVz6mrnXWrPwvda0kpZSUyzceGHq7yeTvJolY&#x2B;D9RsEgMDzfWeqOHxuWnnFQb6GA0Xb7N5Ez&#x2B;G13K7lr0471xTLdeyrn9r5BwBgCea0ARdJrq&#x2B;zKmxzwaQmBeivBlRUbSb585bHncABdgynK0agy2/hd79C6ffFJY8F/YkFms/V6xcTgKskCy22T/laOOcpOAtf&#x2B;1H5t9Bk&#x2B;5id7CXUz49r7CfxTQGnsYbkLrGA2V9nAACSmNMG3G5557X00XnjATM&#x2B;FDhb&#x2B;/QptHAj&#x2B;vVr7Xz&#x2B;8SHjJ7oupi7TnIXWmMkN4FN4K2hM4fedCRcceXJmG3e5JJoFSnXZso1msOl7kkT0AAAjmNMGHC73xPNJWS1ZQT32egD&#x2B;0VYn2zqu9/Yx0GgAYFOXqW9G7rF167FVM3LWAOyo6PfGd6fjyzkcNhVMmP0G&#x2B;C5fg7loaUMAACZgThtwl1wH1EggpxkA251fgkZTynL08QDQq1uThlDcpo2uS3LunVLwWS2qPAngGPIKl8ET5IqN596&#x2B;vG78oC1vcQvNTVLUFNXf4gQx32sKbaNJbL64s&#x2B;T/&#x2B;iR7/oTnAIDlmNMGYGMt89s&#x2B;&#x2B;dUd/NcAMEuOqPkVrtYycze54NBGRs&#x2B;KsDyBD8B8wq9/6T2nvfyDcAxdNrj8XmfkK0nOq2mSbUZOBEbsmEhrwecfAGAWc9qA68hR7sIVHZKUMXndYVQHugCWyw1lXf4gb1/K2YH6lcaK9m5hAbPJt30&#x2B;qwBive4Mwt0ymDDX69bHPa3U6zda7l9ZyxO3Efqo/C4AAOxgThuwt6FPlpUbH10VPZgVEeyLmuzAhUiEd6dv0viuG096EOYNB4pu4EUvzhVpVL7ef2OXleeKDgYAWsQ36uRtuXtR9PYl5Rr3nnsQb7&#x2B;Ohb4pTB02oFf30aWCBQBgI8xpA07QPhw1fmxqakEyV5k9uZ5NRXWdLi&#x2B;z0DLAhYLUOzF2u153s9LV8mbOTmuZ&#x2B;tyrbFrwRQYASUGPV3/TiLvHwpgDI/3YmXfF3L7sNIXwQyMHCdhBhwoAYA1z2oAtJYc9dgnAcvHnVR3Z16GvACy46r70Sj9SWHhlx&#x2B;kFlm&#x2B;Y8nS3lkYQZmADQJG6qhL&#x2B;HSyoEllxU9JPUEYXHYv8A/viow4A2BRz2oBdWR4Xr1zsp1H16WuehJptW&#x2B;B4c24gJylqruDBq/9PHedv5ep3zbm1tqS7uh&#x2B;h5S9rALtLrrgmLM9Wt8rRzJvYqntm3JJ2&#x2B;iF8ieB48i8dvwIAgF2QaQP2NiIc9ac7xBVLXD/YQvyZLCbZa5sA5ks&#x2B;NNS/BZ9M4UShMRsbUDOXbtV9dXSVMGFTfJUAWKJvTfWFfX59jFN9eMldCONRTPFjNMvHCciCD3D8YaZDBQDYCJk24AQ3L/3SeOItK/cA6KXiWR4lrR6vLTDzoWFchnH&#x2B;d1Oc&#x2B;Xudu8ynCMBeus9C07ze/q2y/QgHFedvF3yZEongDExiAwAchnXagKOMePScW&#x2B;/BmtE9cv0aSACGujnHJlQGi1cXk2dctTSgW&#x2B;9no6HHwQE3HmeuQKXZ0wdwmPg27n7iL8nmftjlq3PVys3CgAl3ynOPaA2&#x2B;YnCSS35tAQBXYU4bcKBeYdh51UjGVdp0/2untCYwU99Pvv&#x2B;rmtwmv2KBoiXWcom6ojcGl9va4794dl3L1hhpAcAgYd6wMFOk/X54Q0f3tR8CoCP6VwCAM5BpA47Vq2ZXckLb7r3hETGzfjYJcC0/G517VFeUNCp6Ze7tu9zQ9FWtJt9/7DSg8sQ7Tou0c&#x2B;4A9tIxZVX0RdZrXtrCjq5/vu3n8lphOMlOupGvIeyutOcPAIBZZNoAFNurN5wb8DshQjYSgQOHUWb97TwFW67jQ8ld7vw5rin0n41gQhu1IgGYJX8nJv/eYnkth0H7LUpbWuhs8GUEg&#x2B;TfDqoFAACOxDptwBXqurCNC/l8xCWFVkmeVNER1tWyI5wAcr871amLit&#x2B;mfX8BJ4wM0Bef3P2GVpFm82161gBuoEy2tWx/eWLJF3x5dTk2F7/oT3bVCnaATUFqX/PbYerGAgBAHea0AZB0qatmrd9ccUb6Uwim0MXrtFtrDWCO7p/84LcMOaV3PE17CosDzVR36evetfxkAdxgxASp7rcvYWW4JRO8koXu5VcqN1v6ev2LgSPl5rHJvx0WJoYCANAFc9qAG8nDXePxm&#x2B;1PtK2N9Ow4J6Pi1Ky1BtCXXN2x8X5S8a4Dft3ksz7gBCu0f36szcwAgEGE211jpzS5Zcvznifc9i2fPmAEA&#x2B;YAAEci0wZcTQ6PXezdqwikqcizuqLmp3xIbPKHFhoB6C74wI/7qCeHBTz45aqzxcOOXglafalM5S741AGwTB5k1nL/H5fG01vYr/ZDg2QpS74dsIvSUF3&#x2B;vdNEzX17nvyuAQCWI9MG3K5o0e&#x2B;6jccVFHeniRxyUwPjPETwAuA8g7LsJ91VNAbNwdpoalev41SOmeCeDOAkwT3N3fyHfgUM7ej631&#x2B;l3XL5xZptKpVmAcnPwb7g967u4xpHytW/cfy&#x2B;AACMYJ02AP&#x2B;X30P1I8z4EXnHTrCpsuy5ZYdazlfu98dZt9J92Wk9XMgtxjBz4avku54fEmafbebtzsIqdABwmDm38dzdu2Jw4et3QdE2W7pMgB2aZdhKO1Hy2hb81gAAdkGmDdjVoJkNIx4vvm5wl95zPBa4ZSO9znqX1sNJ5KC3723kdVOXpNmGnmBypMUg&#x2B;keNuVdWH2FyEEmXLQPAjsbd9Hpt&#x2B;fX7omhHFf0T5Yy00qF1RccA2FH66c39asSzXYtmnTIiCgBgE9UjgY0NXZNgcj0xU0u4ldI0VNGg177L4wGxluxFx2dedXuRF5s50oTTnLaUjv93eQhz8ucVx6n8LrvkswQAvu4jwPwtJ&#x2B;e&#x2B;BHtsv/d2nD2TVB1wPS3w2g7AAVp&#x2B;TfSb4rcGAGAcmTYAWXFftteKDkEH2vgqQd0PL36oIQzluy2jgAlyn7SWqULJ1J18u2j5tTrs18FCWj3I8Q/aRfULOi7mEWynfSMAcIDRM6dz87qU3Y85/WG/69Lli4ZvGWwqucJiy0Q0/e7c9lnOHACwHTJtAPBOU78u&#x2B;QShveCMv0EWVEe7opA4Tm/Er&#x2B;n7GbOcdFcq&#x2B;tXTz/GSN9JS2zY4hooDeN140VPUon8KBA9J5fdyewRg2TFjrZJzVoL/XXuOfddpFrbjxwvJ76ndrzXO8Pob6v43N9iuy2Hw6wAA2A7rtAEo07HLe8Aj9ZgwYvf1vSMK&#x2B;BzZyKgmfx6CjEvfsqh1/Ej&#x2B;vHhbs6T8OHGT9n3YF3yE/EfG8X5HrJoWbNat58fyHgDsGzoGYomilcwWGr123S7tAMyhjDgAANgCmTYAUwlV13d89NlywHVBxRONEJOgXcUv3esUt76/wtvdEJazcFsoukGVTjjjIwHgTqtu79PG0/iWd3T108TbD9LCFzcup/mNq/6gVryRzh4AYF9k2gAU2zQrNlSwwHvfyUC5uW4E5yiSm7H0Wtap0dCiTBsJHmTMrxaVu2&#x2B;Pzpjqt9xlv6ToABzDQiJqXJ8/OccrN5lvcugxdAK0fpsMrcM4r3cSfb8x3nLF8fCEAQBwANZpA042eqWuioWIqjdiVsXxVw/u67tixO4tj2rC1NLcTzp&#x2B;9uSh4kd&#x2B;LPX3wOrT7/gkrvQY5PuJhQtq4RgAoE6wDFKX1T2rj6TLdnJfWJrTMXs/b/8W7tvVxyX2XSMtuLOZ/dUGAKAImTZge5azJkK4eGQkGS8K7YfNHR&#x2B;IJFefBlrESbX2VbKKfn4Mv92SJ5u8FdS1trwQfcXE2VKl5R8bj8E13dkDOADgEZRMWHsw3cUhzGvgUPRNMYfZ6zK5HTCZ2Q&#x2B;eT44p&#x2B;HwCAM5D9UjgEMuXNMDDf8bdt2heEKsQnKDInMxEbi&#x2B;WJzyNUPRrfuR9&#x2B;9QrCwCTyfmSheu39arzljyF6l70pl&#x2B;p&#x2B;jIhynBv03ZAu/jS&#x2B;4t8Cx31LiUWgp02bgQAgO2QaQNOY6FTO2ElHsuERw/JKhlMzsBMFbUBB91V9vps69uhNN346TpUYm2rTvgC4tkNgDPoe8tPsq3vc/Dd2Rxi2H5duLLQ0H/yk4m34CfTPnWsxAYAOB6ZNuBArlbhwmOIu9E396pvPndsxw&#x2B;D26dg&#x2B;psV/te4XuuvjNiRu17zH160POgBADzcHVJZdN1gbYOiL6Au02WSf59v&#x2B;VWwmXHEUPFSBZohnoMOQFNzfvmvCQAA07BOG4CB9l3YvDt5ZbW6pRRYrQ3j9MqxnT0Gv2Ut97N/f7uvcn92cwG4XK6Con6xz9zWXu/Afdd7LrpX56o7&#x2B;JXYlZUSF3YwNMHOtITHeR0tyEp/WebjMwkAuApz2oBzdF8YDH3FU0&#x2B;C0kBcKRjBR1EjaCWh0W5bpm4Cmg7AAV6rCgcdxeBf45&#x2B;//q&#x2B;wO83LNComWLdPyy6t57Gk162ZvNhxLziSPo8evLJvx&#x2B;n1N45CkQCAO5FpAy5iOZdD8ZNxaFU0qo6TDw6we/1aVTyJMNKq80tH&#x2B;iMVuK0BuESve77B26afeaooCDm/aJ7SawK1y15y8x1z/4TDxB&#x2B;zXF3ZQf3G7tULAAA4AJk24FhBlzcXzWKtZGTSPVwhkQm9XmNgS7NHWwx97ftLVLcqW8cDAACsNe6xeFybcX4/sOibve7wzCbbiqpntxytnHEs2jLxwu7oJQIAsBbrtAGHKF2FeO2SBvAp52d0mcbRfa04nCG5nnluARXBJR&#x2B;heBhvxe/m2U&#x2B;yqpslt7XkRxQADiBPgcql4uQbrCb/tHZts5bZV0VHfsnXB7O9kVTRmfcFvz7Jj9nZv1kAABQh0wZcoTH06rjItpEI35q1TREMdi59fsF1xGf1Z3ioigXYija&#x2B;49Oxjim00hfwJQLgKrn7rTLfZur7ZfRNOz7foChlxwOoWIsuOLZxrWHtuqOXorRxS45N&#x2B;GVh8BMAAAKqRwJ3Sa6sriwVMrSiyBaF44wovQT65bLrtk&#x2B;dmbNdeHGV97rGYcL&#x2B;7uJtbs2dRfwXAICGPNHN/UXZfxbW9FolOVdP&#x2B;WXhvqZzX9Y2V/T0TzD&#x2B;C0usYYTqT5TQE96l5DsAAPORaQOuICwVULEC&#x2B;bggkC57kaKafnWVdnC5odO5bJJvifIUq9tUPyeVP1fJjYxbyggAbArucrlq8L0GYGm203fU3Wt40v0b1sJXtrysWvuWg1ZN9lvkPCWOMa0CAQAAeJBpA27R/gA0eFl7NNjy9hvEl8wf91rR/q&#x2B;fAS7KnXKfJXko68gjWkAeGh//pH0dMsupo3EP4HjoAwB6LnfiFkl6fj6oEz4/7yJMjintnMh7yf2ThVTT6zfa0IO00AIYoVe1Unpc2A6DCQAsxDptwC38iuoLC6rQWV8ud/WDla5dgf6iOM1f6a3j8n6Yo2LRrJt1vIuObtiiFTVeV7XJVSHTvzI4GOXp8/EDAGfQUklFi5mNOAZ9kKLMO&#x2B;b6tw5LDtMCx5uWZuODhEGUtylSawCWI9MGXEfIsmjWJYofwrIq8kzLl50ozZ8RvRun&#x2B;TjddgU1v2Vdfg0NNmxRTdrc2w2eFwCcYWY/UL6ln/RAc3ln1d/7tEX1lscU6C4ZlVd8tunIwQ79bYobGgALqB4J7KqogFvRU&#x2B;PXkaF0vtea2f50WM/z&#x2B;sv&#x2B;usLH7uSKIkGFrtwW/Ncf00Slv&#x2B;9F0w40Cw4BAF4NGtcvLORctOt2cbXMFu7rXrm15QXHpjWyv6/glCm8trs45aYcWndStxb48DQDwHTMaQOA/fRaqMPnh2Sa1Cxh2L6C2aiPxtGvu4ifJbWcbOlqbaYaNsgX&#x2B;v8knJf7oXDWyQ/Yx7u3mGoHANjOwrvotF0HVR9z9CtMF&#x2B;19bUfXr65cOp9Dn1BUpmz5yt4FGQWc5PXmQ10lADYxpw3YXtHQM3nhcf1ANjo0RowYeJgbxcxF35o8Vv2Si9vlGcS&#x2B;cZ2foY8zjsnXF325vG6wdJsAAFPir48Jd/XclOihZZztfFW9HqHmCz1pUJISy8XFSIUPiZ2POqAn12jhUw1gIea0AeeLOx9B99qfo0C/BL5gLK0wtJY4HHNUJ7qEj&#x2B;7Q&#x2B;56Fm&#x2B;rrAjBzdg0AGM111ZT9t9etxT9c0uWbcyQ2e7PjvsQJ/W4gDH6afCSAUpepzACwBJk24DSNnWYirjsJxeLiocRFy/7BjlxBvyUHM5Q8Y08YDl/RGsGYyvmrkekLQOmPRznYufrRLQDArKJYYEngkPz2yR3JiIrrC&#x2B;XOvXoLyXbLxQXVFRGoHd1XfNWUy7AR6cM&#x2B;&#x2B;T6TK25f8cgCAEageiRwl&#x2B;R616sOBna4AJjo62zBYmxHXu7GJ1BFO1pearWx9FPdcQp1ht0/6WsRAwD6ar/3Fn1v2pni5lR8O28UEPmruAn/qqfsJLT3rzZq5H25BQ6VPweMewIu7h4AdsGcNuBk&#x2B;mGPyhqSyon8dOItqL4KwThWZb9WmBWH2N/&#x2B;&#x2B;m//9PX/t2TXd/56zrk77dW27pnL6409SNAOPzIAQBv/3l604uZGHTl5sloyrjlvQk/dJSt913nttqlcwP56Nbl82JH8wS66j/GcCsA0ZNqAw8ld8CAO7xVdE4/tzl3BLh8Jlt3GNKMfET6/GtXVk&#x2B;ao/o3b6xkrAEAwemSJne&#x2B;LosLImiDF2te6zF2L&#x2B;LDjn&#x2B;fivurYLQgZ9mq63b3mIaYdCaDUeKOIQzA730QA8KB6JHCLiioruEGci3VPIlq2WTctEuhlWulCaw8y4hLBRW&#x2B;vK/xorREAAHMkvy8WFvtKTsJWJiT27aPW9Xlaql/Qz7eJ/hjMUn4pFFXTAQCDyLQBF5EfoRIa3aMiPO648BKfNAzSdzUyYS9m1yGb/8tlsBEAALFpoyiCmVIVW2hEmCMIGkd/iePaa30zlKzDpCRcMvpjsEm/qjQ3AQAHoHokcKnqsv7PX5I1RvziIVvUWLsZY1FxsPgxUPsGLdf3jyux1N3hKf0EAOhrSUl5vxtwZ8&#x2B;2dBHWESx3nM5DI8OginXUAGB3ZNqAez098saUWxHWb7NpwmOI3Kpv5GKxC4MfzlyhyJZ7&#x2B;ycaJ2HwxAEAje65twffhleduPwC4rJNBVEVFxHW6IfuyXehjsvGK48HANqRaQMwNQQlqLNJPwGxJS9rYYAt9nLn07HlGFgKANup60TFUUCXr4C40MWn/Du9V7eQlUdz&#x2B;Lrf11UfVGxEXyty2r4&#x2B;G/6&#x2B;EAID&#x2B;yLTBmype42vod/fyaCdMmXWyNeibw4sWVx0xI6wtaEPgDRjga19FHPH7D/B7LtuirUWAIBLzJywMudWH8/Dnplsg9OxlMW1xTkBDNK33tIZXx98D/7/7N1P6vTImShq1WfP3IuwwXhietoLqZF3YNz0oMFwuEu4XCjwoDnG0AvwyAvx1NSkMNiLOB7adQfZR63Wn1AoFBGKCD0PTVP&#x2B;fZlKpVKZel&#x2B;9EW9AX748vQNAuo6WjQ1MkOrlLbzT8oPzYVHBfJrlOtmSz9umUprVuzidG&#x2B;qrCtCv&#x2B;B/81cMy/vjfvAg2fhnaHbDyHkeLbdf0iVVELECCmJ&#x2B;Ofn/Y/SpC18xpg&#x2B;61PDlsuVeBAUotvwUqWPUU2u0yNDlDXmB5Duz&#x2B;6/1zIDCfsk2BXd1t/HvnrVmeDeBxHV2hwpZX7QbbGJz2coh5WL92Z8OHH5/xzDxaaBYYSd6F1i69aF8CbUv8PEJ3VNpgEANMKh/gLQypWpvH1Qvtdhx1hnThau08XEwKPyBhy7uN78c4te4nY2McB4AB1L9Hmavt8Hbs1PJfty&#x2B;UsH5b5CMJcwyBcupcv3rP5o4uiJ2&#x2B;HUD3SBhHuVAm&#x2B;TK/bAwSnq2yfXzaK1LCd99&#x2B;vfy/B/fEidG&#x2B;q59R5RysceFfv0vvope3DEBA5I95s7/5uxe1VXPy08dX0&#x2B;xhbEdCa9PAFgDijfcT3dQVEMhCpQ36thttlKhUPV5ioR3Zp7KlPVEkOrzSvzmt/aYthyNsT&#x2B;/TvV3NCYj/gvh5ByCjwDUl5tpUfxqfkPKj/qA64QdwR6e/Iaf36z6pXMxQdaA1Km3QvcCw0PYFMjrz21oWzsOTP7Ld82H1l&#x2B;1YWifJMHLd31ndOPtsc7nxBmtLkedw5GIqt3cHgGes1jZ7JBg&#x2B;uo5EtnZcNY3cjtk/nehWU1M704Vc5ck5PMuwT8CjSlyqjoYebjO7vmzrZ9s3Yrl66JdKG4ygzUvvMnSIj4SOqm4594x8jj7W7On36Qs5SVg6Oh8qZGUJp&#x2B;LpenLxeu8zBsAsS2yTd&#x2B;zazZB&#x2B;ZTsmZvX3B/V7Gzej5RHoenAnUE79H4Qef5xPJ7EdXXR6fLPwZiptMIiRLsCKbX0pdydipLP6teLv7t3/uFtITm7&#x2B;Ut2ZRhC5G24dAjSu3K908p2&#x2B;3Qdn2aWEq1LGC9lRJYlZhbDBkYd&#x2B;uUsT484AyvD6AkBrfvj0DgDdu7QgEGNLOBlWLYbuW61WlXHLXLLtFuXjmPaagWxH9N/5Rd0&#x2B;9/MXBx&#x2B;gF&#x2B;Xi6mpL7R5d9LNkDSKKp&#x2B;x&#x2B;fD4L4I7Ti8LwPzLbNpKn/SSBZqm0ARmEc&#x2B;n4fHj7sG1Gp2l143J1/kl7uurOy20LV015JEdq8DgAsLUbtIR/w5dPOSpiff5ef2BcoI3z6gFpXZdLTGvj1OpE2r0d7JACyRrP5opSToMBqLQBme1m8nfmy4dvDUjnmrVqdxApYf6NM4Slvj7uXGvwbP/Y13EAYNpUzk4fPMXFOatV0Io6mvZ0NBfKjcXunM5W9JnCeHarX9u6e1ruv/KSLCZwE&#x2B;OR8TFAFipt0Le5LBEobtWPVJ5aXoIGxZwM802i5BQ9HNkrthUVLo5KEmar3&#x2B;Si03Od8ACdGuCieXr3cMrX2VjPcICiBrgqVZB2MQrcxHhzDRK69uXpHQAyCEc/D8ZG5UKBo7FUdCS5p2i5Z3HJclnm3SWaR/oU2v&#x2B;d&#x2B;e7br&#x2B;f/e3pfALglckJbs5b7H1hvZnVr8ur1K9xhnsqEH9CR3dxt92ExW8vy9e/3N&#x2B;TmxSh8&#x2B;Ztnpfd7fOBVzGkDyso7o2XVtjvcplIs0qCj8yG8mMfVZhQxfUdZSpgCe&#x2B;nj6P2DyPsjtvqP3g8OAO3YnTD9SKOL1Wst12/e/lHQPoYBQj4YWLPrn7W2P1PcxOv7169tax&#x2B;/otA7c9rgFZ69WuedZrHc1GqbRrZ2IfAJlnitz384GY5EjmdMUPTDbTAfCyt3kM1jAxjDpR/zwESxFxLvteM0LPFhwSOW37hAg99yueHS8m5Ag1nMpdl&#x2B;yYdrO/pkq8GDA4SZ0wZ9C49U3Y6IeXbKl0CBq9KWWLMw26mbGdTugPT7m43hkwWApcDFdxURPRsgxazfxjBKtElgYM1OtxrD1UaRu7/JL1lV&#x2B;vRYhZvxJPygrU7&#x2B;Zo8MEEOlDUawezHeNtDbVt16vIoHUvTdP/b4Hl9lG5LuBqlXY1bNiI5cOpK7Tai2f6nQ5qLBj/L04JTT4NEAIKPkCLbxCUOBN3Vzh8NlvPBLU9rV7vG8jTPhcburcoRX3IzZyHu4xAAfukfCqz0YDKU1CojZ4d0tz50Q3hz/tSzQBO/Op&#x2B;bjXgofye3Bz7uY8x0tpC43D86R7UiI0yG9LRwNAAqJL5XtXg7ma30vF4ss&#x2B;1ki3hND5lWzezxwZJWvZc9oLr16y5a7GriPtDqYl47nth9V0p4CbTGnDZimEed&#x2B;jTeZ722sBlzN0a263T8uP5er4xz7VaLM9trT&#x2B;9kmxgAdSQ5ZX3KJWUX7kccqvhIpZYDHPdhDYhjJ7RAzvkq/H1ygqWZCzTLceRIYgEobvNFuDePZ3uhXX/Rmb5xL2bi4pzuqdDHKdXC6qc1v3PxTUO7gnI6UbNalu5bldwdgHMtAdPVjuwrd0/psTw1caFaDeO50Mnj8vRBJrE4MJ0l2MbOlMx723n&#x2B;T0w7F0bvebq334wNs6R4JL7LszheoVA0c0V7tTLgawTTwkWnTqr/EpUi0o94U9V06OC8/kp9v/VENbOyGmZHih3D6CQWIcTSReq6o7f6iHl2SulgfK/mSenPSuWvTgwKt43mt00lCvrBF5f0ydv3VDi/8eeTzgxa54kningFtM6cN2PH4Ag9ZxlKtRvjOJcY7WzZatr7d&#x2B;mjkp3Bz7iPVzvZqL3Tpx63CabM7EcGPDMDLreLV&#x2B;eK1jWN3F3oJX78aD4riY/X5sNx8R&#x2B;1M73stR/7lnADlXPp5TFile6R5Wts1Rz7/EXNhvbnGKjAMlTboUnJKmRZpNdtPUs3sbSLP/ECrJU6lffGTv4ydfjTJRdzVWnfz1rq7zXf6zTp6QOkmnABj2F4sPleQmFgo8Eub8ee3XIiV0FU&#x2B;1zpDvVyFYTA32&#x2B;GSRq/IOhwZeA&#x2B;VNuhVwtV6pGUPEnYp8ikKM40LfDSBVKHBc7gj78x1I2u6ubY80vkZWDkcgHirwGb&#x2B;Ob00s//0UnXzh7rc7/zVtuGKbdCjSyuH&#x2B;Xqe2r1qlNP4JxI5NHD7mLRryjuzZmBJpQ34b&#x2B;FZGg&#x2B;WoJZ3FuZ9Sw594udFXd0&#x2B;NYVPRTdK4gVy1/d8C&#x2B;IT&#x2B;LSRtgM3VzldI2f5Zez3LQM84v7P5s0JIsIrzocAACAASURBVO0PQVuFfCJA6ELkj9Ly6&#x2B;yrfeqo/&#x2B;HsUiPE4W27NG/FLzrwnuMGBKi0wRslpNzL&#x2B;lYvMUTaMra7j7dYdy9u1mLfJjy5Kv4ALstUbzjsWd6jnxQAqsnVkG01eKKRi/7N9CSm2aarNmS0GrMVWR8irNA696NKK0PGbHDs4waEfXl6B4Da4i/8R&#x2B;WlZ5Pq3b3arsuV189&#x2B;/odGbiVAFqendN4TfuBa9aVf1IRnte9zLn1OmMr9agC45HM5vnlRXv3U1/&#x2B;1350nnesW8xGJANzne1SfgBygJpU2GNDAN7VnCbcJ7h8W9bYu7H7Kw38jLolZsmX5P4&#x2B;O3ra4Mp5wR82r59X9&#x2B;5utudloBYCnXPqh3l7x52EWj4QB4VV7b248V1cM4ONoVBYZ5Tqw/X5Ap6NIlxes5fyzmyO2twu8JWwEGIZKG7xOcvB0NJns2fpTYK/mB5w&#x2B;/mjLWfaQ&#x2B;lafso/yVOB7ET/Eu&#x2B;tjnpBi5erENZ6EVdmMYwCoL3nwx2mrt2oeiTcuXbNc3RjSncgtedSacDHS1eHI83/3250ivllLiVMoy3xxYAwqbfBG94PU3ZGtd3frhk9Mc78x5qUHi/UbJ96NsT1EpylW&#x2B;JCOccxPx7MP8B6TZf/d80MK8KDTy3rkI0/N6UPeJXWXgUeJq3NgZn/k/rvMwX2&#x2B;R5HyrqA5dkKdMG5y1EMB5KLSBuObY6PSYUEL4W/gPS6z&#x2B;ly1xulimt3CIYKP06zp0jSvmllH/Fe4dG&#x2B;rdkYblHZ0GPOukQNAp67WnPIW26aIqOZOW7BAROTaxwsFTvtl7J1xgJovWnxSc&#x2B;lYvbwPfPzxdAYCkVTagESnEXbNnVlaTt4PTNaJ&#x2B;fuRO2m2KI3H3R&#x2B;Z&#x2B;FQ/&#x2B;i76NfWSmqYdSb9gAO&#x2B;0O9giPqIIJw639uyKEq/lysirXPouh78dvcTMj4tp2JurG/Co7qzHdnTAM&#x2B;wWMJwfPr0DQFU3l3sNbHMe7LN6iRZCkGULhZeEkpBLC0MdE762uRpSXd1&#x2B;C794Me4ULPM2pVluNvs2Achoe7c3vm3G6toRvsIWuiIUygK2l0VXNF7otKiW9gWUvFcYZbj8dNr8&#x2B;Yq8Lty5ARV5IUvePvAS5rTBS1Vrtz12y8TdzmlFu9VBNd2dxjd7RSYPRBh7AYM7Io&#x2B;kowfwBoF7lEXjjSyXmEsb6St8gmTZmxmeEjEW0mw6U&#x2B;EcmweOGzMB3KfSBq&#x2B;WJZzaDh3abvPSoko392fXdpfu5/m79wu0WWNg7eQbqwYgRz8d2Xc48pekX0fdae50XAGgF1ebvyWMTZmCQXi1RCDXZgvN84a&#x2B;xHwL4r&#x2B;Gg0XX8bajBtMmtF06gC0f7YwLeR79PXLZ8jbLkECDdI8EMthtL7b798itlYhjTpdJL/Gi7bTQhLDAufpIo8jIPQn8yMy380qMpR3vq71K6QNvLcshHenQAYxk2wr&#x2B;4&#x2B;jH/84kgJplqsrjRcr1wIQHxVfUdBq/6vSIRf5gXmrn2/IhjRnnkXcQ5OOJMDAAc9qAaSo2SKf9uGS3/WPYUVkxfgvQju2EsNXXtp1vcTt7MvU/sHG1/5Hr1V96142v9wDAkaPYIH74/&#x2B;nGd58yV6fabya5u53eYwPe6f7XLXk2VUI7mVGdzicO9NGJ2dpW479XgbcQmPN39R0VnUsNvJNKG9Tz1Vc/yL7NBhdSOtqfsZc32BYnWo5cYQr&#x2B;esyd&#x2B;ls4jeN/De7vcLgL7qsk/Aiv&#x2B;nkGHgBAmwI/1HP5LW3Uxe7/PH3RQpL3/9LGj6YAdpfmMLCaZ&#x2B;OdutrYMeT9VTYG/lU5/egTJhCfDjcc&#x2B;3wDitI9EjoW3&#x2B;zrqlyNX3LFfEWbG1xtXHP0&#x2B;O0g3PmRdxrIaD5Dds0mY83uWEffwchfy&#x2B;XDlpPPsq80uZwPd39rAJS2DXS3V4fIYlv4vvBqdEv8gzMqWnILbER4T/tiZgvdn4Qa&#x2B;C4M/B2Jafxw5&#x2B;5B3g02pVy2KGcBsjCnDXp12mGgpt18&#x2B;2ofidb2f3a1DhcZnG0784QfGb8PkKb9vCLwrWl/57vgMALw4Azv&#x2B;NF7rYXHkWNcIh8MFVyaI9XU120ku78MpyXMqwOjx/vNydjIBCAjc9pgKCUGSB7FebsjXvO&#x2B;dGWBiDZ7arEdGpx3&#x2B;xCvl9PPt&#x2B;am8EHLMh5idV3wGQF06pGOjuEgvMKlf3cfyhUYBsukGEblotpLaniRbSfSHhBuutO1wPuKb030uXzkqlwCBKi0QZe2tzJLR6jhKV/Lfdhtolh03/K6ubdpH4SyAY9o6qy7&#x2B;t0p9K1p6pjkErhNGbOCTsyWZ0MeQICXm&#x2B;9RPliB233p7MFAlq1tb&#x2B;nGZEbSAR60yugDj0nOduf/Hm/Ablj8EQv/UHyOW8xPce/HM3Jy86VTUc4C1KF7JPRt2076kZLbsn/LzR2o9kZihMOv1Qybm01sWni/vMeQXUT4WK3yHT/YM/KRzhyAF0qLHLK0Z7&#x2B;0mlquiHr3/d5/O01lOvDx7NkosNx1tRg5/2S94Xje&#x2B;al/w/EBHqTSBlwWDuPSuoc1m22WXmHu/hS6Zg8dbeq6xtbvnlezKrNtH1ConOajAeCmtBbHRSPhykvWLUcuivApKuYESz7nA3cDlrcRus5K6iv6kT3uaOByv&#x2B;8IeCeVNhhHg1FIg7uUYJsDnA5HvZQ2GNxKHdWy2YTbQ/Gp4xi/KuUcHfxLv0hHc5d3t&#x2B;YuCQBHbvaIm&#x2B;&#x2B;9bq9up7W3XMWqz2Xu0p5fel2XUe4IfEfCTzn6p/m/0wLv&#x2B;GFeTvtTp&#x2B;PnxhA4IWNOkksnkrMOKM06bcAtaTPY0jy1PsRHYE2FwFMGjolhl3O&#x2B;QZE/m6v1OeZfMPdHAMglEB6fhhBtrmSWJeDf3Ui/615Tx&#x2B;4589QE0JhXcRpvJfyAdHEYlwlFzMOWf4k8JvPCdauBy5ca/zYl8qABLTOnDTqWUPuZCnQjmUd6bvcn7YVOo7EWbuXnin5aeC/QiLS2URlf5c0uVeMAIFJkN7Caqx3nWlU672bDG5EysJI9o8&#x2B;4te1mB567eXVO4Vbgdgq74o9VR0d1ef74wYd&#x2B;qbTBUJYhWiOX50KFsUbe3VJy44LPOKyOokDIK/x1zvvVeOG37IVvGYCmBKpHMXeoj1qopV3gAtO14wWKbeGJ4LsTOBrMa2hc4JyJuV9/tDJC4C9HrxWYRbcss8VsrTvbL2/ydzn&#x2B;iaMeTEtvAGNQaYORPRV87E5uC6S1q3xguRj46Ws9GGAtR5&#x2B;t3vLVHP7mCLi058JLdPQ1iR8Se3PwbGCzn//YLs7R0WEEoDVXR&#x2B;tvV2XbvQbduTBlvIbevz7GVETcVuYjPlCssDPcFL5PcloT7ch2aEVas8SRTuz7EyKB1qi0wQgavDwH7sne2c/s3WbyupQM7xbnYCSXkoeuU8cs4tczqDlR2IxbANJsY92Y6WuB&#x2B;Qq716NtM49Grlm5bpE38nboyG5he1u9zviK27N91PP20pjg5I1Pm8abvR/SXJP/tltYjg7s6CglTIAGuqDSBh271H5k/qea8UeJtm&#x2B;7wUeDtcawcKuNq9vJskuQV2RCdfqTFXhMQC9Z1qyFL3IL&#x2B;wDASMKX49Xt46Lrn0Xu0p3NriaCHz0yvijYXTBDBbvTPevMfIr8Oo963sbk3aO&#x2B;96ISlj6Jmf/XowHeAqDSBgNq7W5pzRVrH3/vV99Cxp4wj793yC5h/YOBM/wSsjfjAoCl0zWcpohrd4mxZSUudlcrDT/7v6s1Z98T3qBcFFd05tYAVvXybdP1yOceGew34ahvx3zoIk&#x2B;z5AUFO&#x2B;IbB7374dM7ANQ2z2yr/Lqnr7ga0JplPeGnYq&#x2B;rbSRzRVTx8&#x2B;TSuqJDIaffgu25Peqpe/TrUS23HPXAAvCUqw0ej6KCwO3a3ts8hDuGZUwWGFveKC7mbBw7boxPru&#x2B;0hy3a2LM18/udj&#x2B;0bftwCX5nlCfCGQwHDU2mDLu0GuJ1emK/eXr&#x2B;68ZZD1RK7957Mh0aEi/fhe0OX8orAY4Y51QNF&#x2B;nK/ZsMcPQBadrXrQ6epzcryjSxvMW8f&#x2B;dRoSDoSvl8fuZH7U6/ecJbG//5cqpOFi5djH9jdd3f1d36&#x2B;8dXRsUrL6Tp6g8CS7pHQt5tlle6WNwuos7RDgnBPmKK79/h7Z2yrpdS259ulVirb5wa&#x2B;O8spsEPmIdaBAODl0i7xDV4fwy3&#x2B;rnbJhquynFQNfrNGMmpGMwV/4pLvZQ1zrGK6KwN9MacNmKZagyjLpY7zDf2Ws9OjqYeN7HNfQ8PI7uqPgFJQCeFPwZcUgLe5v4Rz&#x2B;5fORnIBRrLKi0/PsfA3pf0vEe0baZZkwpodU9zdqt1myN0dH3gzlTbo1bbD9VW7JZ&#x2B;iV/HPPtdZbGk3jolcnKzoGmaVi4JHUdrV7IuBNfLpH5Wi37B6QWCwZ9fNgQGgQfOtzKcWrnZZpynbBqfvkZZl3D9QA6QzN7srxffMbO1Yna5&#x2B;Mv/3cs&#x2B;vvs0XfhlhDLpHwgg6ugZn7yAfv4XWCkvlQsZA94lV5Nda2Eplyc1jj1KItK2dnopzJ8khT9rKAzzHO4AAvNzR0kf19yRSoL12y7vNOw18TtZpNrOtoLR8SCOPwJ0DtXsEWrg/c9/R6MmYMRZjHAHAnDbo2HKcy81YZzcmaCQETHhrMXveQjOZ1ZF/fH94iUvfqfAUz5tzNJ3zW&#x2B;UGMDraAIyn67uTZi1QWXfzh&#x2B;qLvEsQGNR7&#x2B;uBmxfwc7T7m0kGLWZyywSN28xZZhRIm0AKVNnivZS/H3V6UTdXbbroTERZVZweOiqnVdoBGXEoCt&#x2B;fM6cyz05cg7FKPkWQ&#x2B;IwBohFCcQq7WcVtIjWu6Hw&#x2B;/7Yjd1GN3xEs3xHa7sF5KkIdfMQHeQPdI6Ftk15GjS3vk3K/wv5aLkAp1Ths7ZNm&#x2B;u1WDmm35pP0YlyzCXQpjBmbO9fj5Wcst5NnLAltrx&#x2B;frtk2iivaS3e5DodcCAOARc5CZHOmNGn6XMB/nVXLUqeQbPtkTwGbv1RylxkdfuuUdmNPT4&#x2B;gGDtAjc9qge3emoMVPbHpqClShWTKBOV7NqjDF0Li8F2rtE29tf3KJ/4XJ&#x2B;Fs06sEEgPt0cefltjNvhrQ7T2j73U&#x2B;OwNu/jRAW2P/VOvfbSWkZX667M/D0jezWz3o/W4BTKm0wjt3oJD5yCmw5HGNVULSL2p2Ip/7RKF1vU2x7ifCnnDH5HFubLXYj96e13QaABOFAZTkk8WaX7FMZo&#x2B;iYOM11nPvGPovqJ7bdHc9L7QpvHs&#x2B;jiV99uZoURxaz51tSPR4TYEn3SODQ0WW&#x2B;63vu2ZslPnI0Mr4LwdwLxX/oTo/uKLMB8CpzVHzaduy0vV78MMSj59bMC7rOyMgrcp7Qe8K/VXfH1T/tPiV&#x2B;GOKRwQ5v0bsNwxyrtIZSR5sa5rDAm5nTBsPKMjn9aJTozalgN91/6Y5S06P11fK&#x2B;RDgJaba5KCWkfZodfadyiblPl7ftfpbvly8pAC&#x2B;RfMmb79G7aNIdJ&#x2B;0lMXluTBvAMQ777rQqPQ&#x2B;PGL0KbKm0wchioqL4Qk5TTeQyBiurusLNmlM5FY7/0cngRsPLNfKt70KJ747jDwCFNJXgBAjFWZmDzPbP3t7tHuHBvpKrnGV1h&#x2B;RmZfElKwKubLPCp/YEqEn3SBjcZxL6zYBm&#x2B;fSrq8GVlj1Wu984oqgKXQV23&#x2B;Pjb5zSYmZoERY/siHmMY48AOQS6Iq/HRaTdy2i7N5zq5qw7Msi9Oi0K&#x2B;wU95VxJIvKcleqBWlvYXeNugGOBrBlThu8RSC9vHTzt0FXR1RNVyLpo86Z8a9YwuM7wDACa1MnJJyBebQDn7TlfhNeeDABIEF8OlNhSFmFZEEkwK63nRgxzSTedkziZRkjyK6bdV&#x2B;gX&#x2B;a0AVGj4XZHiiWP6Hl8yNjNMUSP7/&#x2B;saKC2OkrtvGuyCH8TL33c8rTpuM1s9uXE33AwASDS1ag&#x2B;/PiYq7aQmKdcDQIbWQShkPrfRPOQrurrcC3nR5ZIb50/8AYqbfBe8Zf5ZZxxs0156YD4KHzZTtPZXe83vOUcO5jfI2Nm42NQGnT6weUtsw3pdKBi3i9ms78/ANCjwB3PyDGIBXYKblmd0kOepXmzmPnx25LktqPsANF4IIUvsSRHO0es5q/68rWWPTPbORpAUSptQBG9VGJOC4ena9RNBxP&#x2B;6qsWvVnd91Xib0XFfFmGl&#x2B;WNZ1wtBgA4knAvWGNnnnV0pr2kzLb73xk3u2uMb3dMp80htfBdeMmhBibrtMGr7I5dqjC65&#x2B;rssYx23&#x2B;AqrDw9CPEPfjxgzfvq8wcXc57Qr0BmntYWI8M&#x2B;NSZ8TLZ/uf99GfIwAkCDLq3iXGJJ2gdzJXq0PQlffvIUylVHOqpy&#x2B;bBVrpflcI10/gDxVNrg7eLXE9o2YOzCcnGjVevIEh4vtmVXaPAgLQifq0df&#x2B;d30Y7DTfml3BOjqIFT4bQEAyrlUb5spkvGIq6dcp6foMrMOV7hVR4oabNpfYAzlnTeyPAn7OiBARiptQCXt34CeQ/kxuiNWW7&#x2B;t0&#x2B;PzcjdPj1U2O3AuYXYaALxHfL1tvNF1jKrHE/WRRaN7PFC7VvWeo/&#x2B;ZRWsH7eroh&#x2B;Uv&#x2B;f3j09rRAOqzThu8yCqG2H1ATGO0S68YWOEpebPJEt5dfCeZq0&#x2B;Bp1z6UgcGkC4XeR5MrlGxlw7OkEcSADoVuSDW0id&#x2B;CEcRLazuzHv0GF6etlS533Ml702PpmRsSNPdL1XkIImbWwAIMKcN3iUygtx92Ge8z9XxZa2tWBDe4J0d3h6cSw30KzSfufrxRY7qsorbwN75ye62gry6iMvywTHf62HSewDoV1rks80gTnMKU&#x2B;Ioqruzaxk2h7NLjSIDwsct/IDTDZ6O225fuAdp8nnV7wEBslNpAy5ICD6W9bndsLiF5Q1ilnALhF&#x2B;RO99CRp2Q85foMkEXfOiz&#x2B;G/uwCNkAeBVYqplkX9Me/Xl/xROMKrdFZHTNvXOr0n8b44K5Wx7iyN8cOb7Ra9arRxIoHskcC4helh1Uzzqorasb7V8Wz9yANdpD8l23uPVrp4D9wlkFh4FOfAJEP79SVuSsJ0vOwCQUYUgXxRB7yLP4YxLrH1qIa/67hy931XKdjpN8HQLu3951p3POv6WDsBVKm1AlG3AcfOmc2B&#x2B;2yMShqxm2fKDjgonu3WFt&#x2B;UtbxP4fAcusH2Em76e/h0AYLrYYnoZXG07T&#x2B;bdMagse5ntdDhgZK46Ul5TcwjgMAdtaXdCW2TP/yEPCJCF7pFArMDEjqOug30liqcz0uJt&#x2B;70sZ&#x2B;9tJ/zdea0swh/WaWtN&#x2B;hWugrdwcj7ravfUwHqWDiYANO5zEV9lPRlzhPlV7m&#x2B;khQ78cFVklhGzuMMl7X9TIr/RMWuoT9dvxWxvSrR/xGIkTEE&#x2B;bSN5d5&#x2B;Aoam0AZcdTUfbZqGBCtPRBgP3qZ91dce2oerR1JlG3mxrswwpasgUIrJuHX9nKr7MdnQ7YICVwwHgVXY7eWxDgqvlt6Mo5ejvVyOHRkbvQWR/iLQ0M7wgxdEDGnd/CmDkqNnTR44k4c6GrpLAfbpHAinip8wHHhbomjJ7qmnh/AaPsui8k94inzL/352XDth917sPoGtD5ldX31Rk9jXksQIAYiwnt8Us6XpV5M3xyO0IWmjTaQJ7J8c8bSyZttmOxL/H8OprI02Tje/lq3kvkJdKG3DLzVBsGdz0G9UFBu7lKo9lGQN4yf3OFfTlJblopN3ZbIEBAYGNAAD9ipxw9omjroYK4ccItuldlpXYtk5j7I7ymmpf85EO2n27y/vtrqrwnmMCZKHSBtwVSCyTB0bttm15cH5bwrPiB1IlbDx&#x2B;&#x2B;3cM2audrTenEMkDHsOPefMhBYDBXAqJnw0AFOdoR3yYnWuF467D71X6ELj7kXcKYHiUQO&#x2B;y9OYFiGedNqCs8JoBCU3JH1mEIHIlhuUKz5dWdGs2Kw4f6mYX1SPG2DlG5HLradsMGPuoAsA7Xbq&#x2B;3&#x2B;/5EbPQ9e5TRu0Fx7PiE/CEaDlXLjnSqV7i7sdIOXuWMc26kgAlmNMGFBFTmooMxHfnt0XuRomA8mj2XsJr3Ryp91S43MI&#x2B;cMfA4xZv2u0fcucnCABgCob9WeIKoR0lZG8qc6fMFljlfaTzXyPZgMgTMjnbHelEAh5hThvQpUsD67IHTGnDWsPLNccPANx9cOSCUrzZG86KcsO3d3utZH8VAICEaW2TyITe3CwgDXbCR3aLuf&#x2B;u&#x2B;z1u90&#x2B;YzxaW25lvsNzcN4APc9qAUuLjlfjm4K3FQNX2J631QTmt7Q8vd3MR9dMvslMaALjj6kpURbOMp1a/ZjDzWmIJjfhixom2lvtfcvNbVqgHSXeH9PQcA2iKShtQ0FxC20aKCR0g2xxwtH1rhfYw0C5jq0IkelpsEw1TR3i2aMITT3&#x2B;sWvsVAgAGcFR7SFjZGkpbnW93AubxVv6&#x2B;&#x2B;Z3Nm2sc3ZBp39UBCld1d0CA9qm0AVVljGaaCscD8eu2R8F9MVurU2zrMWRnDOHUtMSZ6YQHAIq6GcBfenpTyRS9yD7BSGg985VcKlFmuzR2GSCBShvQitPIsq9pUsvQ7WrSm/xOnyoDqEBQ0/wFKTrbbOCF1gGA&#x2B;uKnuaxaepR4FYgXP70yLWAOb3akTDPQC7FE/8wxDtrWnfc10ukENOiHT&#x2B;8A8Dpzd4jdNWlPjZQ9hlc4n4/S9o8JL7T8nyJL&#x2B;nWUl5b4ZfBNAQAyWoX3y4rabi&#x2B;&#x2B;5SOFJdQ3h9nlTr9tDL98uZFO&#x2B;8r3Mfo6dIHhBeM1FwUGZk4b8ICXDCPK8h4TwsrT4lzpUPUNHy73XZq&#x2B;efTg5Nmfp38BAMhiG5xvo5rdUKRQ0C7sIVI4Vr96Ig154h01OZzveARSntN5bC&#x2B;pMC3fph89oGvmtAFPujRAqcfRTEUD5Wbjxe4&#x2B;JgAAeMRq&#x2B;k5yIL3sF9JsmsAwCp1jfZ267aS9fR23pdKTGvs9MkCPzGkDHjaP9jqKgXKtW/v4Mm&#x2B;7b2TbPzM84S9cuot/g&#x2B;1kBXBV3kmx1mMDAEqLDzBe0vwDVro78wMJdWAxtr7eIwCXqLQBTTgqIO12VrlfbwvXmS41tbtkd&#x2B;cDHSeONhL&#x2B;y9Gehw/de6bc0bjAUuFTyfNK6gsAlHMp0kgLS3JFMnMYZnAeFQjCly596Xo/bqsBxwnPAmiK7pFAQ8LR1aoRys2w8vG2KjHNMBP2MFBmW73ufATmp6yWXr&#x2B;j96CfasJ14se/pwAAGV0KbG72k7xJL8qXmE&#x2B;w7B904OR54UmV/JZPl3PrRWBxylxvp8fDAozEnDagP7mGWMZsodz8tnjbfQg0n9w6rV&#x2B;e/uUqAS4xtsNX63/RnKsAQONO&#x2B;1LkjaCOtmYeyXiK5rlOmJuGP4C73TXvbFBmBzxOpQ1oVGBVs2EUbZRxZ4zYYMeZLmS/rRO&#x2B;d6BNDQAwjIzRe81u82R06dN5fCzpSLIfyfpd9CsI52XxG3HeAi1TaQPa9bkVnn3WS2sR6ukd/7QdFoNS36U5oOGlwu&#x2B;3h73zdACAvnzCqoyZzmdTu93macrV8oMP8b5qx3C5BkSdV4yU3PvnwRUoAUqzThvQh6NVza4uLTZnjEdrlT0l5i3sJs/bxvpp72WbRYtoAQCgI1mSmmZv7rOUN4Gt02qFgJh13Huxu/LF9r/vvF/nFdAgc9qAbqxiqeX/vBmSZmllMIbTRd2Gif5pSq6V2J2iAMAbzA0A0mKnq896W07UuEsRbwvrjo&#x2B;hflPHLr53p&#x2B;u&#x2B;b4/bUf&#x2B;SyLPUKgBAs8xpA3rySETVVBj3mWoWjkG3M/ZWW9h9cMxLX9xZ&#x2B;C/bs&#x2B;7S4wEAOJIwNSSt55umF4&#x2B;70yXy6OPL&#x2B;5nOZ&#x2B;NIp8rySBb9Fox00PJyZIAuqLQB/LdtmtpInrDcsexFiO1kQXUOMnpk3YjHv7MAANWk9cPfXS539a9Hnd&#x2B;or5fF2EY6T44O43tS5qv3Q5atSq6OtgTonUob8HYxbeuaHb95Nak&#x2B;aph&#x2B;6YlwJLKn66UvVJtfPQCA1pz2gY/pK7CbX&#x2B;Rq9E0hq8/lKA7fngMv/EDjT2YpcOBEinl6Wj3yheckMAyVNqBv2UeTNTs87XTHTpPntC6RbR4N3uBSliUlAwAIS0gHVilGswMQX6uFj6OFfehXs0fv0nDeowru0cjg7Y&#x2B;M2w7AAFTaAC54djjnKk69Mykt4/5rCsEscHJemn9551QHACAyfHKDu19HH3HND/Q9UXpag9bIzQ4jeQH4cCdbgF6otAF9q5lIrAZeTY/W23YdDTKtVmYL7ANvVq5XpJMNACDZtl3kaXol2m9BfCV10qQkInkP58vZT/i&#x2B;vkFHe1uiTt/XkQFY&#x2B;fL0DgBkkDcgS1jv91mrji7h9o/JHSZFvdR0OqHtu2&#x2B;/dk4CAGx9MoLILODzSGHVGCrkp2ME4ZHLS5d&#x2B;6WaVaC5yOnGtiyMDEGBOG9A30dhH5ICyhDJbwhGWq79BfAXXyQAA0ILADKdGRhCS4GjC1nKtrCyfb6dRfThtOfo6dPpmK4tZS/7oL58jPG/BAQcGYE4bMLKYAXcJId2DI&#x2B;AuqbmQ2xhjG99sO/A5/ODTv9zcmd2/t3&#x2B;OXTqMAAD1ncbt7UdcfIg801Q&#x2B;bl1nypF5X/IKbVPnxwdgyZw2gFif8VarsVftWI1R3Q5ZTW5MH/nSU5OHhVNNfWRHp6LsCwAgI/PbulbtMxovCN8uvv5RaE278Q5gFg4LMCRz2oC3OB0qdbX7YpvR4edt7u7b0di9O&#x2B;lEYL2H5G1SzdV5bJ8H&#x2B;3ABAJp1aYGlCrNJhI6PS/4I2kx4kwVynzud8PvtxnEkfoJaZOvIfg8FwCUqbQBrY2eDpwFx8oQ2OpJWY9uuWZ3r09/djlMLAOCqwMC78FOO/vX&#x2B;mlVmztGFXOfkSO0QS6R7wxwcgBXdIwH&#x2B;WziN7DEbPGrnOBdObvaNpDuB0zjt0192Vb1jdTY6FQEAajrtJ5mxUfzcKUHIR1GRfWt6zPQzypKFhdty3tkyQC9U2oCXWg2qmmPB8YLs&#x2B;Z2evjWx79gu1diOqOeLyAAAIABJREFUbnzs9gApOrMNAIBqCq3fFogtRYA33V8i4T12i2ovP0Srt//5SsYfk&#x2B;WD1SyBl1NpA3iL8CLPJXrC0L7dGtvu/7x/E0SnfgCALoQThy1h3iNOa2zb3u&#x2B;F9&#x2B;h5gelZkW8//mG7DfYbEblvV7P4q7Pf2jw4AIVYpw1gmi6GgF3Hi0dd4y8t3BXzKrk2RSGn6wfk7Q7UuzHeBQBAvMjlpo66xoW3vPqP7TZFXwEJH03aFjqye84kLFgYf&#x2B;41ewwrfHeO3rj12IA3M6cN4L8sA8HTPntXh3m2JpDTBv6VMdT/fHe/KR2dZv1&#x2B;09vhtwUAOpUwv&#x2B;2oUf92s7tPP9oUd4y9XNZRv9Or89heFfavpqLef&#x2B;&#x2B;fAz7kCQYQw5w2gFerML&#x2B;NvuyWnE9nv10a&#x2B;3ln9&#x2B;jO8tzwwwIAnQrcQP/8U5Y&#x2B;dUIF6otPT7ouI2Vctf2FXUkBYpjTBrAjECzOI&#x2B;OGyQOzvJ3BjgmFjJSGrc72kd5aLn4QAGAwR6P0Tp&#x2B;1O&#x2B;xG&#x2B;JTd1RmEY9ieVKLQpTpHY&#x2B;xzDCCGOW0AIWnJZI&#x2B;yDNB7Z9uNMdy/63H6rJGyr5ef4TFTGF9&#x2B;iADgJY669qXNYLsZLgo/pr1jOFIQPgXbaaS9020ZeLAjFhb/Zk&#x2B;X2AB4OXPaAE68p9g2JS3DMAmsO3ezkUjGPiTNWr2FUb/&#x2B;5RwNrwYABpa2ytonbEgIHj6Pt7TbNET4faTQMn4DTwR8Z/kQ4BHmtAHEek9s2nUDeuIFhhvvrtbGy4XPhPByfX5SAOCFtrFBzACmz2OkJMxiloWex4xmWRYBAK5SaQO4IDC/7X5M3y/LLXQn1&#x2B;n6knN&#x2B;ebhWZ7sT/mM1vnj5Tw4RAAwvHBQlFNsgxurkcS7l7au5S2wPcESlDeCaTxp5lEwK7mlfwrIZ26essrjl12Gk7MtqBLPAPTK/ewDAtEiUjh5wqZGdAINd23Ps85eEE2akNe12a2x5v0RGGQKEWacNIJ3Fh7YckB7lSpkGS71iymzvPOGV2QCAgMDaz/Myz8tMarvg1tVF1wQkL3F0PiSfAGPkL7qVALTAnDaAW141sCvwZsXlnYo/gefbIrsbybxbnXjtab87Zlb5DQBYCucO8VW0UwIPlsJnXeWdacFrkzWAylTaAEi3urf&#x2B;ztSlUzF105isbNTM7XRC22vP9lwdNV97AAHgVSLH6t0PDN4zAvIlbzPe21YN/&#x2B;TdR0Pfrh6Bef7ovIXl1u7tKcC76B4JkIcwlF5cOle3jX2GPNXji4vKbLv/My2lBwBe4moEdalL/0tqA929tchpixnrZLun2fZc6u5ILiVE0acfRLhZBQCRzGkD4BZROAFDnh5vGzY7KYwBAAculdDCY7bCGxGN9CXy8zoaxbUrHHhHduPoOnrfHp&#x2B;834uuDw7A48xpA&#x2B;CuwDjB5CkvPCXwkV2dDJdtn56zfRdvK7O5qwUA5BUozgUWBmY8WeLMmFrdGGfUncO1O63t0sxRAE6ptAGQwRjZC7t8uLuGbyMZuE8xUgceAOARMfW2gQOtIUW2i5wfnP3V826wZbvfjju1NPE8wH0qbQDwdqYezlno5wbBUUb6ngNV&#x2B;lbF8AcQAIhxWm9b/WXZOWOO2ZZxxaViDy0oN3yt6zMh0Egj4/vq&#x2B;hABtEalDQDe69LSCP2q0PJx7Ns6BpUDAOVcqrcFCFceFDj421B8dz7Wctxb/OtGzu7qS&#x2B;BgJr&#x2B;1sbMVgBZ8eXoHABiZaL5ZP/v5H45SuN6XCl8pV00caR2IvPn80VM6PTgAQECu0DFmO8uI5bQJAS0IfxyXzpx5U&#x2B;E&#x2B;E0MGnMkZzZBHA6BN5rQBwLuUGCPZrEK3WgJFyhIvV9TqnkVCd5p5hGzGOykAwDudBhWm5nQk3AI08LBLxjgfYg6CPhMALVNpA6AgmUAvxkhQ84o/Jv0evcjbHwAANYXrbcspTdKNanZHZWXZZrnH9&#x2B;KoVcZq9l7a2/9sR4QPUJpKGwC82sBJ12pNiOXkre27Xi4OcbTB7d2cgY/eJdvlNxwZAOCmOZyIbBSp8Pa4QI&#x2B;EyI9mmLFukYXJOq0yGj9WAGOwThsAxYns2zTeemxHi88Vqv30fvRO73f0/gYBgDGEo1bVtcdl6U5/KTdpPEwtcU5uR7YB0BRz2gAoSA7QpsE&#x2B;l&#x2B;0K4cs3&#x2B;JIBoXf6&#x2B;SS3ozHJDwCoJhCxlGhsSDWrT/b0cxzyg14ehPAbjHz7Qx4lgJaptAHAi4yXcUV2Exp7sPPpu4uph91vuDTe2QUAtCbQUnLseK8XlwLC3Y7uWbbcoDuT0i4t2Nb7gQLolEobALzCazOu&#x2B;Hsu21XHx1A0FR/pQAEAHbEqW4OSI8PhP8qaTTgAeIRKGwDQk2UxbDUyNPtC62mPb0qgw1KurQEAPCK5AzZ5HcXhXUfRGeU9RR1qgDZ9eXoHAADu&#x2B;uSWy/9/9LA3Z6Fvfu8AwKheHuAN4J210rR3rcwG0Cxz2gCAcRzlmVcXWh9Pxrf8wqMHADTO/LZCih7SmLWER5LxLB3&#x2B;WAF0R6UNAGjaahmDq26uys6KQwQAtOYTLt4MGllRtkywPWglhvo5zwEapNIGALQrMsO/NB72halpzFsOH&#x2B;oXHjQAoAvLGEaxrQu767oN8MHFZC5p9cvlERvgQAEMSaUNAHiFIYflXn1TR&#x2B;vVAwB0bY5wFNuyKB0xroLSAT6y01FrNw/pAIcIYGwqbQAAXUpI10&#x2B;fIocHAGBWbgG8&#x2B;LCz/QD19PgY6wYwPJU2AKCgT1ZZKD0&#x2B;Ghy6aiK0ekqJPakvV7o&#x2B;r2uy&#x2B;vswBwoAgCORobK&#x2B;CJEiC5MjVRkB&#x2B;Pjy9A4AAKT77tuvl//39O5Ucv9Ox/JYKbMBAP2a45bPfwhj4h2FlMlLgr2hGvezn/9h/r/VP8UcrrkUF3OsnMwAHTGnDQAY0EvmaeUdXzze8WHpy4&#x2B;&#x2B;Wf7Pf/zt10/tCQDktSq2EeOoM0S5XhQlNpvX6dtfHbSj5hC7ujgCACRTaQMAasvY0XGZD4eH33aa3AbWip8Hbl8tto10fIi0KrN9/qLYBgDkVa5WV1rRtda2x0RADjAYlTYAoKptjpqckIfT3QEy1TvDZk&#x2B;3tlxGYoBjxZFVje2nP/7JNE1//utfHtodACCzhFh6O5brDY0fA8KNNDOGyi8/zgADU2kDAOqJzy3jbxnIV08FDqYa28C289g&#x2B;ZTYAYADLGDhcEHokFBwgyJyP8P3CZL9T/WjcJ&#x2B;DXqQJaoNIGALTlZuVsmCQ2bwUxeWV7OrUtswEAY7g0dm35H6sqkTLbkdMjnNBnYvfxvR8oHrSM9rWFhxaotAEAlZyOBr1fWxoyWb3TMZIXUmMDgFGFY8LVxKn4nu2C8Fl48tl2feg0wxwuHrEb7Su2weNU2gCA2pIz/FEXZgvUID//cy623RyD3O8hIoYaGwCMKssMqtIPG9Vq3JsyG0/ZXYB5sgYztEGlDQDIrMTK4btbGyNN3U7sy/6&#x2B;xjhQhCmzAcDbpK0Zlmti1jACx2EZRScf7e2gOkgg2ofGqbQBADnFrGpw&#x2B;rBCbW0aFHMcdh9jWXVmsm4AeJtVBeioJXugqJaw2Nubxbdz3z5M0M5Non3ogkobAJDBaea5Wo/9yFEi&#x2B;s4M/35HTcYm6waAt8lStlkFkEdlpBfGmZGHd/eIvfBwUZpoHzqi0gYA3JVlrYL4tPbOaz1uOcR41UnmtBiZ1rKGUUm8AYCtq8v69h5d13EUt0M5on3oi0obALB2qTPhnTzzamI/6o2AVa1x95Bu37sM/7UuZd3zSukAwJDCpbXw1KujtZBf1QLxUuVsexy2Tx/4WFGHGhv0SKUNAPhv1Yo3q6rSUTq6TFxfm7KaysbsatatzAYArxW5fPKlR/YrnHTs2h6fmKcPcKx4ljIbdEqlDQBIF7Pc&#x2B;soy&#x2B;YypHvWerMZk9Ucji3fHzE57S2vc30/ap8wGAKxcGowVHzSOFF4uD9Gl1h0xG/wY6XDxIDU26JpKGwAQ5bTPDFlcXY7eZ/EGCVm3MhsADC8&#x2B;Pg/869iNE0q/uyylO1BjgwGotAHAS13qgrLKUVcppfSysneOR36t&#x2B;MT7qLr257/&#x2B;JfCvAEB3rq4rthv5j11jm45HsCVHyMMfMR5xP9oHWqDSBgCvEy6bTdGtINNSzfnlhlyA7eoqDrvHcP7751hJ6V/r0uDWcJkNABjDUfQY&#x2B;cewkcLypRLLHo96rKgpS7QPNOLL0zsAAFQVbk743bdfF0oaV&#x2B;Nnh6werRaBiHnK6dHWtPOdvvzomyw9ZJZlNiU3AGDXJwVoOdRMyB0yjuo7WjsZkl2N9pXZoH3mtAHAi8TkqJ/HHOWT2StkY6Spdw5L5AzCMQ4UMWTdAMAllzoirlomtB9ktjZEr/0jRuOsygZDUmkDgPdaptkaFSa7c9CObov4LN7patYdLrOZxAYATHuzu15YK7oZWr/wiFFCwoi6P//1L8uYf47wjbeD1qi0AcBb3Bm7miW33FaPuk5Zd4tklypkp5PYjuYXMp6MvSJl3QAwsFVL9uV/r4LGsYdtRTaHvNqW49LsQIiXZUSdgXTQMpU2AHidZfZYee7UMIlrYC36q4d0NZtw9enc2036oIEMAJDgUtg5UmAZLjF&#x2B;RHZoD28csrhTZjsaRbea6wY8TqUNAMiWeMtL0zhur3Up6/6P//27&#x2B;b//7V9/ufrX1RDX7YhXqTgAjO1TcxqyCfnRTL75L0fpzHiHgr5kbA5vQhs07svTOwAA1BDorzLS&#x2B;NZy6mTpPov3&#x2B;PKjb&#x2B;IT7//4379bltmm/1l1AwBeKyZ6/JTfKuxMIeEyW0By8/zejxgtuBTtf2zLbKpr0BFz2gCAu1b9D1cGSFNjUvr7b3OAA0Wk5KlsRyyNDgDMBosqj5YuDs/eu1Rms0AyeWVcgxnohTltAEAGA5fZMlodJUuyvdDVwa3Jc9dWJTcVOAAYVfKUr67N7/p0/llkmG0eG1kkTGXbpTM8dMecNgB4l930Oy2rHHIRiEJUIsmSci/tFuF2l0bfzcP/8bdf590fAIA6lmW2yKdIWyjtznC67RrMH8pp0BFz2gAAmSeUlVZmW2bg//avv/z8X/zTP5m59R4A4CWGn5WVkLOMfUBox82uFdZghgGY0wYATNP/XWvt6rOW09o&#x2B;T&#x2B;&#x2B;6aFdteQY5/3tkmcq2LLD927/&#x2B;Mj4VX5XZ1NgAYEhviy0DLdlXDwivJw33XY32L63BfMRcN2iQShsAvEK5DPNtif1NDtd73Gwgk31k6zJjv9k68suPvpmm39zeIwCAC44ymvCQQWU2CkkYUXdnDeZw&#x2B;U1neHicShsAvEWF4Zyr&#x2B;W1Me9P&#x2B;eIOMDWQudYw8kms2W/bV5gCAl1tmKLmi5d3ERyhORvfLbJ8gf/5jctcKoBEqbQDwIoHOKgl67xu56hVZbv9l9a&#x2B;SpYHMnTltf/7rX8JNI5NHvCqzAQB5XY3Ak8cOCsjJJXtz&#x2B;IBlYH9UYNMfHhqh0gYAr5aWrK4y1e5qbFOf&#x2B;0z7cq3TcLN15FG&#x2B;rcYGAF0brFx0v2YW2ILGEpQQHxXP8fxq7tp0Yw3mpYyd4YEsVNoAgAti0lSpLC90vxa1TcKnTK0jP5TZAKBfwwTYNYe7DXPQaEFyc/j/&#x2B;N&#x2B;/W5XW7u&#x2B;MeWzQIJU2ACBRX&#x2B;sfRI5pjdn/0xsEzR4ESkguRKUtxrYcHvub/&#x2B;//jXlKoRrbV1/94Pvv/562ZQDghXaj6Es9Nlbt36GCmwsw37TtDL9iQhs0QqUNAN4iOS&#x2B;Nf0qzSe8ye//Zz//Q7H7SnYQGMh9HI1t3Z7Ylu5N4H721f/nnbNPsAIA3CPd4nKKLbavH6AZPBS10d1gW23IvwPybW3sGLKi0AcArHCWi4ZlepxWpLkpW4cGzn8Lb1YG0cHNwa1ot7dKzSkxlU2YDAB63Csi7SEnoTkKN7XQN5uTWkbvtIjWHh6aotAHAew1fNMr7Bo8mw8ntXyhjD5m0fHv5rG3ircYGADxuN3j&#x2B;/GX4NISupRWidjtYnI6TS&#x2B;gMP6mxQZO&#x2B;PL0DAEBVc1p7NNPr8391d6qGLG/KTQGmuks1rFZTX/3rn//6F2U2AKBBJcJmg96oIEstah4V92//&#x2B;svkeWy7/vG3X6dF&#x2B;19&#x2B;9I0yGxRlThsAvM427x0&#x2B;Qc3&#x2B;Boc/YmRxVGb7t3/9ZXwFLv6RamwAQMtWIfT9iFpMTkZ3htMdrcGcl6ls0DKVNgB4u/YT1KO2javHzP999OCj9djCi9XtbifmYQwpOU2dU&#x2B;6bs9ymvew9OeuelNkAgBxiIvb7xOEUEh/k7wbzpddgNqIO2qfSBgA0LabzzOoxkXn&#x2B;UeHt6JESe5LFj3L95NuBSW8Zy2wSbwAgIDIA1l&#x2B;d3mWc8hU/oW0Z7VuDGQag0gYAr7BbVRqjdHSa22d5m2McK24KJKs//fFP5v/&#x2B;pMf3565trVJ3WTcAUILiGe9ReQ3mTzy/ux01NuiaShsAvMWQtSJ3AXjcssY2/2WZJyeMbP0k4YHlHyaJNwDwDkNmMTTi5tpsp&#x2B;0oTjcyHSQLJZrDC/WhKJU2AGAEnwxc4Y3KtmW2LD759lGJTo0NeqcjMdCvmNWRYXhzuB6usc2T2C4R7UOPvjy9AwAAieY8PznJXz7RnQKuCpTZEhrLxDzlH3/7dQuJ9x//lL8xJryNoSFAg05/mvx28SrLaP9oWbXTQlq42LbtWpEW7X/50TeBqWzKbFCBOW0AAFBKTO4d&#x2B;ZQWamyTMhsADCq8qPNujc0MXbp2FCQvC2yf/07rDH9Kc3gYiUobADAIY2ypaZmBz7l3TDPJhB4yJdZpmExlg6e5Qw20YxVIr36dhNm8R8bm8NtpcPNf1NhgPCptAMAI5P/UlFxm&#x2B;wg0itwW4RpJvJXZoJzPJUzVDWjN7oCAQqsj&#x2B;w2kBYXKbLOMof6kzAaNUWkDAJoTmbrPCbkyG71YjmM97RtZosY2mcoGAJwRXfNCMWswR67KFrlmcyMj6oAsVNoAgLZcTezdCOBBCRPaZsskPFeNbdIuEno2X9HM7QCeEg6t/ToxqlUw/wny06a4rcpsu8W5RkbUARmptAEAHVveC/ju26&#x2B;Tq27uGnBHeADsnF2fTmL7aGRwa6DMJocHAAJiYnLhN82ax9LFqLkGc/YRdV999Z9pewJsqbQBAM9Lq5CtymyRz1o&#x2B;0nw4booZ6LrtIXOUjbc/lU2NDbJzJQIeV/&#x2B;HSJmNplRbg7mFGtukcQWUodIGADxsN7e/tNa6Mhv1/fmvf8mSfs/aT7yV2aAorSOB&#x2B;sTDsHS1zBa/BnP7I&#x2B;qAm1TaAIDHrHL7bfvHSw0htY6kmm2ZbbWWQ2Ah9O2EtvYTbzU2KGT3yvWzn//BhQmo4Opwt9Ofps/PV9pzoR2RneFXAj0k2x9RB9yn0gYAPGObhKcN55e387jtWg4//fFP/v1//T/bR&#x2B;ZqIDOZygbDubPaKMAl5X5tlNnoXSNdKyZT2aA3Km0AQN92B89&#x2B;/hiT1cv8SRCzlsN2WluFdRqmKlPZ/vin31k&#x2B;HYrSSRLoiIECjCGyOXy4S&#x2B;SSqWzwKiptAEAlnwx896bhpVXZjra83WCY25fct53NtpQ9654amMomV4fsVjepl/8zcOkEyOJmHB7YJvRi1Qd&#x2B;/mNMZ/hd/Y6oA5KptAEAxS1T96LLz8jqeUp8n5n2B7eqscGzYu53q8AB2&#x2B;WNTx&#x2B;2fUyJnxE/TfRodw3mGJrDAx8qbQBAWad3DHNl47J66tgW1SLLbI0k3uGCmTIbNEI3NiBgd8HjbTBc7WdEHM5I6q/BrMYGA1BpAwAKKpreL&#x2B;9CSu95yu6abVv9Jt5qbJDdfM0KXyUV24BdR78Mq2JbZDUOSFiDuc2pbGkj6oAsVNoAgFIi7wIkbGHmZgHPipnN1nXircwGXdBMEt4jsgAf8zA/GrBSeQ3mx0fUARmptAEAxUUO3oeubTPzRmpsU&#x2B;6pbHJ1yMVtbuCS3bXZdueunT7mPr9gDGyY5vDhUP&#x2B;rr/7z0gsBASptAEAGkUuyw6gyltkCWfdUMfHO8upAMk3egLD5JyLQabbcz4gfKIYRswbze0bUAclU2gCAu3Zz&#x2B;&#x2B;0KalfH0poAR5v&#x2B;/Ne/rNLvVe49auKtzAblLO9ZJyzPZkU3eIPtTLUV1S&#x2B;4KRzkz4YcUQfcpNIGANwSLrOFH3Zpm9COT7FtN/fud50GNTZ43OouefzV0HUTXmVbUVv&#x2B;5f5wN2A6KLONOqIOuE&#x2B;lDQBY&#x2B;2TjGUfF3kzvjc&#x2B;lQe/pIaPMBpW5Jw5klKWrhGgcpkFH1AG5qLQBAOkCy60njKLdNr&#x2B;S1dOFt9XY/vin31k&#x2B;HWq6OgLGGm8wnoSmsgnPghfadoafXtMcHshIpQ0AuODoZt/qL8nNapbFNncJ6UIj6zRMFctsV3cMuGS&#x2B;FCasvjY/XrENRnX61c7SNNIPCK/1khqbrhWQnUob1PblR9/cuU4DPGKVqAfu3&#x2B;2uEjFdGVcrsadZ//jbr5cJ89sSbzU2qCxLz7ftA1xn4Q3uDHeDt9ldkm1qJtoPB&#x2B;HKbNAIlTZ4wOdyq94GtCBmzPtp1h0/tJYEqyTN5eNZ949/3qls1RJvZTZ4UNod8KNLvOluMLxtP3bD3eCSRmpsk6ls0A&#x2B;VNniMyW3Ag5bJ9naEe2SaHc7Y7yzYxsdukuby0bUeE281Nqhv20s5/g64xZmAmeIZJGikObypbNAXlTZ4ksltQH1Ht94CI9/n/9ZVpppwkqbY1qNOE29lNnhKzP3xm90gNZOEIW3DdQE87Fp1hp9MZQNuUGmD57lhCtQRn2Pv3nqLn/S2&#x2B;0JHr&#x2B;4G39YySfvqV79Y/ev3v/193d0hgx4TbzU26MXuFfb0Su36CyPZNpOYhNkQIcvtuB5H1H0e/9VX/3lp34AAlTZogsltQGkxZbaY&#x2B;25pi7ol3AR8p3CNbf7797/9vVEavahWYwtsUJkNsnv8R1iLSCCS4W5N2Y0MRfVdM6IO&#x2B;FBpg9r&#x2B;5Z9/eXRJU28Darq0fNqdVHy7fYn9VkyNjb7kHdw6SbyhMS2E7quuzp//&#x2B;Rk3Y9YaMCmzNeYoOHx89AZp1NiAJZU2eMDngheot4mxgKISUutVlp6WnEvpj8xJmhrbMB5PvNOeJfeGqx4P3QOT2xTb4OUMd2tHYFDdpzP841cTrno82hfqQ2tU2uAxJrcBj9gm2KsR8TFOb95ttymx35U2le3TQLLMHnGXqWzwNi2E7quLbGTL6GK7A1RVukEFd5xG&#x2B;wL77qixAbtU2uBJJrcB/Tpdj21ZbJPbb8XU2D5Zt4luHWk58U5&#x2B;FhCjhXrbtBnpsjsyJmGEDdCFo5BbKP4IzeHHY0QdEKDSBs8zuQ3onRUgLonMug1u7UvexDt7wUziDXW0MFRuLqQtl20LP2U1UKbs/gFZ7baI9KV&#x2B;3KUy22daWwtXEAJaHlEn1IcWqLRBE0xuA5oVGPl&#x2B;9E/y&#x2B;QBltiG1nHgnPwsIaHyonAsxDCymfO5H4EGmso3HiDoghkobNCRQb2shYwdeK2H1F7Zk3UOqVmMLbFDiDY/oeqjccqzM6rIecxMfaIS5a00R7Q&#x2B;p5RF1Qn1oikobNKfxEbIAYZL8LVn3kKzTAEzNh&#x2B;7xF&#x2B;XPIw2mgWYFCuS0wBrM4zGiDrhEpQ1a1PUIWWAw81ovy/85/2V5Y06NbUuNbVQSb2B2GrpPT9fb7nCJhy74kj5Ic/jxGFEHJFBpg3Y1PkIWeINtR6ndh8ntdymzDUniDex6z1A53eqgNb6JTxHtD8mIOiCNShs07T0ZO9A4PWoukXWPSuINhDU&#x2B;VG55O37uRPf5j7Tl2SzqBjUtG0jOf3lqZ15OtD8kI&#x2B;qAO1TaoLY//ul3Vy/PjWfswAvJ6o/Iukcl8QYiDTZUbnVnfzvyRrENavJ1a4GAf0hG1AE3qbTBAz4XwkuX6rGXfwCatR05O8nwj83pmZR7MBJv4KqRhsrtXveXC7UCvIQa25CMqAOyUGmDx6RNbpsGGiELNGK&#x2B;TRZTQlNm2yXrHlXeGtsk8YY3aT90X13T48tm2ycuC29CBWA8ov1RVRtRF9iaaB/GoNIGT0qY3DaNNUIWaJ/7ZWG5su7vf/v7m1sgrxYGt6Y9S&#x2B;INTekidN&#x2B;dwl70iQC9UGMbVd5oX9cKQKUNnleimWQLGTvA2DJm3Z8y2&#x2B;c/JPAt0C4SyKiLPvC767Gljba5NFceoGXKbENqYURd9gQBeJxKG7QirZlk4xk70D5D0dNEZt0xlbO5zBb/FMppIfFOe5bEG2oacqhcWmFsftZcnJtDi7mrJEB31NhGZUQdUIhKG9QWKI&#x2B;VyNgn9Tbg2LLMtroX5tbYkfgaW8zWIh9GHRJv4JI3DJULTG7b/afVCB7FNqA7amyjamFEnalsMDCVNnhAuDyWN2Of2hghCzQoMJvNTbFduWpsqmsNkngDaYac3DadLcC2rJ/d6TMJ0Jq8azDf3AgZGVEHlKbSBo8xuQ14yvbemRtkYfEptzJbjyTewE1DTm7bjQ3CFbj5AZ/nLttIBrYJ0IISazBPOsM3wIg6oA6VNnhSicltgQ02MkIWeJYy21UVprJ99atfqMA9QuIN5DLqULlAkLAqp8U8RTNJoEFXo/2bA&#x2B;&#x2B;oyYg6oBqVNnhe3slt4Q02krED7XDDK6DQyFZaULPGFtigxBsG856hcvE1Myu3Ac3K1bhCr8gGGVEHVKbSBrXtpt/1J7dN6m2AMtux&#x2B;JGt4XQ6JtmWkNeXd3DrJPGG93nzULm5gWS4ZrbsGDmv5basulngDXhWicYVRte1wIg64BEqbfCAo8pZzYx9aniELFCBG1tHVonZUdZ9mkWrn7VJ4g3kog/8tFmJTXQBdCFXjY0GNT6iLrAPon3onUobPOOocnaase8&#x2B;K8DkNmDFXbCAXFn36UQ3efsjGl&#x2B;nIflZwIPeObltNTttK/yvu48XnwAV1GkO/9mygL8yI&#x2B;qAZ6m0wZMSJrcFnhVgchswqbEFZcy6zWZrkMQbKOedQ&#x2B;UCxbbl35exR7h1pGIbUFSuaF8VrU2Nj6gzlQ3eQKUNHmZyG1CHu1fnJGRUAAAgAElEQVRHMtbYZoFF0dXhKmu/xpb8LKApLxwqd1RFWz3gdH7b1QlwAFfFBPyfAP7&#x2B;GsxUVjPaTyuYCfXhJVTaoAmByW3T65d/ACgnocx2dVF0CfmDJN5AIbtxuKFy06JsdjTEZ/V3ZTagKM3hx9bpVDahPgxJpQ1aEci937n8A0BRJaay0Q5T2YDSDJVb2tbVVt0g526Tp10iT2t1ADGqNYeXSjzCiDqgNSptUFta7l0/Y5/U24BBVa6xlZjWZsxsWN7BrZPEGzhgqFzYUbEt/JSjpwPEuxTw74bWqz/G9JakjvZH1An14Z1U2uAZabl3zYx9amaELEAu5WpshUpfgZ30&#x2B;7yr38T79LWAZrUzVK6FS8OqnHZaWguv5abYBlxVdA1mneEfZ0Qd0CyVNnhMoclt08XwwuQ24CWyZN3VJpPJ4RNIvIGnNDJUrpHQfbd4tqyZff4pXEKLmQAHsFSncUW5Ytvjv96N63dEnVAfXkKlDR6WfXLbNO4IWYA0ldtFfl6iXE1O68itfhPv09cCOmKo3NJcb1uu0Bb5rJXlE01xA7YswDy8FkbUWYAZCFNpg&#x2B;el5d7ZM/aphxGyAJd0l3VH7qRf41n2Gtsk8QYiHIXNlYfKtd8HXmEMKO1mwF95EFsXKUlT&#x2B;h1RJ9SHt1Fpg9ryLuRQf3Lb5A4v0INVSpYlp43Jw5NfKPKJJrQt9Zt4n74W0L6E1hTvnNw2XW8FGVjpzcptwKyvQXWBPRTh72o/1E9&#x2B;FjAklTZ4QN6FHCpPbpuaGSELcKR&#x2B;1l0zt/cLPEm8gTb0MlSuhQvHsjx2qeo2V&#x2B;m25TpVN3it&#x2B;s3hSxfDWvihbkr70b5QH1hRaYPHZJ/clvCsgF5GyAIs9TWydbq4k4a7fvSbeJ&#x2B;&#x2B;FtCj9ofK9R66b8tpc8lNsQ3eJm&#x2B;0H9&#x2B;yIrnY1kVK0pT2Q/3kZwFjU2mDJ&#x2B;Wd3Jb8rACT24BelK6xJVe5dncmeQ2Jl//qSryBNhkql9elbpOKbfAefQ2q0xw&#x2B;QfvRvlAfOKLSBs8zuQ3gplxZ95zoBjayGtD6/W9//3nw54/L/yavQOKdkHVPEm8gN0PlIgUKY3OjyFWxbbfwdnX5N6Bfj9TYqr3Q4z/LLWi/xpb8LOAlVNqgCV1MbpvU24D2ZMy675TH5ufOhbeM5o2/9mdW4g20JrktpKFyAJeUq7GFg//k19IcPkHNEXVpbd6F&#x2B;sCpL0/vAPDf/vin3&#x2B;1epP/ln3&#x2B;ZEAqcPishIAiHOOE7oQB5ffnRN/PPzle/&#x2B;sXNqWwZs9yjTaXt5MvLbMtPeSt8pTsSTqHTprLtPivtUgt0JBCHB56S91kBPYbun&#x2B;lu25lqy2lw2381sw1GVWcqW8YtJ5TZ3hnkz06j/asbDF8xA6G&#x2B;Mhtw01fff//90/sAb/HVVz&#x2B;Ypun77/9&#x2B;&#x2B;siao&#x2B;lLdNx6eaQIMX7wT7&#x2B;Zpunv/&#x2B;ffn96RLlVYCH212dMRr4HqWpYde&#x2B;fvqqlsLYuPamAwuyd/xn6z4WeFn5i2wdYuMXMDyWX97KgCt3oA1PeDf/qNkL6ECs3hl/&#x2B;0CubDzeFXj0/bPWW27KH&#x2B;ZCrbdUJ6yEj3SGhR5XY0u68V1v7yD8Co&#x2B;loIPY0am8Qb6EsgDs/bBz7wWgE9NpO8NE1NmQ1G0lpz&#x2B;BI0jTSiDhiPOW1QT8JQEZPbYFTmtCUoVGPbJrqBEa&#x2B;7jua03RnfOr34J1Ti3QUDYHmt8MlvclsWu2W21Sy31T8V3iM4ZE5bRkVrbIGWFYEGFVurKW6aw19lRF1ThPSQkUob1JN8AWu83tZLxg5NUWm7pOg8tt1eMeHH7D4&#x2B;Zjvxe/LOH89GamzhJ74n8Q6TlvNapyd/46H76TYbvADt9pNc/kWljQeptOVSs8y2&#x2B;5hImsPf0Ui0b0TdTEgPGam0QT13LmDZc&#x2B;&#x2B;0IT8B3WXs8CyVtkirZCxXZjsdVMiOth9TaZtuDG6VdU/BxLvEhUnifZO0nNeKPPkbr7f1FboHprLN/6TYxlNU2u6rvwbz0cOWj8/YsmIS7TdTYws/8YWhvpAeMlJpg3ruX8Aaz9hPt/nOgBJ2qbTFKL1Iw&#x2B;7y5vFPz7Jj0&#x2B;sbyEwS7z5Jy3mt&#x2B;JM/&#x2B;6C31w6VC09lM62NZ6m03VGicUVMhex0Qpvm8Hm1P6IuuZNz74T0kJFKG9ST5QJWM2MPPzFtg6&#x2B;NLGFFpS2swsjWaVNpC7zQ6jExxbmrO/bOn8fK6zQEtmkq21XScl7r6slvqFwWy2KbShtNUWlLk7FxxUqhzvBHm4rfmUZ&#x2B;TitrZESdUP&#x2B;IkB4yUmmDejJewGTs0DuVtiPVRrZOFyttu10ik3dS1j1JvDsnLee1Ek5&#x2B;Q&#x2B;WyWzaNVGnjWSptCXIF/LtFtVyVtulezC/a72JE3Wunss2E9JCRShvUk/cCJmOHrqm07apZZpuuVNqOtqmBTJouEu/kZ72EtJzXSj75DZXLaLtym0obT1Fpu6Roc/hGOsNPon0j6vohpIeMVNqgnhIXMBk7dEqlbaVEje1jlWxvc&#x2B;/kSpsGMmkk3mOQlvNad05&#x2B;Q&#x2B;Uy2i7e9tSe8HIqbZGqNYe/WmlLzghOt9zUb2Y1lUfUVb6wjkdIDxmptEE9hS5g7Wfsp9t8ZwDKy6m0zQqNbN1dYmE3kc6VV8fv22t/9ExlG4m0nNe6f/IbKpfLsofks3vCm6m0nSqxJFuWSttuo8jk3RPtT0bUdUhIDxmptEE9RS9gMnboi0rbVH5ka7iuNv&#x2B;xQqVNAxk1tvFIy3mtLCd/&#x2B;0PlhO4QSaUtrH5z&#x2B;LTF1TSHv8lUtk4J6SEjlTaop/QFrP2M/XSbr41KeSGVtqKLNMybDeTh28eUqLQZ3Do1M7g1/ESJ91XScl4r48lvqBwMQKXtyFPN4e9U2jSHTxOI9o2oa5yQHjJSaYN66lzAKsccRshCmjdX2irU2OaNP1hpk3VPprINTVrOa2U/&#x2B;dXboGsqbVslov1Ap8cslbY7&#x2B;za9&#x2B;JfQiLreCekhI5U2qKfaBSz7NDUZO2T3zkpb9pGtdypt24XcMqbiGshMEu/RSct5rRInv2Ib9EulbaXcoLrdutr2L3UqbaJ9I&#x2B;rGIKSHjFTaoJ7KF7DsuXfl5R&#x2B;mF8esvMHbKm0lFkKfziptR&#x2B;acfHcht4y79NofMYn3G0jLea1yJ796G/RIpW1Weg3m6axX5O4Dbu5GeMde&#x2B;7tnRN0whPSQkUob1PPIBUzGDm16VaWtziINU2q7yFyVNln3h8T7JaTlvFbRk7/3oXJvvvzxWiptU5Ua27zxSz0tNIfPzoi6wQjpISOVNqjnqQtY&#x2B;xn76TZfG8UysJdU2srV2D52E&#x2B;mj9Pu04cydPdRAZpJ4v4y0nNeqcPIbKgcdeXmlLW/jiktj5nb/dTpIEO5TZps6H1En1N8lpIeMfvj0DgDFfeKJbbTx&#x2B;ctRtHH0rM8fAzHKH//0u4QAK7zNLz/65rWxLHSqdI2tHbLu6SzrnppPvE9fDqCmo3A6LQhPjvkDTkP36cXXRHiPdgL&#x2B;oq8u2p&#x2B;MqAOIYE4b1PP4UBGT26AdY89py74Q&#x2B;tFGrs5pCyyrnrCfsu4Pifc7PR7VwFNqnvwmt0H73jmnrVCNbRvGny7Mdvr4XPvz2h&#x2B;03kfUCfXDhPSQkUob1NPIBaz3jH16cYzLSEattBVapOG00rZ8wGnbmfA2r&#x2B;7b9OIfpXZqbOEnmspWQiNRDdRX&#x2B;eSv/Lun3gZXva3SVnQeW2BU3PyXQCv4owfc35nX/o61E&#x2B;0bUVeIkB4y0j0SXie5sUzNdjSBbU6aSUKT2ukeMzsd9JpG1v0h8QaoIK2juz7wQHZ5l2SLVyikDxDtT0J9gOvMaYN6WhsqUjmOyd5SYHpx1MsARprTVmEh9LQ5bdtRrjd3Utb90XviffpEYrQW1UA1T538JrdBm14yp61Oc/ij6WjL8D5&#x2B;ipvm8MmyR/uVlywR6scT0kNG5rTBe9Wc3BZ4YoDJbdC&#x2B;Qu0ii26hRJntZz//wzRN3337dcKW&#x2B;1I58Q5sU&#x2B;INvEr9yW1HTww4ndw2vfvmNfSotWg/ZmsG1SXrfUSdUB94kEobvFqJjH0KVumOnhgQ3qaMHZ6SvV1knbYwJQa3fspsn/8YuNjWe&#x2B;J9&#x2B;kSA9uXt6G6oHBDQYHP4GKayJTOVDeAO3SOhnpYnZVcOcbSjga67RxbKugOVttPukdNer8i8o24DPzJzpW0adFpbOOueJN6v1HJUA0U1cvJXHosgeocjo3aPzN4uciW&#x2B;e2SgXeTpBi/t25t/lHofUSfUT9ZIVANjUGmDetq/gMnYoZpOK23lFkIPT2iLqbRFPiVtlwJT2T6ltYGLbb0n3qdPJE37UQ0U0s7Jb6gctGC8SluddpHJlbbdbWoOn8yIupdrJ6qBAegeCfy3vO1opojlHxKCNss/wFOyZ91HGzlKoauJGdy6LK2Nqp0aW/ITJd7AwLIH4frAw8tpDj97Q6g/tRTtC/WBAai0Af/DABn7ZPkHyK3QyNZAse0pGsjMJN4AXRhjqNzLr7nwuHKNK26K7zyZsMGYX55Rl2FuJ9QPP1HXCqAjukdCPX1Nyq4/sSB7U4Lp9TfKaVkv3SMrjGxdLbewfJX571e7R1ZYp2Ee6Dpe98heEu/AEyXeFfQV1UBGzZ78&#x2B;sDDIwboHll/DeajF0rrJ5&#x2B;2S&#x2B;Hm8CPF9lvtRPtC/cc1G9VAj8xpA/ZVntwWeGKAyW1QlAYy8VYJeb8k3gCdOore&#x2B;5rcNqm3QUWFamxb3TWHHya2X2kn1A8/0VQ2oEcqbUBI/XY0R08MsPwDZJcx6z6dl3b6xBjJO1miXWSnTWZ6SbwDT5R4AwSid33ggVmh5vBZtrardLQfqKt1GttvtRPtC/WBIam0ASe6mNx2ujPqbRApMutelcFiujs&#x2B;OIj1iFXZPsJZ91Smu6/EG6CQ&#x2B;pPbjp4YYKgcPCX7kmy7QX6F2lsM0f5HOzW28BNNZQO6ptIGRCmRsac9McAIWbgjPuveptPf//b328cHFlF7vOom6571kngHnijxBtiqObkt8MSw06FyL79GQ3YVmsPv5gU3PdIcfgxG1AFUo9IGXJA3Y7/zxACT2yBBuQYyKw&#x2B;Oaf2Qdc/q19gCm5V4A2Q3wFA5oTvk0kJz&#x2B;Es&#x2B;g/PSXmLew5f/evQyos5UNmAMKm3ANQNk7JMRsrBwNesOT0fLNVmt0KQ3ZbaZxBvgJeqvu2yoHDSl3&#x2B;bwz05l&#x2B;&#x2B;7brwOLtzWul1A/8EShPtAdlTYgRS8Ze2BnZOyQvXtMFiUazkxqbAumsgG8TeV1lw2Vg3akldmmi83hWyDan7VTZitUnANok0obkKiLjP10Z9TbeKeEJdk&#x2B;jwlk1xkrZHlz&#x2B;CxZ9zyg9btvvz56TPvjXkus0zBJvAE60ctQOaE7ZFG5OfyzRbjS7SJ/9vM/BLKAdrRTY0t&#x2B;olAf6JdKG3BL/Yz96IkBRsjCUnzWHU6YP2snhF/r8cT7tMwWkzYv62e9pNlbEm8AuhgqJ3SHmzSHf6d2on0j6oB3UmkD7qqcsQeeGGaELOSqsS03cilnrtmjMqbGFrOdxqepxTCVDYClAYbKCd1hV3zjigGosc3aqbElP1GoDwxApQ3IY4CMfTJClnGVqLFlecz8yDujXANrSPhGS7wB2DJUDsZzNeCv1nyixEtkifb7bVYxM6IOoB0qbUA2MnZoU64yW80mkJG1t/A67fdXZeuaxBuAMEPlYAyFmsPvLsO8ekz9aXN5m8N3XWwzog6gKSptQGYydmjKnIA13j1mmbSn7WquBjJvKLNJvAH4MFQOupa9cUXYswlFoebwPRbbSoyoO429jagDCFNpA/LrKGMPbFbGzgA&#x2B;p/HNlLhaRn3nhXK1i9zNz7/79uuYvL2REl39GltgsxJvgC4YKgfdiV&#x2B;S7VJz&#x2B;JtN3XMp1xy&#x2B;kYj9DiPqANqk0gaUUiJjT3timBGyjOq0zLZcoWFX5VGryzlt8U1ptIucNdUuMvmJEm&#x2B;AR3Q0VE7oDu03h99W7GJqeLvvRbQ/M6IOoGUqbUBB2TP2mCcevWKAEbKMJ1xmS1sCrZzV/kTm/Fmy7sj5apEPe5DEG4D7uhgqFxO6T&#x2B;ptjEtz&#x2B;KsaD&#x2B;MjmcoG0DiVNqC4yhl74BXDjJCFWeN5&#x2B;3S7gUx8vt3&#x2B;sg2msgGQUYmekIbKQS5Zymx9NYefLgb8q&#x2B;j9TnP4o21WZkQdQBdU2oAaZOxQU9rybEcTy8ql4jFbDizSMJUpft&#x2B;fvlYzFZd4A1DCUSydPOLNUDm4735z&#x2B;NN/zatmc/hVAP&#x2B;GeWyTEXUALVFpA&#x2B;rJnnjL2OHIzUXRl4/5/re/z56QrzZ4tGzD6mGla2x9kXgDUFqJ1hSGykEazeHjhcts7bes&#x2B;NAuEqAvX57eAeBd/vin3x0FW&#x2B;FIscQTA/7ln38Z3uyXH31zepsbHlHizCy3WHrAI2W2T&#x2B;Ldfvp9mngn5N6nv5aBFDrwxMDOyL0B2ncnCD96VtoTw4TuENZOc/iYYuHLq&#x2B;OnP1nKbAANMqcNeEBH7WjCmzVCljY9kkjffNHAkulZsu55ZGv7VbSwEln3JPHmiq&#x2B;&#x2B;&#x2B;sHTuwDUZnIbPGuk5vBb7TeHr0mNDaBTKm3AY7rI2E83q5kkTTkdr/3I7LTp6SXZOkqtA8ZoF3n6RBqnzAavdScIb2eonNCdfvXVHD7yYeaxLTU1ok6oD3CV7pHAkzpqR3PakSZhs9C7yLpdm4Nb8yo9Z66pdpHTjYxd7t21ZZnt&#x2B;&#x2B;///v33f39wZ4BHpAXhlfvAn25WM0n60mNz&#x2B;N34/8Hm8I0r1y6yRI93oT7ALnPagOeVmNyW9sQwk9voQq4Bqst2jpXlbRdZVIXU3VQ2WrCayqbGBm82xuS2STNJuqI5/NYn2i8XjVfrilG/XWRgs0J9gGQqbUATsmfsMU88esWAmIx9Um/jIRlbR57m1ac9Z56dxxZOjLPMP6szPLajxPvOE2ncairbg3sCtMNQOaijcnP4jPnC7mN6bA5fLuwfY0SdUB/gQ6UNaEjljD3wimFGyDK2yCLZMk9ePeUN7SJLGyPxPn0i7VNmA46MNFRO4AHxkue6lYv2SzdyL6GjEXVC/VFZgBnyUmkD2tJLxn66WSNkeacWamxFh7iGs/dcuX1HifedJ9I4HSOBGB0NlRO60ynN4T80hw8zlY1LlNkgO5U2oEUdZezhzRohS2V38vDT55ZIzkvPY/vu269z5eSBrDtj2j9G4n36RNpnKhsQ785QuexPDNAHnu6cRobxxm4Of1&#x2B;1yXAdjagT6o/KcDooRKUNaFQvGfvpZmXsNKLcCNamGsgsk/BPwpyx2BZ2Mz9/pMYW2KzE&#x2B;7Xk3kCatKFyJZ4YZqgcI4mM8HtvDl9zVbaVjBW4MUbUCfV7J9SHclTagKaNlLFP6m20Ie/UtAez7lXK/eCqDPdfusTg1qnPxPunP/7Jn//6l/vbIY3cG7jDUDkYTwvN4YvajeTz1vaMqKMRulZAUSptQOuGydgnI2Rp0icN/qTQy//etarSJSTevWfd2Um8l37645/c3wjJ5N5AFiMNlWs8VuENNIcvpOt2kVOfI&#x2B;p4kOF0UIFKG9CHRzL26Xrga3IbbYpJoefHfBZpOKqo3cn2MybeYyzVIPGeqbE9S&#x2B;4N5DXMUDmhOy17bXP4as0ke2wObwFmtgyngzpU2oBuFMrYJyNkYZOoNzu4NT6vPkqM5y082G1yMpXtf1Jme5bcGyjEUDnoUSPN4Z&#x2B;N1dtsDp8c6p8&#x2B;11S2gQn1oRqVNqAzJbrKGCHLe5RoERMWk3XHJNUPLoSencSbdsi9gaKSR7w9MlROH3g6tYrwO20Ov4r2f/bzPxzlBd99&#x2B;/XywfED6VroWjG9aSrbZzidNZifomsFVKbSBvSnr4w9vFkZOxVsE&#x2B;9LSreLjEmq75TZIp8r8c74RLog9waquTPireZQOZPb6Mh4zeFP3QnXu16VrdMRdbpWPMtwOqhPpQ3oVS8Z&#x2B;&#x2B;lmZey04GiuW&#x2B;lFGk7LYIEH5FqnYeAaW3izprK9mdwbqMxQOaiso&#x2B;bwqzlqq39N3nJlRtTN1NieZTgdPEWlDejYYBn7pN7GE&#x2B;4MYt1Vf0m2o6c/u7rDUonBrVOfiTePk3sDD7qz7rKhcrCr8ebwgYB8fszVsL&#x2B;18ltrI&#x2B;rKPZH2CfXhQV&#x2B;e3gGAuwLhYDiivfPEtBj0NMI&#x2B;jdGhnFXJ7atf/aL0Og13kuTIKtrjefiXH31TqIdM5TJb8u8eTZF7Ay04uqD8yz//Mnz9Snti4BXDTjcrdOcpHTWHf3Cy2nfffl1h4N1pqF9oKltatSz5iXRh1bVCqA&#x2B;VmdMGjOCpyW1Hzw0wuY2WNbJIQ67paKedJ0szlY2m6BgJtOPO5LbsTwwzuY1OZZ/rltwcfhXbh0P0LBW4FkL9yVQ2KjKcDlqg0gaMo37GPln&#x2B;gQ49knV/cuajHDsmqZZ4TxJvUsm9gTYdBdLJ7dz1gYfpbPBc0a4V4XA9SzD/eMuKDyPqaIfhdNAIlTZgNI9k7JMRsvQg&#x2B;5Js0/UGMkfChbRc5bHHG8hMEm&#x2B;qk3sDLetrcttkqBxdWQ2wS8sFMjauCDsN1BtZhtmIOpoi1Id2qLQBAxpsctuk3kYO2cts1bLum3JNhosh8aY1cm&#x2B;gC4bKQSGNNIfPRXP4Ok&#x2B;kC7pWQGu&#x2B;PL0DAKVkXzI95onJy62HH2C5de746le/OMqxk0e2zon3P/726zs9ZLJ7aqDrlx99U2I59NNfFcuhc&#x2B;Srr36gzAZ0JHDJS47AT6&#x2B;8yaF7eMtCdyp7pHHFz37&#x2B;h1Wcv2oOf/RPR4&#x2B;5o07jihJltphov/IT6cIqzhfqQwvMaQNGVmhy25Q0tDbM5DYqS07Isw9uzZ4Yz5PYPluuUOp7ZHBrYMumsqHGBnTK5Da4pOXm8GGRKUDkcs43dyasta4Vp881lW1sprJBs1TagPGVWDK93PIP4djX8g9kUWiRhmV961nV9kHiTWvk3kDvDJWDSI03hy/Xwr2d5vDaRVKZ4XTQMpU24BVk7HDHMuuegmW2mD8G/p7FvPHSSbipbLRG7g0Mw1A5CAjU2Co0rnh2klm1MpsRdbRGqA&#x2B;NU2kDXqSvjD28S&#x2B;ptVNPgWugBy8R7lYRnzPkl3jRI7g0MxlA5uKpQ44pnLUtrjTSuMJWNynStgC6otAHv8lTGfvTcMCNkedbNrLtaU5eaCtXYppL5c9GpbD/98U&#x2B;mafrzX/9yf1Mkk3sDAxtsqJzQnUIebw5fNPKv2Z3eiDpaYzgd9EKlDXijEkumn1bFjJClIzHtIpe2qXXNMltM7p0lP5d4r3zKbDxL7g0ML3nEW4ND5YTutCOyzBbzx9KOmsPnrcB1N6JOje0NhPrQEZU24KVKdJUxuY0x3JnKVnPAafwr3t&#x2B;r7hLvwHPV2EYi9wbeo8QcNUPleKfG20WuBJrDZzTMiDo1tmHoWgHdUWkDXk3GDkt9Zd27tmukN1tm63cqW4JVZU63yfvk3sALGSoHN43UHD7XCL/uRtQ1GOqTneF00COVNuDtusvYw1uWsZNsgDLbR8Z5dRLvLLYT4H76458ott0h9wbezFA5SHMp2l82bFz9pYJqfTJaG1HXSNcKgfqDDKeDfqm0AUxTsYx9SirUnbL8A3m1Nrg1nFo3kngXqrGFt9xdmU2Tyezk3gBTh0PlTG7jWR2NqIsM9XWtuPSiMcTtLTCcDrqm0gbwXwrVzJILdWFGyLLr&#x2B;9/&#x2B;/qtf/eLS4&#x2B;f/LnG2bHs53txark2FSbyzCKfrprUlkHsDLCXPUas/VE7ozlMaqbHlDeNLl9nqj6hrZCobzxLqQ&#x2B;9U2gD&#x2B;h6cmtx09N8wIWe6oUGaLedjPfv6HvAW5O55qFxnYcrn6HH2RewPsujNHzVA5xtZIme2mT07xSRnub82IuiyswZyXrhUwBpU2gLVHJreFnxsgYydBoax7mf1mHLhqKlv2J1ZgbGxGcm&#x2B;AsI4mt53u0mSoHDm01hw&#x2B;LCbab7Zd5NTtVLY0u0G&#x2B;ZhV3GE4Hw1BpA9j3VMZ&#x2B;9NwwGTuzcAPJRka2riaxBZL5OmW2kRLvmOfmtc2rldkyknsDRDK5jSH12xw&#x2B;5mFG1GV/YlGC/OyE&#x2B;jASlTaAkPoZe/i5ATJ2/vG3X38&#x2B;5aOEvJEyW9icb0u8sz&#x2B;xBMNXi5J7A1xiqBwvlz3aXwXk1eLzjJ4aUXcnYm9wKtukzJabOB/Go9IGcKK7jD28ZfW2l/ik2Z962zLlnnJ/&#x2B;o2sr5ZmpMQ75rl5HdXYJOFZyL0BkhkqxwtVGFEXX2Y7XVPNiLrsTyxNhJ&#x2B;XUB&#x2B;G9NX333//9D7AW3wupS6i/XpkVFq5nnUy9mf94J9&#x2B;M03T3//Pv2ffciCfLPGhLyttuznz0QN2S3Q1x8mGE&#x2B;/67SJPn9ts4r2yzcM/Nbmjv2//yTw5uTe0TEjfkUdaNBe6cS90b9YP/uk3JUL6jzlerdwcfg7U48P7mG7wn8eM3Ry&#x2B;x6lsgSj96AFby6eI7QMswAwDU2mDeqTlY&#x2B;goY4/ZsqT9KeUqbdNBYlnos06utE2bhLz3wa3TiIn3qU8iHUitJ5W2K&#x2B;Te0D4hfV8MlaO0opW26azYVmgqW0KlbTouttXvOWlE3SWnobhKWy6G08HYVNqgHmn5MGTs3Fe00lZTrkrb2INbw1tuOfEOWKbQRzWzKS7rlo1/yL2hC0L6HhkqRznVKm0flZvDd1dpM6IuwRyK7wbhkX0jVdpOCfVheCptUI&#x2B;0fDAydu5Qaauvu3UaAs9tZCrbLKZmZk5bmNwbeiGk79Qji6QK3d&#x2B;gdKVt0hw&#x2B;jhF1ybY9Krb/ekqlLUDXCniJHz69AwC9urPW&#x2B;nQQVd95btjpKu6WW2dgEu/HWUQ9QO4N8P&#x2B;3dzc5kyzVGYDzu90zvAiQkCc2QzP2GliDJSRPbIl1IFmeIbEG78FTGAITZMlehD1sPg&#x2B;KWyT1k5V18iciznmeATK3O&#x2B;uWzNeZ5&#x2B;03IvIEGyfwZ8/l5Rl7y&#x2B;i&#x2B;/JWM7qX86f9&#x2B;cebh8DsavWYrsqLuviRb7saenQzPQ5bTQR2aNoC4Jol9&#x2B;doFL7/SNE8gzcEAACAASURBVE3f/eCX/Qc2eIvgvaMf//BHgUWpcvgC2RvgTEd0Zm2Xyhndixjif&#x2B;g//uFnDodfc223K&#x2B;ruh/blk&#x2B;F5yagPpWjaALYaLrEvf7IVsqQheO8o0JZZ7vqS7A1wvmRL5YzudOXks&#x2B;KtqNtL4IhIlpnzoSBNG5zNqx1SGiuxr/lkK2QZ2ogd28K1PWxlW/&#x2B;bJfA1ZG&#x2B;AtiyVg6F1OO0fGhMOFVgYZy3dMqM&#x2B;1PRd6y8AhcyfrzcvZSGHhfl4edD/ze9&#x2B;9ezan/7k5&#x2B;Frl7385O9&#x2B;8MuXAQbWG/09DdPBW9n6rNl&#x2B;/MMfzYP0yxbt5jcI4Q/J3gA92DiBP/ull2NG&#x2B;Mn&#x2B;8pON7hSx/KP&#x2B;8s/vMy&#x2B;TdXhiX76w&#x2B;aI6dvTx8cWoD2XZ0wan&#x2B;vz8dn3o2tyWks1tcE/HFrt29NStZrt3s87GDADQnM1tMJAOp/2ht7Itr6K7Geavv9mQ/4yODYrTtMHZ5mXbNE0fH188gPOR2OGqcs02bvDeTgK/J3sD9MlSOehfh6P&#x2B;y2u7HfXDL2COXVuEUR/4&#x2B;Pz8bP0doCiP4QpabXM5LmYI7Xv58jf/Nk3Tt//919ZfZKu//bv/uP7fJ78C/WrE4L1wbVcd28qlrGsOjfyv//nv2Kfl4KEPaVz/OPuznFKT1TNG96F9&#x2B;Zt/SzDSz70c76&#x2B;/If2KuoP&#x2B;XPdTs12m7vvR/dk0vlCzzS&#x2B;pMNvPObUCuPCeNmjm5rVt3tyW0hGvcFhz7rzXP1BHw&#x2B;Adft1Ct29lO076gL1g/oj//Pwme0MapveUjnh3ctvR3fTOEf74h5&#x2B;dU7O9/Bk&#x2B;9K1sC9fGvlLzt7Jt2ZFmN9tDN8vpjPpQmT1t0J517hW0Wg1nhWy30uxpm9pta7OV7WgL61sXVqo&#x2B;uyr2aaPziId8/v0ff/Uv//nP1//qj3ZWNrexUsE9bac5aNpv9ae4h2n/4dS9Zk/by5qt5p42oz4wp2mDLthsXoTEzpWmbYs1q7MLBu&#x2B;XbzVfuHBakahX5uf1705P37TJ3pCY6b0CS&#x2B;VYQ9N2hBFX1HXesU2h9XDPLrxXrWkz5wP3nB4JXbh5MDuLJquDjqMJX7vs5Sc7joYm1gTv3mq2E86QCR/nsu85ME6VuXBiJKR380fb9J7SQQdCOgceFqzJmMcdF7nlcPiFf&#x2B;/Kb3iyLQVYyvJsPTUb8JA9bdAXD&#x2B;wikm1um6yQfZ89bQEjLm7deO0a9281D1z48NrtG9fWnCq55puMxaMcSrG5rQKb21iQb0/b5HD4d64dqGMLnDyx8Kux0y9G56EPLLCnDfpyszbW8tiskm1um6yQ5XvzWL6vQYP3QFvZetiO9l//899DR/GbB7fsDRU4mqKCjRP4s1&#x2B;yuQ2uXm5l23Jqha1sOxp6Vt/oZs436gM3NG3QHWfRFDHicTQOk&#x2B;Shoxe6Ct4JvPt2hxHJ3lCW6b2I8ATe51I5ozv9sKLu3o9/&#x2B;KMtK&#x2B;r2WkLXw1K8TlhOB7z0tfUXAB77/Px2fZB/fHzxIM/qN7/71cMB/fIPFwb0yy/tfu1LP/3Jz5djw3c/&#x2B;KXjaNjRoME7/C/tR&#x2B;DUl3AUH71jm2Rv4G56n9wNMto4gT&#x2B;bEF4O2AvXLlszuk8Ok6SdEUf9jdeu0ckLmO8lGNoDzPnASt7TBl1zBnQdrf5O3&#x2B;sfWsn0nrbpmHc5CN5rbHkLwluvZLj55Ie/uvItDuEv3CfZG7jhtlCBN7dx5T1tYSNO&#x2B;yd3bDu&#x2B;g3n9K5MXfmnhkme/Ovq075kOrKdpgwF4tBeRL7FPQvtzyZq2aRbIt6fxNWcZFQze95arso2X79K0vSR7AylZLVeEpXJMSZu26eCybcSObeHaHUf9cNP2MhcsfPLK1XLLl0yPmrahR32PcuBdmjYYg2d8Hfn6Non9oXxN216SBe8114bt3rRNK1awLvzqW03b0MH7Qs0GLDC9F2F0R9P2lj5X1PUz6u/YtE2rV9Ed0bSNPuqb84EA72mDMcxf/DB5c1tqB73Cwesf6F/Djm35w3vbypaA7A2kd7k5eO9yege9O/m49y6//GSjO8dJtqKu7Kj/cnWdUR&#x2B;oyZ42GIxHfh1WyOZmT9uNZMF7zbUbvVy4GvuQ4/a0jR65rzyIgbfY3FZEvtF9Mr2vk3VP23Tu4fBG/WnbeRUn7Gm7/PM6L2CePLKBN2naYDye/XUMl9jXfLjEfqFpuxK8Yw5t2l4eXFOzadOxAWFuIEUMN70b3bdL3LTtJdm0P9DJ8Ls3bctGn/Y9qYGNNG0wKkNAHfkS&#x2B;yS0a9q&#x2B;lyx4r7l2F89y7/ambXq0WHVl07bjF&#x2B;uQxy6wkdVyRQw3uq/5cKP7Ak3bAqP&#x2B;W45r2t4q4ab3mzajPsCkaYOhiet1NMwJVsgeRNMmeG&#x2B;haTuZ7A3swvRex3B9m9E9TNP2TLJpv/&#x2B;T4Rc&#x2B;4a1j4Z9ddf97Lr/BnA9woWmDsYnrpeRL7FPh0F65aXuZuqfRgveaa/e1Y6G15gUMG5u2oeO37A3szo2ljvBf2VsqNxBN271kHduaa7cbsWlb/9265YkM7EjTBhkYDuqwuS2Nsk2b4L3dvu8h37dpu/ml0RO4xytwEKvl6rBULj1N21y&#x2B;FXWjnwx/UNM2&#x2B;pA/eRADB9C0QRKmhFIk9gQKNm3HdWyTmu17PTRtaajZgKO5z9Rhc1timrYrK&#x2B;rCNG0n8/wFjqBpg1SMC6VI7EOr1rQJ3ns5oWlb85m5mzYPU&#x2B;A0bjh1WCqXlaZtGnYrWz&#x2B;jfp9N27MvNvrk78kLHETTBtnY3FbKcIl9zYcXSex1mrZ8W9ladWxTtBXb&#x2B;LHVmjbZGziZ6b2UIyqBl9e&#x2B;vHzLJxcZ3Rdo2qyo22jHrWMvw8LDz3yraRt67DfnA4fStEFC4no1w/VtVshONZq2QRe3brz2UJq2Q8neQENuQXUMN7qv&#x2B;fD0o/uCyk1bw45t&#x2B;cNH2cp2cfQ7mF9&#x2B;5nKddv3V0Qd&#x2B;z1ngaJo2SMsYUYrEPpz0TdugwXvh2rYd28V9v7VL46Vpmzw0gQ5YLVfKcNO7pXLPlG3abGXbRQ8nwyfbuPaQUR84gaYNMhPXq5HYB5K4abOV7Th9Nm0JorjsDfTDHamO4Ub3NR&#x2B;edXRfULBpG3RFXYej/hHnVWjabniqAqfRtEF&#x2B;BotSGtYMXv/wlqxN26DBe&#x2B;HaTjq2i/t&#x2B;a6&#x2B;9Ze&#x2B;&#x2B;hv3y&#x2B;xOEcI9IoENuTaUM17dVXir3UKmmzYq6fWnajuZ5CpxJ0wYlGC&#x2B;qGS6xr/nwZIk9X9MmeJ&#x2B;gq6YtQQL3cAS65WiKUiyVG1qdps1xkft6WYlNZ51XkbJp8xgFzqdpgyrMGdWkTOxTotCerGnrM3i/vLzb4P3M/QvJWzVtCajZgP65U5Uy3FK5UqP7ggpNmxV1R2jStHkBM8BxNG1Qi4GjmuES&#x2B;5oPz5HY0zRtx3VsU&#x2B;Hg/YymbRcehcBArJYrJeVSuRyj&#x2B;4L0TVufK&#x2B;oSjPovX8A8tWjaEgz/Rn2gFU0blCOuV5MysU/jh/YETZvFree7fzuapu1dsjcwHNN7NZbKjSVx02ZF3aF6a9oSjP3mfKAtTRsUZQSpRmLvzehNm&#x2B;DdxP3b0XY87OVhJk8Qua88&#x2B;IChuYmVYqncQLI2bbayHe3lC5ins5q2HDwlgeY0bVCXQaSa4wozr38IGLdps5WtoZObtkxR3CMPSMDmtmoslRtCvqbNirpzHNe0PfyojR/YOaM&#x2B;0ANNG5QmrhdkhWwnBm3aGi5uXf7wZMF7PU3bGrI3kIl7WimWyvUvU9NmRd2ZXr6Aedq7aUsz2895JgL90LQBRpNyjivMrJBdb7imTfDuk6ZtmQcckJKbWzUpl8qNNbovSNO0WVF3Mk3bdp6GQFc0bcA02dxWUsrEPo0T2sdq2gTvbu3YtE2PAv/QZG8gMdN7Qc&#x2B;mmm6XymUa3RckaNqsqGviMnjPp25N23rmfKBDmjbgLwwr1djc1tAoTZv3NHTuiKYtQQj3OAOKcLurxlK5Do3etFlR1499T5hIeV7FhWcf0CdNG/BXjCwFSexN9N&#x2B;0tV3cuvzhBYP3M/s2bTl4kAGl2NxWUKsZyVK5h8Zt2qyo642mbQ2jPtAtTRtwS1yvSWI/WedNm&#x2B;A9Ck3bDdkbqMndrxpL5foxYtNmRV2fDm3aEsQETzqgc5o24DFDTEES&#x2B;5m6bdoE77Hki9BhHltAcW6DBVkq14PhmjYr6rp1UNOWIyB4xgH907QBTxllatK3naPPpk3wHo6m7cIDC2ByNEVJRvfmBmra2q6oW/7k8OWZRv3dz3v88Q9/lCMdGPWBIWjagBfMNAUdt8TVCtmr3pq2lMF7zbWj07RNnlMAf81dsaCUm9umzqb3Z0Zp2qyo61/WN6tt4YkGDETTBrxmuKnJCtlDddW0HRe8HRd5tOJNm8cTwEM2txVkqVwr/Tdt3a6o25IUUo76mrYbRn1gLJo2YBVxvSaJ/TidNG3dBu&#x2B;Nl6fM3g9Vbtpkb4Bl7pMFWSp3vs6bNivqBqJpu/L8AkakaQPeYNypSWI/QvOmrW3Htvzhgvd6NZs2DyOAldwwC7JU7mTdNm3drqgz6j&#x2B;jabvw5AIGpWkD3mPoqem4wqzs6x/aNm3jvqdh&#x2B;&#x2B;XJFGzaPIYA3uJoiposlTtNh02bFXWD0rRNRn1gZJo2IML0U9OIiX3N5zdJ7K2aNsE7mWpNm6cPQIz7Z0FZl8r1Vrb11rSNu6LOqF&#x2B;8afOcAkanaQOCjEE1ZU3s0&#x2B;mhvUnTNm7w3n55VnWaNg8dgI1sbqtpxKVyHY7uC/pp2qyoG13lps2oDySgaQPixPWyRkzsaz7/zMR&#x2B;ctMmeGdVpGmTvQH24o5akKVyh&#x2B;qkaRt3RZ1R/6ps03Z9MHkqAUPTtAFbies1td2flGCF7JlN27jBe/vl6VVo2mRvgH2Z3muyVO4gzZs2K&#x2B;rSKNi0eR4BmWjagB0Yj8rKmtin40P7OU2b4J1e7qbNwwXgII6mqMlSuSO0bdrGXVFn1L9XrWkz6gPJaNqA3ZiTapLYY45u2g7t2KZ2TWrZ4P1M4qbNMwXgaO60NR13GmTbwyRblW2tmjYr6vKp07R5&#x2B;gApadqAPRmYysqa2KfDQvuhTVvbxa3Lny947ytl0&#x2B;ZRAnAat9yyRjyaovlSuYfOb9p0bFkVado8d4CsNG3AzpxFU9ZxhVnzwySPSOwHNW2CdzXXQJ4mh8veAOdz763JUrldnNy0dXtc5MbLTftTjabN4wZITNMGHML8VJbEvtIRTZvgXdAlkKcJ4Z4dAK24A5dlc9tGpzVtVtSll7tp85QB0tO0AUcxSFU2YmJf&#x2B;fl7hfZ9mzbBm9F5ZAA052iKsiyV2&#x2B;Kcps2KugoSN21GfaACTRtwLBNVWccVZjlWyO7VtB3asU2CN6fwpADoh3tyWVmXyh1dth3dtFlRV0fKFzBPs8eKZwqQm6YNOJy4XlnWxD5tDu27NG2CNwnI3gC9Mb2X1XCpXOej&#x2B;4JDm7Zut7KdsHSyoHnTlqNm8zQBStG0AWcwYFVmc9tDG5s2W9lIwKMBoGfu0mVZKveWg5o2K&#x2B;oK8gJmgKFp2oDzmLQqk9hvbGna2i5uXf58wZuVPBEA&#x2B;udeXZalcuvt3rT1vKLOVjbW8OwAatK0AacyclU2aGJf8/mBxB5r2gRvEvAgABjI/KY9uW8XY6ncGvs2bVbUMTqjPlCWpg1owOxV2XHvbxjr9Q&#x2B;Bpk3wJgH3f4ARuXuXZancS3s1bVbUkYAXMAOVadqANsT1yhIn9ml1aH&#x2B;raRv6PQ3bLycN2RtgXKb3yiyVW7BL02ZFHaPzjADQtAHNGMWKK57YVzZtzRe3Ln&#x2B;&#x2B;4M1KbvgAObifl2Wp3DMbmzYr6kjAowFg0rQBzZnJKquc2Nc0bYI3ObjPA2Tirl5Z8aVyD4WbNivqyMGpFQAXmjagPXG9uIaJ/eUnbPzwhcS&#x2B;3LQJ3qQhewPkY3qv7LjCrP&#x2B;lcg/FmjYr6kjAswBgTtMGdGE&#x2B;ok2mtHoKbm5baNoEb3KQvQFyc5&#x2B;vbNDp/Yiy7d2mrfmKurZdKWl4BADc0LQBHTGrFTdoYl/5&#x2B;Teh/WHTJniThvs5QAXu9pXZ3HbxVtM29Iq67aeJkIM7P8BDmjagL4a24uok9vum7WXw7vm4yO2Xk4bbOEA17vyVJV4qt7JsW9m0WVFHDm74AM9o2oAemd6KS5zYp&#x2B;9D&#x2B;7xpE7xJw90boCb3/&#x2B;Iavt&#x2B;3&#x2B;ea2NU3b0CvqbGXjyguYARZo2oBOievFHdf9bL982crEfmna1vxs9xy8t19OJrI3QGWm9&#x2B;IqLJV7aLlps6KOHNzhAV7StAH9MsyROLFffrxf/mAL3gzB7RqAC0&#x2B;E4hrunWpVtj1r2pp3bMufb9RnPTd2gDU0bUDvTHW0Pe3koAD8smnrOXhvv5xM3KUBmPNcKC7xUrnpUd/2sGk7tGYz6nMmp1YArKRpAwYgrpMvsS83ba2C95pPELyZk70BeMgAX9ygS&#x2B;UCZdtN02YrG2m4jQO8RdMGDMOcx6CJ/eHnP2vaeg7e2y8nE/dkAJZ5UhSXb6nc3LVvmzdttrKRhhs4wLs0bcBITHukSez3TZuOjYHYygbAGqZ3Mi2Vu/en//vFpWmzlY003LcBYjRtwGCMfUwpEvtN0zZo8F75bycTN2EA3uXZUVyapXIPfXx8eflT3fOov/1yMnG7BgjTtAFDMv8xemK/Nm2CNwNx7wUgxhOE0af3Z142bT1P&#x2B;0Z95pxaAbCFpg0YlbjONHJi/&#x2B;3vfz1N0z/8/T&#x2B;FP8FWNk4mewOwkQG&#x2B;uHFH94XPX2jaeu7Ytl9OJm7OANtp2oCxmQgZNLFvadoEb07mTgvAXjxTGHR6f/b5z5q2Q2u2jUvijPrMuS0D7ELTBgzPXMg0YGIPN20Ng/eay8nHPRaAfXmy0LYo2rcDu2/abGVjIE6tANiLpg3IQFxn6qBheitUB5o2wZvzyd4AHMQAz3BL5R5&#x2B;/k3TZisbo3ATBtiXpg3Iw6TINE5if6tp2/6vFrx5lzsqAEfzrGGspXIPP//atNnKxkAspwPYnaYNSEVcZxoksa9v2gRvzid7A3AaDx1GWSr38PMvTVv4Q6yo42T&#x2B;zgTgIJo2ICGzI1P3iX1N0yZ4cz73TwDO5&#x2B;nDEEvlHn7yx8eXwKuXr5e//D1W1LEjN1uA42jagJxMkEx9J/aXTZvgzfncOQFoxTOIqfVwGyjbwk2bFXWczwZigENp2oC0xHUu&#x2B;kzsC02b4E0TsjcAzRngmbZNqidvbos1bVbUcTK3VoATaNqA5MyUTF1ubnvWtAnenM99EoB&#x2B;eCoxtR5315dt7zZtRn3O56YKcA5NG5CfyZKL5ql1/gn3TZutbDThDglAbzybuOi/b3uraVOzcT6nVgCcRtMGVGHE5KKTxH7TtAneNOHGCEC39G1MHQzALxe6rWnajPqczy0U4GSaNqAQsyYXh65vXfkJ16ZN8KYJ90MA&#x2B;udpxUUnS&#x2B;UeXv6yaTv6G27PJuRjOR3A&#x2B;TRtQC3iOldtE/vlR3HND6Gajd3J3gAMxADP1MdSuYcXLjRtzVvAl5eTjxsmQCuaNqAi0ycXDRP7mqZN8GZ37n4AjMjzi4veNrc9a9ravoB55RcgH7dKgIY0bUBRZlCumiT25abtoFW36y8nJfc9AMblKcZFV5vbHjZttrLRhFMrANrStAGlGUa5OD&#x2B;xLzRtgjdHcLsDIAF9GxedbG67adpsZaMJN0aAHmjagOpMpVydmdgfNm22snEEdzkAMvFc46J5ZfXTn/x83rTZykYTltMBdELTBiCu8xenJfb7pk3w5giyNwApecBx0XyE/vj4suaHsHkvSEruhAD90LQB/Jm&#x2B;jasTEvu8abOVjYPI3gAkZnrnom2JtaZpa14Hko8bIEBvNG0Af2Fa5eroxH5t2gRvjuBuBkAFnndctRqql5s2W9k4guV0AB3StAHcMrZydVxi/&#x2B;3vfz1N0/X16YHPF7x5xk0MgFL0bVw0OShioWmzoo7dud0BdEvTBvCA&#x2B;ZWrgxL7QtMmeBPm3gVATZ6AXB3Xbz38hIdNm61sHMGNDqBnmjaAx0yxzO2e2J81bYI3Ye5aABRnVzcXZ25uu2/abGXjCO5vAJ3TtAEsMc5ytW9iv2/aBG&#x2B;2cLMCgMm6E2bO2dw2b9p0bBzBbQ1gCJo2gBfMtcztlZ9vmjZb2QhzjwKAOU9Grk7Y3HZt2tRsHMFyOoBRaNoAVjHgcrVLYr82bYI3W7g1AcBD&#x2B;jauDu3APj6&#x2B;PHz18l6f//JyEjPqAwxE0wawlrjO3MZIfPlxevmDZCsbC2RvAFhgemfuiL5tuWlTsxHm9gUwHE0bwBvMu9wIZ&#x2B;M1TZvgzTPuRQCwkoUpXO1etj1r2nRsbOGuBTAiTRvA2wy&#x2B;zMVC8nLTZisbC9yCAOAtVqgwt2Pf9rBpU7MR5mYFMC5NG0CECZgb76blhaZN8OYZdx4AiPEMZW6vsu2madOxsYXldABD07QBxBmFmXsrNj9s2mxlY4EbDgBspG9jbnvfNm/a1GxsYdQHGJ2mDWATcZ0bK/PzfdMmeLNA9gaAXZjemdu&#x2B;0O3j48uaHySjPs&#x2B;4KQHkoGkD2MpkzI01iX3etNnKxgJ3GADYnSUszG2pwdY0bWo2nnEvAkhD0wawDyMyN5YT9bVpE7xZ4MYCAAexloW58NK35abNqM8Coz5AJpo2gN2I69xYiNa//f2vp2m6vj79huDNJHsDwMFM79wIFGPPmjanVrDAzQcgH00bwM785Tg3HsbshaZN8Eb2BoDTmN6Ze7che9i02crGAvccgJQ0bQD787fk3LgP2w&#x2B;bNsGbSfYGgNOZ3rmxviq7adpsZWOBWw1AYpo2gEOYobk3D973TZvgjfsGADRksQtzKzuzedNmKxsL3GEActO0ARzIMM2Na/yeN22CN5PbBQB0wKoXbrwszy5Nm61sLDPqA6SnaQM4lrjOvZ/&#x2B;5OfXpk3wZpK9AaAbpnduLJdtHx9fHr56&#x2B;fobjvlSDMMtBaAITRvA4czW3Lv8VPh5wP0BADpkEQw3HvZty02bmg13EoA6vmv9BQDy&#x2B;/z8dh2s53&#x2B;rDhQ3z97iNwD0Yz69G&#x2B;CZ3qzNfvO7X6nZULMBlKJpAziJuA7Myd4A0DOr5bixsj/TsXGN/JbTAdTxtfUXACjkMmRfZu7Lq7NbfyOgAR0bAIzi8/PbdXqfPLv5vkh7dpjk6V&#x2B;H7hj1AWqypw3gbDa3QWWyNwCMZf7INr1zcV&#x2B;qqdmYB3yjPkA1H5&#x2B;fn62/A0BF85RuCi/IsuiC/KkHgKH5O3TuOaqEC/cHgOLsaQNow4sfoJR59ha/AWBEjqYAHlKzAaBpA2hJXIcKZG8AyMFqOWDOiZEAXGjaABoT1yEx2RsA8jG9A5NTKwCY0bQBdMHmNshH9gaArEzvUJzldADMadoAejEf0MV1GJ3sDQC5OZoCarr265bTAXClaQPoiLgOCcjeAFCHzW1QiuV0ADykaQPojrgO45K9AaAaq&#x2B;WgAi9gBmCBpg2gR&#x2B;I6DEf2BoDKTO&#x2B;QmBcwA7BM0wbQL3EdRiF7AwCOpoCULKcD4CVNG0DXxHXon&#x2B;wNAFw4mgIycWoFACt9bf0FAHjhMtBf5vuPjy/me&#x2B;iH4A0A3Pv8/Had3idzAozJqA/Aeva0AYzB5jbojewNADxjcxsMzagPwFs0bQDDENehH7I3APCS6R2Gc13b6gXMAKynaQMYjLgObcneAMB6jqaAgVhOB0CMpg1gPOI6tCJ7AwDvcjQF9G8ero36ALxL0wYwJHEdTiZ7AwBbWC0H3ZrP&#x2B;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&#x2B;dr6CwDQhc/Pb5eUcs0qrb8RbKVjAwCyujmXwrRDNUZ9ALpiTxsAf&#x2B;YsGjKRvQGA9EzvFDR/8YFRH4BOaNoA&#x2B;CviOgnI3gBAEfPp3QBPevM536gPQD&#x2B;cHgnALWfRMC4dGwBQzXV6v/ynKYisjPoAdMueNgAes7mN4cjeAEBZpncSmy8DNeoD0KGPz8/P1t8BgH6pLg5iufG&#x2B;/KACAFyYi85kqj&#x2B;BH2kA&#x2B;mdPGwBLrmsGvfiBbsneAABXNreRiVEfgCFo2gB4TVynW7I3AMCN&#x2B;fRugGdQTowEYCBfW38BAMZws7NN1KE5HRsAwDPX6X1ywiEDMuoDMBZ72gB4g81tdEL2BgB4yfTOcGxlA2BEmjYA3iOu05bsDQCwnvcuMxDL6QAYlKYNgLeJ67QiewMABFgtR/&#x2B;M&#x2B;gCMS9MGQJC4zslkbwCAsPn0boCnK06tAGB0X1t/AQAGdrOzTSjiIDo2AIDtrtP75T9NVvTAqA9AAva0AbCVzW0cSvYGANiR6Z1&#x2B;GPUByEHTBsAOxHUOInsDAOzOe5dpzomRAGSiaQNgH&#x2B;I6&#x2B;5K9AQAOZbUcrVhOB0AymjYA9iSuswvZGwDgBKZ3TmY5HQApfW39BQDI5vPz2/Ut65OmhDfp2AAAznRzLoUZjOMY9QHIyp42APY3X59oeSzryd4AAE2Y3jmaUR&#x2B;AxDRtABxFXOctsjcAQEPeu8xBnBgJQHqaNgAOJK6ziWARTgAAD51JREFUhuwNANAJq&#x2B;XYl&#x2B;V0AFSgaQPgcOI6C2RvAICumN7Zi&#x2B;V0ABShaQPgDOI6D8neAAAdcjQFG81PrWj9XQDgcJo2AE4irjMnewMAdM5qOWKcWgFANZo2AE4lrjPJ3gAAg7Bajrd4ATMANWnaADibuF6Z7A0AMByr5VjDcjoAytK0AdCGuF6Q7A0AMCjTO8uM&#x2B;gBUpmkDoBlxvRTZGwBgaI6m4CGnVgCApg2AlsT1CmRvAIA0rJZjznI6AJg0bQD0QFxPTPYGAEhmvlqu9XehJcvpAODia&#x2B;svAADT9H0NM9/81PobsQP/awIAZPX5&#x2B;c30XpbldAAwZ08bAB2xuS0Nf&#x2B;0CAJCe6b0mNRsA3NC0AdAXcT0B2RsAoAjvXS7FC5gB4CFNGwDdEdfHJXsDABRktVwFltMBwDOaNgA6Ja4PR/YGACjL9J6b5XQAsOBr6y8AAE/Nd7ZJdJ3zVjYAgOJuzqUwGeZgOR0AvGRPGwC9c5Jk5/xlCgAAVza3ZaJmA4A1NG0ADEBc75bsDQDADe9dzsGJkQCwkqYNgDGI6x2SvQEAeMZquXE5tQIA3qJpA2Ak4nonZG8AAF4yvY/IqRUA8K6vrb8AALxnvrNN9mtC9gYAYKWbcykMkD0z5wNAjD1tAAzJSZJNzP&#x2B;KRPwGAGAlm9v6p2YDgDBNGwCjEtdPJnsDABDmvcs9s5wOALbQtAEwMHH9NLI3AADbWS3XGwd7AsB2mjYAhieuH0r2BgBgR6b3fji1AgB2oWkDIIP55rbW3yUV2RsAgN05mqIHTq0AgL1o2gDIQ1zfl&#x2B;wNAMBxbG5rxakVALAvTRsAqYjru5C9AQA4gaMpzufUCgDY3dfWXwAAdnazs02AfJfsDQDAmT4/v5neT2DOB4CD2NMGQE42twXM/4JD/AYA4DSm96Op2QDgOJo2ANJyFs1bZG8AABqaT&#x2B;8G&#x2B;H1ZTgcAh9K0AZCcuL6G7A0AQA9sbtuXYzkB4ASaNgDyE9cXyN4AAHTF0RR7cWoFAJxD0wZACeL6Q7I3AAB9cjTFRk6tAIDTaNoAKERcn5O9AQDomaMpYpxaAQAn&#x2B;9r6CwDAqeZlW9nkaSsbAABDuFkqZ3x9yf&#x2B;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&#x2B;jPgCMSNMGAJucE9dlbwAA2K6f9y5fObUCAEanaQOArY6O67I3AADspZ&#x2B;TJJ1aAQA5aNoAYAcHxXXZGwAAjtD8JEnL6QAgDU0bAOxm37guewMAwHEabm6znA4AMtG0AcCe9orrsjcAAJzg5LLNqRUAkI&#x2B;mDQD2t2Vzm&#x2B;wNAABnOu0kSadWAEBKmjYAOMQ1PL8V12VvAAA439EnSVpOBwCJadoA4ChvxXXZGwAA2jpoc5vldACQm6YNAI61Jq7L3gAA0IPdN7dZTgcA6WnaAOBwy3Fd9gYAgK7sUrY5tQIAitC0AcBJ7uO67A0AAH3aeJKkUysAoI6Pz8/P1t8BAAq5CeqCNwAA9GxhbdzHx5dn//zZJQBAPpo2AGhA9gYAgFFcV8vdDPD3Tduz3wkAJKZpAwAAAIAlDyu0m6bNcjoAqMl72gAAAABgyfWNaw9f2&#x2B;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" />
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>